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Thesis summary 
Ageing is a natural phenomenon of the human lifecycle, yet it is still not understood what 
causes the deterioration of the human body near the end of the lifespan. One popular theory 
is the Free Radical Theory of Ageing, which proposes that oxidative damage to biomolecules 
causes ageing of tissues. The ageing population is affected by many chronic diseases. This 
study focused on sarcopenia (muscle loss in ageing) and obesity as two models for 
comparison of oxidative damage in muscle proteins in mice. The aim of the study was to 
develop advanced mass spectrometry methods to detect specific oxidative modifications to 
mouse muscle proteins, including oxidation, nitration, chlorination, and carbonyl group 
formation, but western blotting was also used to provide complementary information on the 
oxidative state of proteins from aged and obese muscle. Mass spectrometry proved to be a 
powerful tool, enabling identification of the types of modifications present, the sites at which 
they were present and percentage of the peptide populations that were modified. Targeted 
and semi-targeted mass spectrometry methods were optimised for the identification and 
quantitation of the oxidised residues in muscle proteins. The development of the quantitative 
methods enabled comparisons of mass spectrometry instruments. Both the Time of Flight 
and QTRAP systems showed advantages of using the different mass analysers to quantify 
oxidative modifications. Several oxidised residues were characterised and quantified in both 
the obese and sarcopenic models, and higher levels of oxidation were found compared to 
their control counterparts. Residues found to be oxidised were oxidation of proline, tyrosine 
and tryptophan, dioxidation of methionine, allysine and nitration of tyrosine. However 
quantification was performed on methionine dioxidation and cysteine trioxidation containing 
residues in SERCA. The combination of measuring residue susceptibility and functional 
studies could contribute to understanding the overall role of oxidation in ageing and obesity. 
 
Key words: Mass Spectrometry (MS), Oxidative Post-Translational Modifications (OxPTMs), 
Muscle Proteomics, Sarcopenia, Obesity 
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The development of the world’s technology and medicine has been led by the natural human 
curiosity to understand the complexity of life itself. From theories to comprehending the 
origin of life to pushing the boundaries of science to achieve goals thought to be impossible, 
researchers have dedicated their lives to the constant strive of obtaining answers to all 
questions. This project entails the beginning of answering the question: What causes us to 
age and deteriorate? While it is widely accepted that it is to balance the population of 
species, what is still yet to be understood is what the biological mechanisms that lead to this 
event are. In order to do so this project explored three areas: 1) the application of an existing 
theory to an age-related model, 2) a study to compare and differentiate between an age-
related model and a relevant diseased model, and 3) the development of methods that have 
been optimised for a particular biological sample. The focus of this project was the proteomic 
analysis of the ageing muscle which was compared to an obese model to determine whether 
the changes with ageing were due to the ageing process or consequences of any disruption 
to the norm. 
1.1. Ageing, inflammation and the skeletal muscle 
1.1.1. The ageing process 
The definition of ageing is described as the collection of changes to which genetic and 
environmental factors can contribute to the increasing advancement to death (Harman, 
2003). As an individual grows older the accumulation of the changes in cells and tissue can 
lead to diseases resulting in irreversible failure of biological systems such as the heart failing 
to circulate blood or the kidneys failing to detoxify the blood with both leading to eventual 
death if not treated. On average, the world population lives to 60-65 years, however, there 
have been many debates on whether the chronological age is a good indicator of an 
individual’s lifespan (Robine and Ritchie, 1991). As discussed before, the definition of ageing 
is the collection of changes that result to the advancement toward death. Each person is 
disposed to having accumulated different changes that would vary the progression of natural 
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death to individuals of the same chronological age. Therefore in order to define biological 
ageing, it would require an understanding of the underlying mechanisms as well as markers 
representing advanced age. 
1.1.2. Theories of ageing 
There have been many theories behind the process of ageing; however, it is still not known 
what the biological cause of this natural progression is. Many of these theories can be 
categorised into two groups: programmed theories and error theories. Programmed theories 
suggest that ageing involves a decline in the body’s maintenance and protection 
mechanisms via changes in gene expression, whereas error theories propose that it is 
cumulative damage that results in ageing (Jin, 2010). One particular error theory, named the 
free radical theory of ageing, describes the effects of the cumulative damage oxidants. This 
was first suggested by Denham Harman in 1956 and later merged with the rate of living 
theory to propose that an increased rate of respiration would lead to an increase production 
of oxygen radicals and therefore speed up ageing (Beckman and Ames, 1998). One 
example of an alternative ageing theory is the Hayflick Limit theory which suggests that cell 
division is a limited process (Hayflick and Moorehead, 1961). This theory encompasses 
research into telomere shortening. The telomeres of a chromosome are a repetitive 
sequence of nucleotides that function to protect the remainder of the chromosome from 
truncation during cell division. Telomere shortening results from each cell division event and 
early studies had correlated this to lifespan whereby telomere length was significantly 
shorter in tissues of advanced age (Gardner et al. 2007; Jiang, Ju and Rudolph, 2007). 
Furthermore cell lifespan extension was demonstrated by lengthening telomeres (Bodnar et 
al. 1998). This was achieved by the enzyme telomerase replacing the lost telomeres of 
chromosomes after cell division and was further used to produce immortalised cells.  Since 
then comparisons of multiple studies into telomere length correlation to lifespan of different 
tissues showed results with significant, insignificant and no correlation and ongoing debates 
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question whether telomere shortening is directly linked to overall lifespan (Hornsby, 2007; 
Mather et al. 2011). Another example of an alternative ageing theory is the neuroendocrine 
theory, first proposed by Vladimir Dilman in 1954 and further explored with Ward Dean in 
1992, which states that hormone secretion and effectiveness decreases in correlation with 
ageing. This is also coupled with reduced hormone receptor function and has been theorised 
that damage to the hypothalamus is what causes the imbalance in hormones. Hormone 
replacement therapy has been proposed as an intervention to improve quality of life; 
however, other studies debate the safety and effectiveness of the therapy in which one case 
was shown to increase spontaneous tumour frequency with oestrogen replacement therapy 
(Tosato et al. 2007). While there are many ageing theories, this project focused on the link 
between oxidative damage and ageing based on the free radical theory by Denham Harman. 
Many studies have shown a correlation between ageing and the increase in the presence of 
oxidised biomolecules (Berlett and Stadtman, 1997; Stadtman, 2006; Friguet, 2006). 
However, some scientists refute this theory because antioxidant treatment studies showed 
very little effect on the rate of ageing (Lipman et al., 1998; Gutteridge and Halliwell, 2000; 
Parthasarathy et al., 2001). On the other hand there have also been reports of evidence that 
transgenic animals have altered ROS levels (Liu et al. 2003; Hu et al. 2006; Lu, Ogasawara 
and Huang, 2007). Therefore there are some who believe oxidised biomolecules are a 
symptom of ageing and not the cause (Juránek and Bezek, 2005). Nevertheless, the free 
radical theory still stands strong and there are those who believe that this theory still has 
some contribution to ageing. Exploring these theories alongside the constant development of 
better identification technologies will enable a greater understanding of the biological 
mechanisms behind ageing and may unveil new information to support pre-existing theories 
or define new theories. 
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1.1.3. Skeletal muscle and sarcopenia 
The maintenance of skeletal muscle is important as it is contributes towards quality life. The 
tissue governs movement and is made of two main types of muscle fibre: slow-twitch and 
fast twitch muscle fibres. These can be further subdivided into slow oxidative, fast oxidative 
and fast glycolytic fibres. Slow twitch fibres exhibit less force in comparison to the fast twitch 
fibres, due to the higher abundance of myofibrils that form glycolytic fibres. Slow twitch motor 
units are primarily recruited as they are easier to excite and are usually used for low 
activities such as standing and sitting. On the other hand, more intense activities require 
recruitment of fast twitch motor units (Atwood, 1963; Johnson et al. 1972; Edgerton et al. 
1975). Skeletal muscle contains mostly fast twitch fibres as it requires recruitment for more 
intense activities. 
Figure 1.1. Labelled diagram of skeletal muscle fibre displaying the different 
components contributing to the structure and function of the skeletal muscle fibre. 
Diagram includes secondary zoomed image showing the t-tubule, terminal cisterna, triad and 
sarcoplasmic reticulum. Image taken from Wikipedia: Blausen.com staff “Blausen gallery 
2014” Wikiversity Journal of Medicine. 
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Sarcopenia is the loss of muscle mass and function in association with ageing. Current 
methods of measuring sarcopenia include grip strength and endurance. While this varies 
from study to study, the current European consensus is measurement of sarcopenia by the 
combination of gait speed, grip strength and muscle mass (Cruz-Jentoft et al., 2010). There 
are multiple factors proposed to be associated with sarcopenia; ageing, disuse, malnutrition, 
but there is evidence for oxidative damage correlated with ageing (Bautmans et al., 2009). 
Oxidised biomolecules in aged tissue could potentially be used as biomarkers for age-
related diseases. It is still unclear whether they causatively contribute to ageing or are 
consequences of the ageing process. 
1.1.4. Inflammatory diseases, ageing and obesity 
Inflammation is the immune systems response to pathogens, allergens, and anything 
deemed harmful to the host body. It can be categorised as acute or chronic and are 
distinguished by several traits: onset, cell dominance and tissue injury. Acute inflammation 
occurs rapidly and can be defined by five cardinal signs: swelling, pain, heat, redness and 
loss of function. Chronic inflammation on the other hand occurs more slowly than acute 
inflammation. Additionally, the leukocytes that are dominant in acute inflammation are 
macrophages and neutrophils whereas in chronic inflammation T cells, B cells, macrophages 
and fibroblasts are the predominant cells present. Chronic inflammation can also be coupled 
to fibrosis and angiogenesis following tissue destruction by increased production of oxidants, 
hydrolytic enzymes, and other inflammatory responses (Schmid-Schonbein, 2006; Lech and 
Anders, 2013). In chronic diseases such as rheumatoid arthritis, diabetes and obesity the 
inflammatory status is synonymous to chronic inflammation (Wong and Lord, 2004; Wellen 
and Hotamisligil, 2005). Detection of oxidative modifications in these chronic diseases could 
be due to the underlying chronic inflammation. During the progression of ageing, the elderly 
are inflicted with diseases such as; Parkinson’s, Alzheimer’s, rheumatoid arthritis, diabetes 
and obesity (Wellen and Hotamisligil, 2005; Filippin et al. 2008; Gregor and Hotamisligil, 
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2011; Taylor, Main and Crack, 2013; Holmes, 2013). These diseases are reported to show 
levels of chronic inflammation. Additionally, some of these studies have been linked to 
associations with oxidation. 
1.2. How oxidants are produced in the body 
Common oxidants generated in the human body include superoxide, hydroxyl radicals, 
hydrogen peroxide, nitric oxide, nitric dioxide, peroxynitrite, and hypochlorite. These oxidants 
can be produced from a variety of endogenous sources such as; mitochondria, peroxisomes, 
lipoxygenases, NADPH oxidase, and cytochrome P450. They can also be generated from 
exogenous sources such as ionising radiation and chemotherapeutics (Finkel and Holbrook, 
2000). This project will focus on the effects of endogenous sources on oxidants in the body. 
Mitochondria produce superoxide, hydrogen peroxide, and hydroxyl radical through 
incomplete oxygen metabolism. Superoxide is formed through the addition of a free electron 
to molecular oxygen. In turn hydrogen peroxide can be produced when superoxide is 
dismutated, which can be catalysed by superoxide dismutase. Reduced transition metals 
can react with hydrogen peroxide to produce highly reactive hydroxyl radicals. Nitric oxide 
synthase (NOS) is responsible for the production of the reactive nitrogen species like nitric 
oxide (Kirkinezos and Moraes, 2001). NADPH oxidase produces superoxide in phagocytes 
with the role of killing pathogens but homologues of phagocyte NADPH oxidase have been 
reported to be found in many organs and tissues (Bedard and Krause, 2007). Peroxisomes 
contain a high concentration of hydrogen peroxide-generating oxidases and have been 
linked to oxygen metabolism (Bonekamp et al., 2009). Cytochrome P450 generates reactive 
oxygen species superoxide and hydrogen peroxide in the P450 catalytic cycle (Zangar et al., 
2004). These naturally occurring processes in the body produce reactive oxygen species but 
the amount generated can increase and create an oxidative stress environment, which 
results in oxidants modifying the surrounding biomolecules. These biomolecules include 
protein, lipids, and nucleic acids (Beckman and Ames, 1998). 
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Oxidants are involved in many cellular processes such as the electron transport system, 
vasodilation of blood vessels, and destruction of pathogens by phagocytes. Alongside the 
production of oxidants the redox homeostasis is maintained by eliminating excess oxidants 
via sequestering and breakdown. Superoxide dismutase is an enzyme responsible for 
catalysing the dismutation of superoxide to hydrogen peroxide. This can be further broken 
down to water and oxygen by catalase. Glutathione peroxidase can also aid in the 
conversion of hydrogen peroxide to oxygen via the oxidation of reduced glutathione (GSH) to 
oxidised glutathione (GSSG). The cycle can be reset by the conversion of GSSG to GSH 
with the aid of glutathione reductase (Trachootham et al. 2008). Nuclear factor erythroid 2-
related factor 2 (NRF2) is a redox-sensitive transcription factor that regulates antioxidant 
genes to counteract oxidative stress. Modifications to cysteine residues of Kelch-like ECH-
associated protein 1 (KEAP1) by oxidants result in conformation changes which releases 
NRF2 leading to activation of genes containing the antioxidant response element (ARE). 
Some of the antioxidant proteins transcribed by NRF2 include: glutathione peroxidase, 
superoxide dismutase, glutathione reductase and thioredoxin (Nguyen, Nioi and Pickett, 
2009). The KEAP1/NRF2 signalling pathway has also been linked to ageing and longevity 
(Sykiotis and Bohmann, 2008). 
1.3. Protein oxidation 
Protein is oxidatively modified through exposure to oxidants interacting with the amino acid 
residues. The most susceptible amino acids tend to be the sulphur-containing amino acids 
cysteine and methionine, followed by the aromatic amino acids histidine, tyrosine, 
tryptophan, and proline (Griffiths, et al., 2002). 
Cysteine has many oxidised forms such as the disulphide, sulphenic acid (SOH), sulphinic 
acid (SO2H), sulphonic acid (SO3H), nitrosothiol (SNO), sulphenyl chloride (SCl), 
thiolsulfinate (RS(O)SR’) and sulfenamide, sulfinamide, sulfonamide 
RS(O)NH2/RS(Ox)NHR’ (x=0-2) forms (Schoneich and Sharov, 2006). Most commonly, 
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cysteine is progressively oxidised through from the sulphenic form to the sulphinic form and 
then the sulphonic form. However, it is ordinarily found to form disulphide bridges which are 
formed when two cysteine bonds are oxidised creating a bond between the sulphur groups 
that contribute to protein folding (Betz, 1993). One study has proposed that HOCl oxidation 
forms sulphenyl, sulphinyl, and sulphonyl chlorides which decompose to sulphenic, 
sulphinic, and sulphonic acid or form S-N cross links with nearby lysine and arginine 
residues forming sulphenamide, sulphinamide, and sulphonamide (Fu et al., 2002). 
Methionine has two oxidative states: methionine sulphoxide (S=O) and methionine sulphone 
(O=S=O) (Schoneich and Sharov, 2006). Similarly to cysteine, methionine can be oxidised to 
the sulphoxide state, and then the sulphone state when there is an excess of radical 
species. While it is considered to be a common modification, it has been suggested to 
impact life span and is linked to the development of Alzheimer’s disease when methionine 
sulphur reductase (MSR) function is reduced in brain tissues (Stadtman, Moskovitz and 
Levine, 2003). 
Tyrosine also has various different oxidative forms, such as dityrosine, 2-hydroxytyrosine, 3-
hydroxytyrosine (DOPA), 3-aminotyrosine, 3-nitrotyrosine, and 3-chlorotyrosine (Schoneich 
and Sharov, 2006). The latter two are products of reactive nitrogen species-mediated 
oxidation and reactive chlorine species-mediated oxidation, respectively. Additional tyrosine 
modifications include dityrosine and 3-aminotyrosine formation. Dityrosine is usually 
generated through tyrosyl radical formation (Heinecke et al., 1993; Yan and Sohal, 2002). 3-
aminotyrosine is a rare oxidative modification but one study has reported to have observed 
this modification and proposed this was a result in the reduction of nitrotyrosine (Mirzaei et 
al., 2006). 
Phenylalanine can be oxidised to tyrosine and dihydroxyphenylalanine 
(hydroxytyrosine/DOPA). Figure 1.2 demonstrates that oxygen can be observed at multiple 
points of the aromatic ring in oxidised phenylalanine producing; ortho(O)-tyrosine, meta(M)-
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tyrosine, and para(P)-tyrosine, isomers of the naturally occurring L-tyrosine which makes it 
easier to distinguish between oxidation and mutation (Ishimitsu et al., 1984). P-tyrosine is a 
natural metabolite of phenylalanine and therefore cannot be used as a marker of its 
oxidation (Hoskins and Davis, 1988). However there are studies showing oxidation of 
phenylalanine to O-tyrosine and M-tyrosine (Leeuwenburgh et al. 1997; McPherson and 
Turemen, 2014). 
 
Figure 1.2. Positions of ortho-, meta-, and para-tyrosine. R group represents the 
remainder of the tyrosine structure. 
Tryptophan oxidation products include hydroxytryptophan, nitrotryptophan, N-
formylkynurenine, and kynurenine (Schoneich and Sharov, 2006). Hydroxy- and nitro-
tryptophan products can be in the form of more than one isomer. 2-oxo-histidine is a 
histidine oxidised product and hydroxyproline is a proline oxidised product (Schoneich and 
Sharov, 2006). 
Protein carbonyl group formation can arise through many different reactions that form 
ketones and aldehydes. Semialdehyde amino acid formation can occur with lysine, arginine 
and proline residues (Stadtman and Berlett, 1991). Characterisation of the amino acid 
residue and the type of carbonyl modification is possible through tandem mass spectrometry 
analysis and searching against a sequence database (Mirzaei and Regnier, 2005). 
Alternatively, aldehydes can be detected through covalent labelling with nucleophilic 
hydrazide or hydrazine based probes, which form Schiff bases that then can be reduced to a 
stable carbon-nitrogen bond. An example of this method is OxyBlotting which uses 2,4-
dinitrophenylhydrazine (DNPH) to react with protein carbonyls and anti-DNP antibodies to 
detect the modification (Levine et al., 1994). There have been studies that incorporate both 
these SDS-gel based methods where one is immunoblotted to visualise the migration pattern 
of carbonyl formation on proteins and the other is stained for total protein so that 
R 
Ortho Meta 
Para 
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corresponding spots can be excised, digested and analysed by mass spectrometry (Yan et 
al., 1998). In order to study a variety of modifications, the number of oxPTMs studied in this 
thesis research project was limited to a selected few (Fig.1.3). 
The oxPTMs shown in Table 1.3 were chosen based on amino acid susceptibility to 
oxidation and prevalence of reported modifications in literature, which is further discussed in 
section 1.6. Sulphur containing amino acids methionine and cysteine are the most 
susceptible to oxidation due to their nucleophilic side chains when oxidised. Sulphur has six 
electrons in its outer shell. Two of the outer electrons have paired with the carbons on either 
side of sulphur in methionine or the carbon and hydrogen on either side of sulphur in the 
case of cysteine. The remaining four unpaired electrons in sulphur’s outer shell can form 
double bonds with two unpaired electrons in the outer shell of oxygen. In cysteine, the first 
oxidation produces –SOH which is then followed by double bond formation with oxygen. This 
enables cysteine to have up to three oxidation states. Cysteine can also form a thiolate ion 
which generates a more nucleophilic form and can lead to oxidation, disulphide bridges with 
another cysteine or mixed disulphides (Yarnell, 2009). Aromatic amino acids; tyrosine, 
phenyalanine, histidine and tryptophan, are oxidised by an addition reaction to the ring 
resulting in oxygenation of the aromatic rings itself. Typically the aromatic amino acids have 
various oxidative forms depending on where the oxygenation takes place on the ring 
(Hawkins and Davies, 2001). To illustrate the characterisation of carbonyl formation in 
proteins and correlation with western blotting, allysine was also added to the variable 
modifications search parameters. Allysine is approximately 1 kDa smaller than its reduced 
form lysine and is formed by oxidative deamidation (Fan et al. 2009). 
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Figure 1.3. Structures of twelve modified amino acids searched using Mascot. 
*Oxidation can occur at multiple places but most commonly occurs on specified position.    
Sulphoxide (+16 Da) Sulphone (+32 Da) Sulphonic acid (+48 Da) 
α-Aminoadipic-6-semialdehyde 
(-1 Da) 
3-Hydroxytyrosine (+16 Da) 3-Chlorotyrosine (+34 Da) 3-Nitrotyrosine (+45 Da) 
4-Hydroxyphenylalanine (+16 Da) 5-Hydroxytryptophan (+16 Da) 5,6-Dihydroxytryptophan (+32 Da) 
4-Hydroxyproline (+16 Da) 2-Oxohistidine (+16 Da) 
O 
O 
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1.4. Oxidation of amino acid residues by different oxidants 
The oxidation of these amino acids by various oxidants has been explored in many in vitro 
and in vivo studies discussed below. Some oxidants have been shown to produce several 
oxidative products or preferential modification to certain amino acids. 
1.4.1. Superoxide/Hydrogen peroxide 
Superoxide is reactive towards cysteine metal centres that are redox-active (Ryan et al. 
2010). Hydrogen peroxide is formed by superoxide dismutase but can be made into highly 
reactive hydroxyl radicals by the acceptance of an additional electron (Sawyer and 
Valentine, 1981). Hydrogen peroxide has a relatively slow reaction rate with most amino 
acids and is unlikely to cause efficient oxidation of proteins but it can produce more reactive 
oxidants such as hypochlorite through a reaction catalysed by myeloperoxidase and 
hydroxyl radicals by a reaction with transition metal complexes (Sysak et al., 1977; 
Goldstein, et al., 1993). Additionally, through combination of hydroxyl radicals with nitric 
oxide, peroxynitrite (ONOO-) can be formed. 
1.4.2. Hypochlorous acid 
Hypochlorite (HOCl) has the ability to oxidise and chlorinate biological compounds such as 
proteins and lipids. It is used as an antimicrobial agent generated by the enzyme 
myeloperoxidase in phagocytes (Harrison and Schultz, 1976). Diseases such as 
atherosclerosis, chronic inflammation, and some cancers are believed to be linked to the 
excessive production of HOCl and accumulation of tissue damage resulting from this 
(Hawkins, et al., 2003). 
The amino acids that are most susceptible to HOCl oxidation include methionine, cysteine, 
histidine, tryptophan, lysine, tyrosine, and arginine (Hawkins, et al., 2003). HOCl is more 
readily reactive with sulphur-containing amino acids, cysteine and methionine, and slightly 
less reactive with amine and nitrogen-containing residues: histidine and lysine (Hurst et al., 
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1991). Tryptophan oxidised by HOCl can produce the stable oxidised product 2-
hydroxyindole but this is not specific to HOCl oxidation and can be formed by other radical 
species (Pitt and Spickett, 2008). Tyrosine, however, is able to form the chlorine-containing 
oxidised product 3-chlorotyrosine when attacked by HOCl, representing a specific marker for 
HOCl-mediated oxidation (Domigan et al., 1995). 
HOCl reacts with amino groups in the formation of chloramines: R-NH2 + HOCl  R-NHCl + 
H2O (Winterbourn, 1985). Chloramines are produced from the chlorination of amines of 
lysine and histidine residues and can also be further chlorinated by excess HOCl to generate 
dichloramines (Pattison and Davies, 2005). They are capable of transferring chlorine to other 
substrates but when other substrates are not available, chloramines stabilise themselves 
through hydrolysis to aldehydes (Hazen et al., 1998). The formation of 3-chlorotyrosine has 
been proposed to occur through direct HOCl oxidation and via transfer of chlorine from 
chloramines (Domigan et al., 1995). Lysine residues are a major site of reaction of HOCl 
with many proteins. Chloramine species are produced which decompose to nitrogen-centred 
protein radicals that induce protein backbone fragmentation and dimerisation. Low, sub-
lethal doses of HOCl react with thiols and can initiate apoptosis whereas high concentrations 
cause rapid necrosis (Strosova et al., 2009b). 
1.4.3. Metal-catalysed oxidation 
Hydrogen peroxide can react with reduced transition metals via the Fenton reaction to 
produce highly reactive hydroxyl radicals. The Fenton reaction, i.e. Fe2+ + H2O2  HO
• + 
HO- + Fe3+, therefore leads to metal catalysed oxidation of amino acid residues of protein. It 
is also possible for a more efficient generation of hydroxyl radicals through the substitution of 
iron (Fe2+) by copper (Cu+) (Moreau, et al., 1998). Other redox active transition metals that 
occur in vivo include chromium (Ti3+) and cobalt (Co2+). Metal-catalysed oxidation is thought 
to occur on both high- and low-affinity metal-binding sites of protein probably involving 
proline, histidine, arginine, lysine, and cysteine (Valko, et al., 2006). 
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Metal-catalysed oxidation is found to be important in protein carbonylation and lipid 
peroxidation, where some amino acid residues are converted into carbonyl derivatives (Qu, 
et al., 2011). All amino acid residues are susceptible to hydroxyl radical-mediated oxidation 
(Domingues, et al., 2003). Whether this is through hydrogen abstraction (aliphatic amino 
acids), electron transfer (sulphur-containing), or addition (aromatic), hydroxyl radicals react 
to different amino acids in different ways (Schoneich and Sharov, 2006). Histidine, lysine, 
arginine, proline, methionine, and cysteine are highly susceptible to metal-catalysed 
oxidation compared to the other amino acids (Stadtman, 1993). Nevertheless, histidine has 
been reported to be particularly the most susceptible to metal-catalysed oxidation (Moreau, 
et al., 1998). This is thought to be due to histidine being most associated with the co-
ordination of metal ions/structural components of metal binding sites (Stadman, 1993). 
The conversion of histidine to 2-oxo-histidine is an important marker for oxidative stress. It 
was initially suggested that histidine was converted to aspartate (Asp) and asparagine (Asn) 
as products of histidine oxidation; however, it was later found that the additional product 2-
oxo-histidine is also formed. The mechanism in the conversion of histidine to 2-oxo-histidine 
involves the reaction of HO• at the C-2 position of the imidazole ring and then the reduction 
of Cu2+ to Cu+ which then leads to deprotonation to form 2-oxo-hisitidine (Schoneich, 2000). 
For the sulphur-containing amino acids, methionine is converted to methionine sulphoxide 
and cysteine is converted into mixed disulphide derivatives (Stadtman, 1990). A marker used 
for cysteine metal-catalysed oxidation is aminomalonic acid which is derived from unstable 
dehydrocysteine (Kang et al., 2003). Mass spectrometry of an iron metal-catalysed oxidation 
showed the presence of aminomalonic acid which was proposed to be derived from the 
oxidative product of cysteine dehydrocysteine. Aminomalonic acid has been previously 
identified in human atherosclerotic plaques (Buskirk et al., 1984). 
Metal-catalysed oxidation systems can also result in the conversion of proline, lysine, 
arginine, and histidine to carbonyl derivatives (Amici, et al., 1989). In the case of metal-
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catalysed oxidation, protein modification is not the only result of oxidative modifications as 
fragmentation can also occur. Peptide bond cleavage could be the result of metal-catalysed 
oxidation of proline to 2-pyrrolidone (Moreau, et al., 1998). Previous studies have showed 
that 2-pyrrolidone formation from proline oxidation was associated with cleavage of peptide 
bonds as acid hydrolysis to 4-aminobutyric acid was evidence of this (Berlett and Stadtman, 
1997). 
Other amino acids such as tyrosine and tryptophan have also been studied. The tyrosine 
oxidation product 3-hydroxytyrosine (Dopa) is used as a marker for hydroxyl radical-
mediated oxidative stress (Qu, et al., 2011). Tryptophan products of oxidation by hydroxyl 
radicals include 2-, 4-, 5-, 6-, 7-hydroxyl derivatives and N-formylkynurenine. The various 
isomers that can be formed by hydroxytryptophan are due to hydroxylation occurring at 
different sites in the tryptophan molecule. It is also possible through the Fenton reaction for 
cross-linking to occur and the formation of the tryptophan dimer (Trp-Trp) and the 
monohydroxytryptophan dimer (Trp-Trp-OH) (Domingues, et al., 2003). 
1.4.4. Nitric oxide and Peroxynitrite 
Low levels of nitric oxide (NO) have shown to play an important role in inducing GSH 
synthesis in endothelial cells and regulate PGC-1α expression which leads to the expression 
of oxidative stress protective genes (Borniquel et al., 2006). NO was also found to play a role 
in vasodilation and neurotransmission and at higher levels it can cause oxidative damage 
but it is not as reactive as its secondary product peroxynitrite (Radi, 2004).  Peroxynitrite 
(ONOO-) is formed through the reaction with superoxide radicals and nitric monoxide. 
Methionine, cysteine, tryptophan and tyrosine can be rapidly and selectivity oxidised by 
peroxynitrite (Schoneich, et al., 1999). Tryptophan is found to form nitrotryptophan at low 
peroxynitrite concentrations and higher peroxynitrite concentrations brings about the 
emergence of other oxidation products such as hydroxytryptophan, N-formylkinurenine, and 
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dihydroxytryptophan (Alvarez et al., 1996). It was also found by the same study that 
nitrotryptophan yield increased at acidic pH. 
Tyrosine modification to 3-nitrotyrosine is used as a marker for •NO2 and/or peroxynitrite 
oxidation (Schoneich and Sharov, 2006). One study showed that low steady-state 
concentrations of peroxynitrite resulted in a rise in dityrosine formation and a decline in 3-
nitrotyrosine formation (Pfeiffer et al., 2000). This was thought to be due to two pathways 
resulting in different products where high concentrations of peroxynitrite resulted in 3-
nitrotyrosine formation and low concentrations formed dityrosine. 
1.4.5. Measuring protein oxidation 
There are a number of ways to measure protein oxidation, both using mass spectrometry 
and non-mass spectrometry methods. Antibodies specific for oxidative modifications, most 
commonly utilised in immunoblotting, can be used to determine the presence of the 
modification. Another immunoblotting technique involves the reaction of 
dinitrophenylhydrazine (DNPH) with protein carbonyls and anti-DNP antibodies to detect the 
modification. Although immunoblotting techniques are more sensitive than MS, it lacks the 
ability to pinpoint the location of the modification or be used in quantitation studies. Mass 
spectrometry methods involve both labelling and non-labelling methods. There are different 
types of tags used: isobaric, isotopic, biotinylated, etc. The biotin-switch method has been 
used to detect S-nitrosothiol (SNO) modifications by blocking free thiols, reducing SNOs with 
ascorbate, labelling with a biotin and enriching with avidin affinity capture (Jaffrey et al. 
2001). Commercially available iodoacetyl tandem mass tag (iodoTMT) sixplex reagents have 
also been used for SNO MS identification and quantification. Alternatively other 
modifications such as lysine oxidation were labelled with the characteristic neutral loss of 
dimethylsulfide from modified lysine and is detected using amine-specific covalent labelling 
reagent: S,S’-dimethylthiobutanoylhydroxysuccinimide ester (DMBNHS) (Zhou et al. 2014). 
Although the labelling and enrichment strategy reduces the complexity of the sample, the 
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focus is usually on a single modification so a lot of information is lost when removing other 
peptides with different modifications or with a different oxidative state. On the other hand, 
label-free methods are amenable to the detection and quantification of multiple modifications 
in the same sample. 
1.5. Mass spectrometry 
1.5.1. Principles of mass spectrometry 
Mass spectrometry (MS) uses electromagnetism to focus ions of a particular mass to 
generate fragmentation data that can be decoded in to structural information about the 
protein/s of interest. This is achieved by measuring the mass of ionised peptides which are 
then fragmented to create a fingerprint sequence specific to that peptide. With this 
information, changes in the peptide can be identified using mass shifts of the fingerprint 
sequence. Different types of mass spectrometers are able to generate different ion series 
depending on the resulting side chain cleavages that are introduced from different 
fragmentation methods i.e. collision induced dissociation (CID) and electron transfer 
dissociation (ETD) (Sobott et al. 2009). 
1.5.2. Sample ionisation 
Mass spectrometry (MS) is a technique that utilises the differences in the mass to charge 
ratio (m/z) of peptides and peptide fragments for protein identification as well as the 
detection of modifications. The charge of the peptide can be generated via different 
ionisation methods: electrospray ionisation (ESI), chemical ionisation (CI), matrix assisted 
laser desorption ionisation (MALDI), etc. ESI is a soft ionisation technique that utilises a high 
voltage to generate a spray of charged droplets of the sample solution and is commonly 
used for analysis of biomolecules in MS (Fenn et al., 1989) (Fig. 1.4). 
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Figure 1.4. Diagram detailing the workings of electrospray ionisation. The sample flows 
through capillary tubing at a set rate. Once ionised, droplets are desolvated and charged 
particles enter the orifice of the ion source pulled by a vacuum. 
 
1.5.3. Types of mass spectrometers 
There are many different types of mass spectrometers each with different mass analysers 
and strengths for specific MS approaches. The two mass spectrometers outlined and used in 
this project are the Triple Time of Flight (ToF) and the QTRAP both from AB Sciex. 
Throughout the project, both these instruments utilise ESI and were coupled to high 
performance liquid chromatography (HPLC). Ionisation of the sample allows movement of 
the ions within the mass spectrometer using electrostatic attraction and repulsion of the 
electromagnetic field generated by negative and positive charges of the mass analysers. 
Figure 1.5A demonstrates a typical layout for a qudrupole (Q) mass spectrometer. The two 
instruments used in the study are hybrid mass spectrometers where Q3 is substituted with 
another type of mass analyser. 
  
Flow of sample  Solvent 
evaporation 
Orifice of ion 
source 
+ + 
+ + 
+ + + + 
+ 
+ 
Ionisation 
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Figure 1.5. Diagram of MS instrument layout and mass analysers. A. Components of 
MS are labelled detailing the main parts of a quadrupole MS instrument. B. Diagram of 
Linear Ion Trap. C. Diagram of the ToF analyser. 
1.5.4. Mass analysers 
The quadrupole mass filter consists of four parallel gold plated ceramic rods in which 
opposite rods share polarities. An alternating current (AC) or radio frequency (RF) voltage 
and constant direct current (DC) is placed to generate an electromagnetic field which 
separates charged ions on their mass to charge (m/z) ratios. The DC voltage enables ions to 
move across the quadrupole and the AC or RF voltage causes the ions to spiral resulting in 
alternative trajectories for the different m/z. Ions with smaller m/z are more influenced by the 
electromagnetic field whereas ions with larger m/z are influenced less. In both cases the ions 
can collide with the quadrupole rods neutralising the ion and therefore filter ions of a specific 
m/z range. Altering the voltages changes the trajectories of the ions and can be used to filter 
from small to increasingly larger m/z (Miller and Denton, 1986; Steel and Henchman, 1998). 
The linear ion trap works in a similar manner to quadrupoles with added trapping 
capabilities. The linear ion trap uses a two dimensional RF frequency field to trap ions along 
the axis of the quadrupole ion trap by applying stopping potentials to the entrance and exit of 
A) 
B) C) 
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the electrodes (Fig.1.5B). The three dimensional version is made of three hyperbolic 
electrodes: a central ring and two endcaps. Alternating polarities draws ions towards the 
electrodes and repels them to the next avoiding collision of the ions with the electrodes. This 
generates an RF field which traps the ions and alterations to the RF frequency cause excited 
ions to eject through the endcaps (Douglas, Frank and Mao, 2004).  
In time of flight mass analysers, ions are accelerated into a flight tube in which the time 
taken to reach the detector is correlated to the m/z of the ion. Both the charge and mass of 
the ion contribute to speed where a greater charge and low mass will result in faster arrival 
times. Longer pathways to the detector can also help enhance resolution. Orthogonal ToF 
analysers pulse packets of ions into the flight tube at 90° (Fig.1.5C). This is then directed at 
a reflectron which has the same polarity as the ions causing them to be repelled to the 
detector. The reflectron increases separation by driving ions to travel twice the distance of 
the flight tube: down the flight tube to the reflectron and then back up to the detector. This 
lengthens the pathway for the ions with the need of extending the length of the flight tube 
(Guilhaus, 1995). 
1.5.5. MS approaches 
There are two main approaches: top-down and bottom up MS. The former provides 
information on intact proteins while the latter is used for analysis of digested protein/s. MS-
based proteomics typically utilises digestion of proteins into peptides for sequence analysis 
denoted as bottom-up MS. This involves cleavage of proteins into peptides by the use of 
trypsin which cleaves at the C-termini of arginine and lysine residues. The locations of these 
sites are important because there is a limit to how big and small the m/z value can be and 
using the right digestion protein allows peptides to be detectable by fitting between these 
limits. These limits are dependent on the type of mass spectrometer being employed. 
Tandem mass spectrometry (MS/MS) methods are employed to measure the m/z of the 
peptide ion and its fragments generated in the collision cell (Hunt et al. 1986). Many mass 
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spectrometers are hybrids consisting of two quadrupole mass analysers and a third alternate 
analyser. The 5500 QTRAP and 5600 QToF AB Sciex mass spectrometers used in the study 
have an ion trap and ToF respectively as their third mass analyser. The first and last mass 
analysers can either be fixed for ion selection or used to scan ions, depending on the 
MS/MS method being utilised, and the second analyser acts as the collision cell. The MS/MS 
methods are categorised either as data independent acquisitions (DIA) in which all ions are 
analysed and data dependent acquisitions (DDA) which involves the selection of peptide 
ions for fragmentation. Examples of DIA MS/MS is SWATH and MSAll where the former uses 
windows of increasing m/z to scan all ions in the first mass analyser and the latter utilises a 
wide m/z window to scan all peptide ions (Simons et al. 2012; Gillet et al. 2012; Zhu, Chen 
and Subramanian, 2014). For DDA MS/MS, several semi-targeted and targeted approaches 
can be employed depending on the type of dataset desired. The most widely used method in 
the proteomics field is discovery MS/MS which filters the most abundant ions for subsequent 
fragmentation (Aebersold and Mann, 2003; Dworzanski et al. 2004). Semi-targeted methods 
also include precursor ion scanning, product ion scanning and neutral loss scanning. 
Precursor ion scanning fixes the last mass analyser to select for fragment ions with a 
specified m/z and scans for peptide ions that generates these fragments. One study uses 
the immonium ion fragment of phosphotyrosine at 216 m/z to facilitate identification (Steen et 
al. 2001). Product ion scanning is the reverse of this method and fixes the first analyser with 
a specified m/z and scans for the fragment ions generated (Hager and Yves Le Blanc, 
2003). Multiple reaction monitoring fixes both the first and third analysers for targeted 
quantitative approaches. This method has been implemented in the quantitation of plasma 
proteins for the development of assays for biomarker candidacy (Anderson and Hunter, 
2006). Neutral loss scanning involves the third mass analyser set to scan with an offset to 
record peptides with a loss of a mass specific to a trait of the peptide. An example of this 
application involved scanning for phosphopeptides with a neutral loss of phosphoric acid 
(Tholey, Reed and Lehmann, 1999). Following tandem mass spectrometry, a MS3 method 
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can also be utilised by preforming a consecutive fragmentation providing additional 
information about the peptide sequence (Olsen and Mann, 2004). 
1.5.6. Fragmentation 
In the collision cell inert gas collides with the precursor ions to generate fragment ions 
resulting in the production of MS/MS spectra. There are different types of fragmentation 
methods: electron transfer dissociation (ETD), collision induced dissociation (CID) and high 
energy collisional dissociation (HCD) are most commonly used. This project uses the 
TripleToF to perform non-targeted tandem mass spectrometry (MS/MS) using CID which 
typically produces b and y series ions that fragment at the peptide bond. These ions are 
complementary to one another and are formed from the fragmentation of the peptide bond 
(Fig. 1.6). Different ions generate a charge on either terminus. A charge generated on the N-
terminus is termed as a, b, or c series ions and a charge on the C-terminus is termed as x, y, 
or z series ions. 
 
Figure 1.6. y and b ion fragment series. A. Fragmentation at peptide bond. B. Fragments 
formed via y-series and b-series fragmentation. 
1.5.7. Data analysis 
This project utilised Mascot and PeakView software programmes to convert mass spectra 
peaks into tables of the peptides analysed with possible modifications depending on the 
parameters searched within. Mascot is used to translate the mass spectrum peaks into 
easier understandable data. The peaks, corresponding to ions picked up by the mass 
A B 
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spectrometer, can produce a sequence of peptides present in the sample analysed leading 
to the identification of the protein of interest where further analysis can be made. Depending 
on the parameters set, possible modifications can be highlighted due to the probability that 
mass differences equate to a modified amino acid, which is calculated by the Mascot 
programme. The likeliness of the modification being present can range from high to low and 
therefore there is a risk of false positives. This requires confirmation using the second 
programme PeakView for evidence of the existence of the modifications detected by Mascot. 
 In PeakView, the data can be displayed as a total ion chromatogram (TIC) or an information 
dependent acquisition (IDA) spectrum. The total TIC shows the intensity of the ions detected 
against the time of the acquisition method. MS/MS data of the ions can be displayed 
showing fragmentation of the precursor ions with changes in intensity and mass differences, 
which may correspond to a modification. The level of detail gained from the mass 
spectrometer can show isotopic distribution. Therefore, even peptides with variation in mass 
due to an extra neutron can be differentiated. An extracted ion chromatogram (XIC) is useful 
to see where a particular ion mass is most intense during acquisition. Narrow window XIC 
analysis has been used to generate XICs from MS/MS methods to quantify levels of 
oxidation (Tveen Jensen et al. 2013). In an IDA spectrum, the MS/MS data for individual 
precursor ions are shown. Using information from Mascot about a peptide that contains a 
modification, the full MS/MS spectrum is displayed and de novo sequencing can be 
performed for the removal of false positives. De novo sequencing is required for the 
validation of peptides assigned to MS/MS spectra and removal of false positive data arising 
from probability-based software detection. The ease of interpreting MS/MS spectra is 
dependent on the user’s abilities as there are several indicators used to validate a peptide 
sequence with a modification. For the QToF, the basic validation method is the sequencing 
of y-series ions as the dominant fragment ions produced during MS/MS. Amino acid mass 
used for sequencing is the mass of the amino acid with the removal of water (18 Da) to take 
into account the peptide bonds. As the common enzyme used for digestion is trypsin, the 
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starting ion is either 147 Da for lysine or 175 Da for arginine. This is because the structure of 
a y-series ion for any given amino acid is the addition of proton to the amine group [1 Da] 
(Roepstorff, 1984; Johnson, 1987). Once the starting amino acid is found, which should be 
the same as the detected modified peptide assigned by the probability-based software, it is 
simply a case of finding the next ion in the sequence until most of the peptide around the 
region of the modified residue is assigned to ion peaks in the spectra. In most cases this 
alone can be used for validation but in some instances using the y-series ions does not help 
in the sequencing of a peptide. This mainly occurs when the modification is in the high m/z 
region where fewer ions are detected. These residues are nearer to the amine terminal of 
the peptide and therefore require sequencing starting from the opposite end. The 
complementary ion to the y-ion is the b-ion. At this end the starting ion can be any amino 
acid but with a loss of hydroxide ion from the carboxyl acid group [-17 Da] (Roepstorff, 1984; 
Johnson, 1987).  
Sequencing with y & b ions are good indicators of the presence of a modified residue but 
there are also diagnostic ions for additional validation. Immonium ions are most commonly 
used as diagnostic ions for the presence of modifications. They are fragmented ions used as 
markers for a particular amino acid. Immonium ions are charged amino acids that have lost 
their carboxylic acid group, however only some amino acids generate high intensity 
immonium ions: tyrosine, phenylalanine, histidine, and tryptophan. (Falick, 1993; 
Papayannopoulos, 1995). Some diagnostic immonium ions used include: chlorotyrosine (170 
Da) and nitrotyrosine (181 Da) (Tveen Jensen et al. 2013). Using mass spectrometry gives a 
great deal of detailed information on analysed samples and modifications that could lead to a 
decrease or increase in function. Information acquired can be used as biomarkers for 
diseased states or further knowledge for the therapeutic drug targets. 
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1.5.5. High performance liquid chromatography (HPLC) 
HPLC is used for prior separation of samples, before entering the mass spectrometer, based 
on their hydrophobicity. As the study focuses on a mixture of proteins, an isocratic gradient 
is produced with aqueous and solvent solutions to separate eluting peptides when bound to 
a C18 hydrocarbon column. This is termed as reversed phase chromatography. Without the 
prior separation, a mixture of proteins would result in limited information collected to only 
abundant proteins. Through separation more information can be collected from the different 
batches of proteins eluted from hydrophilic to hydrophobic over the course of time. 
Developments in LC-separation are required to reduce sample loading and improve 
separation of proteins/peptides. Gel-eluted liquid fraction entrapment electrophoresis 
(GELFrEE) is a technique that integrates gel electrophoresis separation within reverse 
phase LC. This eliminates the need for prior electrophoresis and sample processing before 
injection into the LC (Tran and Doucette, 2008). The GELFrEE method has been used in the 
detection of nitrotyrosine via the increase in hydrophilicity of nitrotyrosine when reduced to 
aminotyrosine and the aid of diagonal chromatography. The peptide mixture was separated 
and fractionated by reversed phase HPLC followed by reduction by dithionite and then a 
secondary separation was performed to collect fractions with the previously described shift. 
These were analysed with MS to identify nitrotyrosine in the enriched peptide fractions 
(Ghesquiere et al., 2009). The changes incurred by oxPTMs in peptide/protein elution 
properties are advantageous when separating modified peptides for analysis. 
1.5.6. Digestion into peptides 
The gold standard digestion technique for MS is an in-gel trypsin digest. This involves 
cleaving denatured protein, from gel electrophoresis, at the c-terminal arginine or lysine into 
peptide fragments enabling the researcher to follow up with standard bottom-up MS 
techniques. Other methods include; in-solution, on-membrane, on-resin, and on-line 
digestion and the use of other enzymes/double digestion as well as the use of surfactants. 
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To improve digestion efficiency MS friendly surfactants such as ProteaseMax (Promega) 
(Duan et al., 2009; Saveliev et al. 2013) and Rapigest (Waters) (Yu et al., 2005) are added 
and work by further denaturation of proteins to make digestion sites more accessible to aid 
digestion without disrupting enzyme activity. These MS friendly surfactants degrade over the 
course of protein digestion. 
1.6. Protein oxidation in skeletal muscle 
Oxidation in skeletal muscle has been reported for various proteins and for multiple oxPTMs. 
Some of these reports include detection of carbonyl groups from oxyblot analysis, oxidation 
of pyruvate dehydrogenase, higher oxidation present in subsarcolemmal mitochondria, and 
nitrotyrosine detection in carbonic anhydrase to name a few (Sugden, 2000; Vasilaki, 2007; 
Dalla Libera et al. 2010; Crescenzo et al. 2014). More specifically many studies have looked 
at the association of SERCA oxidation to ageing and disease. 
1.6.1. Sarco(endo)plasmic reticulum calcium ATPase and changes corresponding to 
biological ageing 
Sarco(endo)plasmic reticulum calcium ATPase (SERCA) is a calcium pump that uses ATP 
hydrolysis to transport calcium from the extracellular environment into the sarcoplasmic 
reticulum calcium store (Schoneich, et al., 1999). Vascular relaxation, cardiac and skeletal 
muscle relaxation, and cell growth and differentiation can all affected by the regulation of 
intracellular calcium by SERCA (Strosova, et al., 2009a). The protein is around 1000 amino 
acid long and around 110kDa. There are three isoforms of SERCA with their own sub-
isoforms; SERCA1, SERCA2a/b, and SERCA3a/b/c/d/e/f/g. SERCA1 is expressed in fast-
twitch skeletal muscle, SERCA2a is expressed in cardiac and slow-twitch muscle, SERCA2b 
is expressed in smooth muscle and a variety of other tissues, and SERCA3 is also a non-
muscle isoform (Schoneich and Sharov, 2006). In humans SERCA3 has six sub-isoforms, 
however in mouse there are only the three isoforms a, b and c. 
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SERCA switches between two conformational forms where the E1 form has its high-affinity 
calcium binding sites facing the cytoplasm and the E2 form has its low-affinity calcium 
binding sites facing the endoplasmic reticulum lumen (Vandecaetsbeek, et al., 2009). The 
high- and low-affinity calcium binding sites are found in the transmembrane domain of 
SERCA (Voss, et al., 2008). ATP hydrolysis allows the opening and closing of calcium gates 
in the transmembrane domain of SERCA through conformational changes in the cytosolic 
domain. The transmembrane region itself contains ten helices (Vandecaetsbeek, et al., 
2009). The transmembrane helices anchor SERCA to the lipid bilayer and allow the transport 
of calcium. Along with the transmembrane domain, SERCA is comprised of the cytoplasmic 
headpiece and the stalk domain. The cytoplasmic headpiece of the SERCA molecule is 
exposed on the cytoplasmic surface of the membrane. The phosphorylation and nucleotide 
binding domains reside in the cytoplasmic headpiece of SERCA along with four other 
subdomains. The active site of ATP hydrolysis is composed of the phosphorylation domain 
and the nucleotide binding domain which are structurally and functionally closely related. 
The remaining stalk domain bridges a connection between the cytoplasmic headpiece and 
the membrane (Voss, et al., 2008). Figure 1.7A shows the conformational structure of 
SERCA, labelled with the active site Asp351 and redox regulated Cys674. Figure 1.7B is an 
approximate schematic of the SERCA structure. 
41 
 
 
 
Figure 1.7. 3D crystal structure and approximate schematic of SERCA. A. 3D crystal 
structure of SERCA with colour coded domains. B. Schematic of SERCA structure with 
approximate amino acid positions labelled in light blue. 
 
A 
B 
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Isoform SERCA2b has a two times higher calcium affinity and lower catalytic turnover rate 
compared to the other two muscle isoforms SERCA1 and SERCA2a. This is due to 
SERCA2b’s 49 residue lengthened tail at the C-terminus which contains an additional 
transmembrane helix (TM11) and luminal extension (Vandecaetsbeek, et al., 2009). 
Previous studies have shown that when senescent skeletal muscle was compared with 
young skeletal muscle, it had conformationally changed and its stability had decreased. This 
was thought to be linked to muscle weakness in ageing and prolonged relaxation times due 
to decreased calcium uptake by SERCA. The conformational changes were linked to 
SERCA inactivation, protein unfolding, and aggregation in conditions of mild heating. It had 
also been noted that particular residues around the nucleotide binding site (Lys515) such as 
Cys498, Cys525, and Tyr497 would be likely candidates to reduce conformational stability. 
SERCA2a was found to decrease in activity with age compared to SERCA1. This could be 
due to the different oxidative modifications that both isoforms undergo and result in slow-
twitch muscles being more affected by oxidation compared to fast-twitch muscles (Chen, et 
al., 1999). 
More recent studies have now shown that the more important residues include Cys674 
which is the most reactive thiol in SERCA and plays a major role in enzyme activity 
regulation (Dalle-Donne, et al., 2007), and Tyr122 located on the more accessible region of 
the cytosolic domain on the N-terminus (Schoneich, 2005). 
One study in particular compared the nitration of tyrosine in young adult skeletal muscle and 
senescent skeletal muscle. When young adult skeletal muscle was compared with 
senescent skeletal muscle, it showed a 40% decrease in SERCA activity. In young adult 
skeletal muscle there was a value of around 1 mol of nitrotyrosine per mol of SERCA2a 
compared to around 3.5mol of nitrotyrosine per mol of SERCA2a that was found in 
senescent skeletal muscle. The tyrosine residues modified in the young adult SERCA2a 
were: Tyr122, Tyr130, Tyr497, Tyr586, and Tyr990. In the senescent SERCA2a, the tyrosine 
residues modified were the same as the ones in the young adult with additional oxidation at 
Tyr294, Tyr295, and Tyr753. Reduced SERCA activity in ageing was suggested to be 
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related to the nitration of Tyr294, Tyr295, and Tyr753. Further analysis with SERCA2a from 
both young adult and senescent skeletal muscle showed that Tyr753 was present in young 
adult skeletal muscle and Tyr294, Tyr295, and Tyr753 were all present in senescent skeletal 
muscle. This meant that age-related decrease in SERCA activity were most likely due to 
Tyr294 and Tyr295. Confirmation of this involved mutating the Tyr753 residue which showed 
no change to SERCA activity. The study then looked upon the mechanism by which 
modifications to Tyr294 and Tyr295 affected SERCA activity. It was found that oxidation to 
these specific tyrosine residues downregulated ATP utilisation by SERCA. Because both 
tyrosine residues are located on the M4 helix, which is in line with the M5 helix containing 
the phosphorylation site Asp351, the helix to helix interaction is distorted and disrupts the 
coupling of calcium transport with ATP-linked phosphorylation resulting in the prevention of 
optimal rates of active transport (Knyushko, et al., 2005). 
1.6.2. Protein oxidation studies in SERCA 
In some tissues, HOCl concentrations have been reported to reach 200 µM. One study 
showed that SERCA activity was inhibited by 50% in the presence of 170 µM HOCl and was 
completely inhibited by 3mM HOCl. It was found that the 50% inhibition would have 
approximately oxidised two thiol (SH) groups to disulfides disrupting SERCA’s activity. This 
was further supported by using disulfide reducing agents to recover ATPase activity and 
Ca2+ uptake. 55% of the lost ATPase activity was recovered through this. The partial 
recovery gained from this treatment indicated that disulfide bonds were formed through 
HOCl-mediated oxidation. This same study also suggests that oxidation of SH groups by 
HOCl may be linked to conformational changes to the nucleotide binding site within SERCA. 
Also the most likely candidate for this alteration is cysteine as it is 100 times more reactive to 
HOCl compared to the other amino acids (Favero, et al., 1998). 
Lysine residues are a major site of reaction of HOCl with many proteins. Chloramine species 
are produced which decompose to nitrogen-centred protein radicals that induce protein 
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backbone fragmentation and dimerisation. Low sub-lethal doses of HOCl react with thiols 
and can initiate apoptosis whereas high concentrations cause rapid necrosis. HOCl 
decreased SERCA activity by 50% at a 150 µmol/l concentration. Incubation with HOCl also 
resulted in fragmentation as a new band was formed around 75kDa. Structural alteration of 
the ATP nucleotide binding site was assessed through the binding of FITC at specific lysine 
residue Lys515 present in the binding site. The decrease in FITC fluorescence was HOCl 
concentration dependent (Strosova, et al., 2009b). 
Eleven of the thirteen tryptophan residues in SERCA are located in the transmembrane 
domain of the protein whereas the other two are located in the cytoplasmic domain. It was 
found that there was no link between the reduction in SERCA activity following HOCl 
exposure and the conformational changes of the transmembrane domain. However, this is 
different to other oxidants where hydrogen peroxide (H2O2) mediated oxidation showed a link 
between enzyme activation and conformation changes through tryptophan fluorescence 
(Strosova, et al., 2009b). 
One study showed SERCA activity to be reduced to 50% in the presence of the 
Fe2+/H2O2/Ascorbic Acid (AA) Fenton reaction. Oxidation of cysteine led to a decrease in 
thiol groups and the formation of disulphide bonds. Carbonyl formation was also detected 
and fragmentation occurred possibly due to structural alterations which formed two bands: 
~50 and ~75kDa (Voss, et al., 2008). 
Low levels of nitric oxide can protect ryanodine receptor (RyR) from activation by protein 
cross-linking whereas higher levels of nitric oxide result in cysteine S-nitrosation occurring 
which would activate RyR. Nitric oxide’s effect is different to other oxidants such as 
hydrogen peroxide where RyR is inactivated. In comparison to peroxynitrite, nitric oxide is 
more efficient but less selective in cysteine modification of SERCA. Complete modification of 
Cys364 results in a 38% decrease of SERCA activity and labelling of Cys344 and Cys364 
lead to an inactivation of the enzyme. The most reactive cysteine residues to nitric oxide 
were: Cys364, Cys670, Cys471, and Cys349. The locations of the cysteine residues were 
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adjacent to Asp351 phosphorylation site (Cys349 and Cys364), in the nucleotide binding 
domain (Cys471), and before the hinge domain (Cys670) (Viner, et al., 2000). 
Low levels of nitric oxide are also known to be able to activate SERCA through S-
glutathiolation at either Cys669 or Cys674 (Strosova, et al., 2009b). However, at higher 
levels of nitric oxide derived peroxynitrite, SERCA activity is inhibited through irreversible 
oxidation. Cys674 is oxidised to sulphonic acid where the irreversible oxidation prevents S-
glutathiolation and increased activity of SERCA by low levels of nitric oxide or peroxynitrite 
(Adachi, et al., 2004). 
As well as S-glutathiolation, nitric oxide is also able to produce S-nitrosothiol modifications 
(SNO) on cysteine residues. One study showed SNO-adduct formation when SERCA was 
exposed to nitric oxide gas and the mass of peptides, which included cysteine residues in 
their sequence, increased by 29Da (Ying, et al., 2007). 
Previous experiments show a comparison of nitrotyrosine oxidative modifications on 
SERCA2a in old and young rats where the 28 month old rats had 3.5 mols of nitrotyrosine 
per mol of SERCA2a and the 5 month old young rats had 1.0 mols of nitrotyrosine per mol of 
SERCA2a. It was also shown that Tyr294 and Tyr295 when nitrated have an effect on the 
function of SERCA. Both the modified tyrosines in the M4 helix may affect either calcium 
binding or protein conformation around the Asp351 phosphorylation site. Not only do 
tyrosine residues become affected by peroxynitrite but both SERCA1 and SERCA2a are 
shown to have a significant age-dependent loss of reduced cysteine residues. Smooth 
muscle SERCA2 can be activated through S-glutathiolation of Cys669 and/or Cys674 in the 
presence of low concentrations of nitric oxide and peroxynitrite. Higher concentrations result 
in the inactivation of SERCA where the cysteine residues affected most were: Cys614 
(~46%), Cys561 (~45%), Cys674/675 (~40%), and Cys498 (~31%) (Schoneich and Sharov, 
2006). 
One study showed senescent mouse models had around 3.5mol of nitrotyrosine per mol of 
SERCA2a, and this correlated with a decrease in 40% activity. The tyrosine residues 
modified to 3-nitrotyrosine are: Tyr122, Tyr130, Tyr294, Tyr295, Tyr497, Tyr586, Tyr753, 
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and Tyr990. The age-dependent decrease in SERCA activity was shown to be due to 
nitration of Tyr753, Tyr294 and Tyr295. However, it is Tyr294 and 295 that show to play a 
major role in the loss of activity of calcium transport. SERCA1 however does not undergo 
tyrosine nitration and therefore peroxynitrite-mediated protein oxidation results in 1.3mol of 
cysteine oxidation per mol of SERCA1 with a 17% decrease in activity. This decrease in 
activity is found to be related to the oxidation of Cys349. Glutathiolation of Cys674 in the 
presence of low levels of peroxynitrite (10-100 µM) shows a 25-35% increase in activity. 
Higher levels of peroxynitrite result in irreversible oxidation of cysteine to sulfonic acid and 
nitrotyrosine formation which result in a decrease in activity. The location of Tyr294 and 
Tyr295 is important to the effects on activity as they are located on the lumenal end of the 
membrane-spanning helix (M4) in line with the phosphorylation site Asp351. In order to 
couple ATP phosphorylation with calcium transport, the M4 helix is relied upon for high-
affinity calcium binding and so its structure is important. Distortion of the M4 helix will result 
in alteration in helix-helix (M4-M5) interactions and affect optimal rates of active transport by 
SERCA (Knyushko, et al., 2005). In this same study it was also shown that methionine 
sulphoxide was formed as well as nitrotyrosine. These oxidative modifications occurred on 
Met126, Met494, Met508, Met598, Met756, and Met979. 
Another study showed that SERCA1 oxidation with 3mM peroxynitrite resulted in five 
cysteine residues modified in vivo and in vitro: Cys525, Cys674, Cys675, Cys498, and 
Cys938. Cys364, Cys417, and Cys420 were affected only by peroxynitrite in vitro and 
Cys561, Cys636, Cys614, Cys377, and Cys774 were partially lost during in vivo ageing. 
Loss of SERCA activity was shown to correspond to peroxynitrite oxidation at Cys674/675 
and Cys938. It was found that ligand-binding studies showed no significant changes in aged 
SERCA1 Ca2+ or ATP affinity whereas peroxynitrite mediated oxidation inactivated SERCA 
and resulted in a reduction in Ca2+ affinity. This suggested that there were either changes in 
the calcium-binding domains or domains that regulate high-affinity calcium-binding. It was 
also found that there was no detection of cysteine residues that had been modified in the 
vicinity of the high-affinity Ca2+ binding sites. This lead to the implication that the effects on 
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catalytic function by cysteine oxidation could have been caused by a change in protein 
structure resulting in ATP hydrolysis uncoupling from Ca2+ translocation (Sharov, et al. 
2006a). 
When comparing the two isoforms SERCA2a and SERCA1 it was found that in vitro tyrosine 
nitration by peroxynitrite modified different tyrosine residues in each isoform. SERCA1 was 
predominately nitrated at Tyr122 while SERCA2a was predominately nitrated at Tyr294, 
Tyr295, and Tyr753. This contrasted in vivo detection of nitrated tyrosine residues in 
SERCA2a as Tyr122 and Tyr130 were the residues that were modified (Schoneich, 2005). 
Another study showed that Tyr122 modification in skeletal muscle SERCA1 was not 
detected in vivo but had not been detected in vitro nitration. Similarly, Tyr122 and Tyr130 
were found in SERCA2a in vitro peroxynitrite experiments but not in vivo. It has been 
suggested that cellular correction mechanisms might remove the nitrated peptides through 
degradation or nitrotyrosine to tyrosine enzymatic conversion; however, it is not known yet 
what really occurs (Knyushko, et al., 2005). 
1.7. Aim of project 
Many of the previous studies on the effects of oxidation on SERCA have been very specific 
to a particular amino acid. Exploring a more global analysis of protein oxidation determined 
susceptibility of residues to particular modifications. While the study had a particular focus 
on SERCA, other proteins were also analysed. The applications of the MS studies 
determined the role of oxidation in the aged and obese models and led to comparisons to 
determine whether protein oxidation affects the models in a similar or different manner.  
Therefore, the objectives of the project were as follows: 
 To develop mass spectrometry techniques for analysing oxPTMs in mouse muscle. 
 To test the MS methodologies developed in muscle tissue from animals with 
sarcopenia, specifically obesity and aged animals.  
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Chapter 2 
 
Materials & Methods 
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2.1. Materials 
2.1.1. Animals 
Hind legs from 8 months old NMRI (control) and age matched ob/ob (obese) mice were 
obtained from the Aston University Biomedical facility with permission from the licence 
holder: Dr Steve Russell, Aston University. Young (9 months) and aged (2 years & 3 
months) C57BL/6 gastrocnemius mouse muscle was kindly supplied by Malcom Jackson, 
University of Liverpool. Experiments were performed under the guidelines of the United 
Kingdom Home Office in the United Kingdom Animals (Scientific Procedures) Act 1986. The 
animals were culled by cervical dislocation and the muscles were dissected from the hind 
legs. 
2.1.2. Reagents 
PiColorLock Gold kit was obtained from Innova Biosciences, Cambridge, UK. Protease 
inhibitor cocktail cOmplete, EDTA free was purchased from Roche, Welwyn Garden City, 
UK. MS grade formic acid, sodium hypochlorite (NaOCl), thapsigargin, Laemmli buffer, rabbit 
polyclonal anti-nitrotyrosine and mouse monoclonal anti-rabbit IgG (γ-chain specific) horse 
radish peroxidase antibody was also acquired from Sigma-Aldrich, Dorset, UK. MS grade 
trypsin and ProteaseMax surfactant, trypsin enhancer was sourced from Promega, 
Southampton, UK. Instant blue Coomassie stain was acquired from Expedeon, Cambridge, 
UK. Polyvinylidene fluoride (PVDF) membrane and rabbit polyclonal anti-S-Nitroso-Cysteine 
(SNO-Cys) antibody was attained from Millipore, Watford, UK. Tween 20 was purchased 
from Fisher Scientific, Loughborough, UK. SuperSignal West Pico Chemiluminescent 
substrate (ECL reagent) and Pierce Coomassie Plus (Bradford) assay kit was purchased 
from ThermoFisher Scientific, Loughborough, UK. Goat anti-mouse IgG horse radish 
peroxidise antibody, mouse anti-SERCA antibody and mouse anti-calsequestrin antibody 
were obtained from Santa Cruz, Heidelberg, Germany. All other chemicals were sourced 
from Sigma-Aldrich and Fisher Scientific. 
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2.2. Sarcoplasmic reticulum preparation from mouse hind leg skeletal muscle 
Sarcoplasmic reticulum (SR) extraction was performed based on a protocol by MacLennan, 
1970. Mouse skeletal muscle was acquired from hind legs of the different mice models and 
was homogenised using an Ultraturrax in 25 mM PIPES containing 0.3 M sucrose with the 
addition of 1 tablet of the protease inhibitor cocktail per 50 ml buffer. This was centrifuged at 
6500g for 30 minutes at 4°C. A sample was taken at this stage and stored at -80°C for 
analysis of muscle lysate. The supernatant was then further centrifuged at 100,000g for 40 
minutes at 4°C. The pellet was resuspended in 10% sucrose in 25 mM PIPES, pH 7.4. This 
was layered on top of a sucrose gradient made by sequential layers of 2 ml of 40%, 30%, 
20% and 10% sucrose in 25 mM PIPES, pH 7.4 and centrifuged at 100,000g for 18 hours at 
4°C. The interface between 30% and 40% sucrose was recovered and the sucrose 
concentration was lowered by the addition of 2 ml of 25 mM PIPES containing 0.4 M KCl. 
This was centrifuged at 10,000g for 40 minutes at 4°C. The pellet was resuspended in 100 µl 
of 5 mM HEPES containing 0.4 M sucrose with the addition of 1 tablet of protease inhibitor 
cocktail per 50 ml of buffer and stored at -80°C. Methionine was added to all buffers  to give 
a final concentration of 5mM, and they were also bubbled with oxygen-free nitrogen gas to 
reduce the dissolved oxygen. 
2.3. Protein concentration determination of sarcoplasmic reticulum 
Protein concentration was determined by a Bradford assay kit and read by absorbance 
spectroscopy at 570 nm. BSA standards ranged from 25 µg/ml to 2 mg/ml. This was carried 
out by dispensing 10 µl of each standard into a 96 well plate along with the samples from the 
muscle preps. An addition of 300 µl of Coomassie plus reagent was added to each well and 
the plate was incubated at 37°C for 30 mins. The absorbance was read and a linear curve 
was generated from the known concentrations in order to calculate the protein concentration 
of the samples. 
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2.4. Assay of SERCA specific activity through free phosphate release 
SERCA specific activity was determined using a phosphate release assay using Pi colour 
lock gold kit and read by absorbance spectroscopy at 630 nm. Thapsigargin, a known, 
SERCA inhibitor was used to measure function (Lytton, Westlin, and Hanley, 1991). 5 µg of 
the isolated sarcoplasmic reticulum sample was resuspended in 500 µl of assay buffer. The 
assay buffer contained 40 mM HEPES (pH 7.2), 0.1 M KCl, 5.1 mM MgSO4, and 1mM 
EGTA. SERCA activity was detected in the presence of final concentration 1 mM CaCl2 and 
2.1 mM ATP, with and without a final concentration of 100 nM thapsigargin. The control was 
the final concentration of 1 mM CaCl2 and 2.1 mM ATP with the absence of the isolated 
sarcoplasmic reticulum sample. The activity of SERCA was calculated by subtracting the 
rate of phosphate release in the presence of thapsigargin from the rate of phosphate release 
in the absence of thapsigargin. Phosphate (NaH2PO4) standards ranged from 100 µM to 2 
mM. The activity was expressed in µmol of free phosphate min-1. The specific activity was 
calculated by dividing the activity by the amount of sample protein used in the assay in mg, 
to give a value in µmol of free phosphate min-1 mg-1 protein. 
2.5. Oxidant treatment of sarcoplasmic reticulum extracted samples 
For HOCl treatment, sodium hypochlorite (NaOCl) molarity was determined by reading four 
different dilutions of the NaOCl stock in 0.1 mM NaOH using absorbance spectroscopy at 
290 nm with an extinction coefficient of 350. The dilutions were as follows: 1:1000, 1:2000, 
1:2500 and 1:5000. The isolated sarcoplasmic reticulum (5 µg protein) and muscle 
homogenate (25 µg protein) samples was oxidised with NaOCl in 100 mM phosphate buffer 
at total volume of 100 µl for 1 hr at 37°C at molar ratio concentrations varying from 1 µM: 10 
µM to 1 µM: 1 mM (protein: oxidant). Oxidation was stopped by the addition of 5µl of excess 
methionine and dried down to around 10 µl by vacuum centrifugation in an Eppendorf 
concentrator. 
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2.6. 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
10% SDS-PAGE gels were made with acrylamide and bis-acrylamide according to the 
Laemmli method (Laemmli, 1970). Muscle lysate samples (25 µg protein) and SR samples 
(5 µg protein) were solubilised in equal volumes of Sigma laemmli buffer, incubated at 100°C 
for 5 mins, cooled and electrophoresed at a constant 125 V with a pre-stained ladder 
(Fig.2.1). The gel was stained overnight in 45% methanol, 10% acetic acid, and 0.1% 
Coomassie blue. It was then destained in the same solution minus the Coomassie blue. 
Alternatively, the gel was stained with Expedeon Instant blue Coomassie stain. Gels were 
photographed using a Syngene G-box by selecting automatic imaging and choosing the 
Coomassie stained protein gel option. 
 
Figure 2.1. Thermo Scientific PageRuler Plus Prestained Protein Ladder, 10 to 250 
kDa. Molecular weights are pre-stained and so are visible for the duration of the 
electrophoretic separation and prior to staining. MW ~70, ~25 and ~10 are coloured 
differently to allow user to distinguish molecular weights more easily. (Manufacture’s image: 
www.thermofisher.com/order/catalog/product/26619) 
 
 
53 
 
2.7. Western blotting using anti-SERCA, anti-calsequestrin, anti-nitrotyrosine and anti-
nitrosothiol antibodies 
After electrophoresis, the SDS-PAGE gel was sandwiched between western pads, filter 
papers and PVDF membrane (Fig.2.2). Subsequently, the transfer process took place at a 
constant 125 V for 1.5 hr. The PVDF membrane was then placed in blocking reagent (5% 
milk powder in TBST) for 1 hr. Tris buffered saline with Tween 20 (TBST) contained 20 mM 
Tris, 144 mM NaCl, and 0.1% Tween 20 at pH 7.6. Immunostaining was carried out with the 
following primary antibodies. Mouse anti-SERCA (1: 1000), mouse anti-calsequestrin (1: 
1000), rabbit anti-nitrosothiol (1: 1000), and rabbit anti-nitrotyrosine (1: 1000) were diluted in 
TBST containing 2.5% milk powder. The membrane was incubated in primary antibody 
overnight. After washing with TBST, it was transferred to a solution of secondary HRP 
conjugated goat anti-mouse antibody (1:2000) or mouse anti-rabbit antibody (1: 10000) 
diluted in PBS pH 7.3, for 3 hours. After washing with TBST, ECL reagent was made by 
adding equal volumes of the luminol reagent and peroxide reagent to a 1 ml solution and 
poured onto the membrane. The membrane was scanned using a Syngene G-box by 
selecting automatic imaging, chemiluminescence ECL and using the default exposure time. 
 
 
 
 
 
 
Figure 2.2. Assembly of western sandwich. Using a western blot cassette, usually colour 
coded with black and red to represent sides of the cathode and anode, the subsequent 
components were pre-wetted in transfer buffer and layered in the following order: western 
pad, two filter papers, gel, membrane, additional two filter papers and another western pad 
from black to red, carefully removing any air bubbles using a roller or pipette tip. The 
cassette was locked and placed into the tank with transfer buffer. Proteins moved from the 
gel towards the membrane. 
Cathode (-ve) 
Western pad 
Filter papers 
Gel 
Membrane 
Filter papers 
Western pad 
Anode (+ve) 
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2.8. Oxyblotting using anti-DNP antibody 
For oxyblotting, oxidised samples were dried down to 5 µl by vacuum centrifugation and 
12% SDS was added at a 1:1 (v/v). The samples were derivartised by the addition of 10 µl of 
10 mM DNPH in 2M HCl and incubated for 25 minutes at room temperature. They were then 
neutralised by the addition of 7.5 µl of 2 M Tris, 30% glycerol and 19% β-mercaptoethanol. 
Samples were electrophoresed on a 10% SDS-gel and western blotting was carried out as 
described in section 2.7 but with primary rabbit anti-DNP antibody (1:500) and secondary 
mouse anti-rabbit IgG antibody (1:1000). 
2.9. In-gel tryptic digestion of desired excised bands of SR sample 
The desired gel bands were excised from the gel. If the gel was stained with instant blue 
Coomassie stain and the stain was removed with 30% acetone at 60ºC. Gel slices were 
washed in 100 mM ammonium bicarbonate for 1 hour and then in 1:1 100 mM ammonium 
bicarbonate : acetonitrile for another hour. The gel slices were reduced by incubation in 100 
mM ammonium bicarbonate containing 45 mM DTT and for 30 mins at 60°C and then cooled 
and left in the dark with the addition of 100 mM iodoacetamide. Gel slices were washed 
again in 1:1 100 mM ammonium bicarbonate : acetonitrile for 1 hour. Acetonitrile was added 
and after 10 mins the gel bands were dried in a speed vacuum at 30°C for 15 mins. 2 µg of 
MS grade trypsin was added together with 25 mM ammonium bicarbonate and incubated 
overnight at 37°C. The gel slices were centrifuged at 13,000 g for 5 mins and the liquid was 
stored in a fresh microcentrifuge tube. 20 µl of 5% formic acid was added and incubated at 
37°C for 20 mins. 40 µl of acetonitrile was added and further incubated at 37°C for another 
20 mins. Once again, the gel bands were centrifuged at 13,000g for 5 mins and the liquid 
was pooled with the initial extract, and dried in a vacuum centrifuge at 30°C for 45 mins. 
Alternatively, with the use of ProteaseMax surfactant, trypsin digestion was shortened to 1 hr 
at 50ºC with 1 µg of trypsin in 0.01% ProteaseMax: 50 mM ammonium bicarbonate. 
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2.10. Settings for QToF system 
2.10.1. NanoHPLC for the QToF system 
Eluent A consisted of 98% water, 2% acetonitrile, and 0.1% formic acid and Eluent B 
contained 98% acetonitrile, 2% water, and 0.1% formic acid. Digested peptides were eluted 
using a Dionex Ultimate 3000 nano-high performance liquid chromatography (HPLC) 1 hr 
elution programme. The autosampler was set to take 10 µl of the sample from the sample 
vial, which was initially retained on a C18 Acclaim 300 μm I.D. x 15 cm trap and then 
separated on a C18 Acclaim PepMap100 75 µm I.D. x 15 cm 3 µm particle size 
nanocapillary HPLC column.  The HPLC gradient was as follows: from 0-4 min 2% Eluent B, 
from 4-49 min 45% B, from 49-50 min 90% B, from 50-54 min 90% B, from 54-55 min 2% B, 
and from 55-65 min 2% B (Fig.2.3). The loading pump was set at a flow rate of 30 µl/min of 
Eluent A and the nano pump was set to a flow rate of 0.3 µl/min.  
 
 
Figure 2.3. Reversed phase elution profile of sample run on nanoHPLC. First 5 min 
account for dead volume. The rest of the gradient is explained in section 2.10. 
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2.10.2. Tandem Mass spectrometry on the QTOF system 
Digested samples were analysed using 5600 QTOF mass spectrometer (AB SCIEX, 
Warrington, UK) using electrospray ionisation (ESI). The source temperature was set at 
150°C with a curtain gas flow of 25, a source gas of 12, ion spray voltage of 2.5kV and a 
declustering potential of 50. For the information dependent acquisition (IDA) experiment, 
survey scans were collected for 0.25 sec in QToF MS positive ion mode for a mass range 
m/z 350 to 1250. IDA parameters were set to select charge states between 2 to 5 and 
signals which exceeded 200 cps. Isotopes were excluded within 3 Da with a mass tolerance 
of 50 ppm, and former target ions were excluded for 12 sec. The maximum number of 
candidate ions monitored per cycle was 10. For the product ion scans rolling collision energy 
was enabled with collision energy spread set at 15 and an accumulation time of 0.2 sec in 
positive ion mode and high sensitivity. The mass range was set to 50 to 2000 Da  
2.10.3. Pseudo-Multiple reaction monitoring on the QTOF system 
Source settings were the same as above. For MRM, product ion scans were collected with 
an accumulation time of 0.2 sec in positive ion mode. Mass ranges were set depending on 
peptides of interest and Skyline software (University of Washington) was used to analyse the 
data (MacLean et al. 2010). This was done with high sensitivity and unit resolution with a 
declustering potential of 50. Collision energy was calculated using the equation y=0.044x+5 
for 2+ charge ions and y=0.05x+4 for 3+ charge ions. The several variations of the targeted 
scans are explored in section 3.2.4. 
2.11. Settings for QTRAP system 
2.11.1. NanoHPLC for the QTRAP system 
Eluent A consisted of 98% water, 2% acetonitrile, and 0.1% formic acid and Eluent B 
contained 98% acetonitrile, 2% water, and 0.1% formic acid. Peptides were eluted using a 
Dionex Ultimate 3000 high performance liquid chromatography (HPLC) system. The 
autosampler was set to take 10 µl of sample from the sample vial which was initially trapped 
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on a C18 Acclaim 300 μm I.D. x 15 cm trap and then separated on a C18 Acclaim 
PepMap100 75 µm I.D. x 15 cm 3 µm particle size HPLC column. The HPLC gradient was 
as follows: from 0-4 min 5% B, from 4-49 min 40% B, from 49-51 min 90% B, from 51-56 min 
90% B, from 56-58 min 5% B and from 58-63 min 5% B. Loading pump was set at a flow 
rate of 30 µl/min of Eluent A and Micro pump was set to a flow rate of 0.2 µl/min generated 
by a 1:1000 flow splitter. 
2.11.2. Multiple reaction monitoring settings 
Digested samples were analysed with an AB Sciex 5500 Q-TRAP mass spectrometer (AB 
SCIEX, Warrington, UK) using nanoESI in positive ion mode. Source collision gas was set to 
high with curtain gas of 20, ion source gas of 13 and ion spray voltage of 2.4kV with a 
declustering potential of 50, entrance potential of 10, and collision cell exit potential at 12. 
For the MRM scans, transition masses were set depending on peptides of interest analysed 
and Skyline software (University of Washington) was used to analyse the data. Resolution 
for both Q1 and Q3 was set at unit and collision energy was calculated using the equation 
y=0.044x+5 for 2+ charge ions and y=0.05x+4 for 3+ charge ions. For Enhanced MS, the 
mass range was set to between 400 and 1000 Da and scan rate was 10000 Da/sec. 
Declustering potential was set to 50, entrance potential to 10, collision energy to 10 and 
dynamic fill time enabled with ion densities set at the instrument default. The Q3 entry barrier 
was set to 8V. 
2.12. Data analysis 
Raw data files (.wiff) produced from MS runs were converted by PeakView (AB SCIEX, 
Warrington, UK) software (.mgf) to run Mascot analysis (Matrix Science, London, UK) 
(Perkins et al. 1999). The spectra generated from MS were matched against the SwissProt 
database to identify the proteins and modifications within the samples. Each sample file was 
analysed with the parameters shown in Table 2.1. While not all modifications were run in one 
search, separate searches with the different combinations of modifications were performed 
and the results were amalgamated.  
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Table 2.1. Parameters used for MS/MS analysis with Mascot. All parameters except 
variable modifications were used as a standard setting for each Mascot run. 
Parameter Setting 
Taxonomy Mus musculus 
Database SwissProt 
Enzyme Trypsin 
Max. missed cleavages 1 
Peptide charge 2+, 3+, and 4+ 
Peptide tolerance 0.5 Da 
MS/MS tolerance 0.5 Da 
Instrument ESI-QUAD-TOF 
Fixed Modifications Carbomidomethyl (C) 
Variable modifications Oxidation (M), Oxidation (Y), Oxidation (P), Oxidation (HW), 
Dioxidation (M), Dioxidation (W), Trioxidation (C), Nitro (Y), 
Chlorination (Y), Allysine (K) 
 
Protein hits were assessed by a Mascot score of over 50 and an ion score of more than 20. 
Peptides reported as modified were validated by manual de novo sequencing using 
PeakView software (AB SCIEX, Warrington, UK). PeakView software was also used for 
MRM analysis of raw data files (.wiff) generated from MRM runs. 
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2.13. Online software 
Protein Analysis Through Evolutionary Relationships (PANTHER) is an online tool that was 
used to categorise proteins upon their biological functions. PANTHER is part of the Gene 
Ontology Reference Genome Project and is supported by the Thomas Lab at the University 
of South California (Thomas et al. 2003). The list of protein IDs were submitted using a txt. 
document format to the online tool. Panther then categorised the proteins and displayed the 
results in a pie chart format. The data was then taken from the online tool to express 
changes in protein detection by MS/MS. 
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Chapter 3 
 
Development of mass 
spectrometry methods for the 
identification and quantification of 
oxidised proteins in muscle  
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3.1. Introduction 
In order to build a set of methods to explore the effects of oxidative stress to the muscle 
proteome, a series of developmental procedures were undertaken during the course of the 
study to generate a workflow best suited to the application of MS technology in oxPTM 
detection. Many studies in the literature encompass emerging techniques and improvements 
to the gold standard procedures widely used in the MS field. More specifically, numerous 
methods have been generated for the assessment of oxidative modifications in both in vitro 
and in vivo systems to determine the role of these modifications in diseased and aged 
models (Berlett & Stadtman, 1997; Sharov, et al. 2006a). 
3.1.1. Oxidation in muscle 
Oxidants in the muscle under healthy circumstances are generally maintained by the body’s 
redox homeostasis. These include adaptive and protective mechanisms most notably 
including enzymes such as methionine sulphoxide reductase (MSR) to reverse methionine 
oxidation (Stadtman, Moskovitz and Levine, 2003). Some oxidants even play a role in 
maintaining redox homeostasis, e.g. nitric oxide has a role in vascular dilation (Joyner and 
Dietz, 1985). Research has suggested basal levels of oxidation are better for the adaptive 
system (Yan, 2014). As discussed in the introduction, the imbalance of the redox system can 
lead to excess oxidant production and damage to surrounding biomolecules. This imbalance 
has been suggested to occur in diseases and ageing although many would refute the theory 
that oxidants are the cause of disease or ageing progression. 
3.1.2. Methods for detecting oxidative stress 
In order to understand what the association is between oxidative stress and these diseases, 
MS techniques were employed. MS is a quantitative tool used to detect post-translational 
modifications (PTMs). It uses soft ionisation to charge the peptides of a digested protein and 
detects these ions that are deflected by an electromagnetic field. The separated peptides 
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can be further fragmented to produce a fingerprint sequence to determine the position and 
identification of the PTM. The limiting factor of this method is that the detection is of 
abundant peptides. Searching for low abundance modifications is difficult. To get around this 
problem, in vitro oxidation was used to generate different levels of modification and possibly 
increasing abundance of low level modifications to detectable levels. 
3.1.4. Aims 
This chapter focuses on three aspects of methodology development: optimisation of sample 
processing methods with focus on sequence coverage and regulation of oxidative artefacts 
using the control (NMRI mice), preliminary development of MS techniques using in vitro 
oxidised samples, and further optimisation of quantitative MS methods for in vivo samples. 
These three core subjects demonstrated the workflow undertaken to attain methods best 
suited for the identification and quantitation of oxPTMs of muscular proteins. 
The aim of this study was to optimise current MS methods used for the analysis of oxidative 
modifications of proteins for the application of non-labelling approaches to characterise and 
quantify oxPTMs in muscle tissue. 
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3.2. Results 
Cleared muscle homogenate and isolated sarcoplasmic reticulum were obtained from the 
hind leg of the mice models to assess the need for sample purification prior to MS for the 
identification and quantification of oxPTMs. This allowed investigation of whether MS 
methods are sensitive enough for characterisation and quantitation in a complex mixture of 
proteins, such as that in the muscle homogenate, or whether a purified sample is required to 
lessen competing proteins and increase the abundance of specific proteins within the 
sample. By isolating the SR, and assuming good purification of the sample, the majority of 
peptides within the sample should originate from SR proteins. In order to test the limitations 
of these two types of samples, it is important to produce methods that optimise the efficiency 
of the MS analysis. 
3.2.1. Optimisation of sequence coverage in isolated sarcoplasmic reticulum and 
cleared muscle homogenate 
First and foremost an attempt was made to optimise the sequence coverage of proteins in 
the control model so that sufficient coverage was attained to maximise the number of 
modifications detected by MS. The first step in this study was to compare SERCA sequence 
coverage in both the MH and SR samples through gold standard tryptic digestion (Fig. 3.1). 
The band at around 100 kDa molecular weight (MW) was excised, proteins were then 
subjected to tryptic digestion and the resulting peptides from the digestion were submitted to 
a MS/MS search using the QToF instrument. Higher sequence coverage was found in SR in 
comparison to MH which was expected as the steps to isolating SR removes proteins and 
therefore there was a higher abundancy of SERCA within the band cut around the 100 kDa 
MW. With fewer competing proteins the top hits are more likely to include the abundant 
protein of interest. In this case, more peptides from SERCA were detected as the top 
abundant ions and selected for fragmentation for MS/MS. 
64 
 
 
S
R
M
H
0
2 0
4 0
6 0
8 0
S a m p le s
S
e
q
u
e
n
c
e
 c
o
v
e
r
a
g
e
 (
%
)
 
Figure 3.1. SDS-page gel scans of isolated SR and MH and corresponding sequence 
coverages of SERCA. A. Protein ladder loaded in lane 1 and isolated SR in lane 2. B. 
Protein ladder in lane 1 and MH in lane 2. The red boxes highlight where SERCA protein 
resides according to its molecular weight. C. Difference in SERCA sequence coverage for 
SR and MH samples. *P<0.05 (Unpaired t-test). 
 
Protein: SERCA1 
Sequence Coverage: 48% 
 
     1 MEAAHSKSTE ECLSYFGVSE TTGLTPDQVK RHLEKYGPNE LPAEEGKSLW  
    51 ELVVEQFEDL LVRILLLAAC ISFVLAWFEE GEETVTAFVE PFVILLILIA  
   101 NAIVGVWQER NAENAIEALK EYEPEMGKVY RADRKSVQRI KARDIVPGDI  
   151 VEVAVGDKVP ADIRILSIKS TTLRVDQSIL TGESVSVIKH TDPVPDPRAV  
   201 NQDKKNMLFS GTNIAAGKAV GIVATTGVST EIGKIRDQMA ATEQDKTPLQ  
   251 QKLDEFGEQL SKVISLICVA VWLINIGHFN DPVHGGSWFR GAIYYFKIAV  
   301 ALAVAAIPEG LPAVITTCLA LGTRRMAKKN AIVRSLPSVE TLGCTSVICS  
   351 DKTGTLTTNQ MSVCKMFIID KVDGDVCSLN EFSITGSTYA PEGEVLKNDK  
   401 PVRAGQYDGL VELATICALC NDSSLDFNET KGVYEKVGEA TETALTTLVE  
   451 KMNVFNTEVR SLSKVERANA CNSVIRQLMK KEFTLEFSRD RKSMSVYCSP  
   501 AKSSRAAVGN KMFVKGAPEG VIDRCNYVRV GTTRVPLTGP VKEKIMSVIK  
   551 EWGTGRDTLR CLALATRDTP PKREEMVLDD SAKFMEYEMD LTFVGVVGML  
   601 DPPRKEVTGS IQLCRDAGIR VIMITGDNKG TAIAICRRIG IFSENEEVTD  
   651 RAYTGREFDD LPLAEQREAC RRACCFARVE PSHKSKIVEY LQSYDEITAM  
   701 TGDGVNDAPA LKKAEIGIAM GSGTAVAKTA SEMVLADDNF STIVAAVEEG  
   751 RAIYNNMKQF IRYLISSNVG EVVCIFLTAA LGLPEALIPV QLLWVNLVTD  
   801 GLPATALGFN PPDLDIMDRP PRSPKEPLIS GWLFFRYMAI GGYVGAATVG  
   851 AAAWWFLYAE DGPHVSYHQL THFMQCTEHN PEFDGLDCEV FEAPEPMTMA  
   901 LSVLVTIEMC NALNSLSENQ SLLRMPPWVN IWLLGSICLS MSLHFLILYV  
   951 DPLPMIFKLR ALDFTQWLMV LKISLPVIGL DELLKFIARN YLEG 
 
Figure 3.2. Representative sequence coverage of SERCA attained by tryptic digestion. 
Peptides identified by MS are shown in red. Regions highlighted in yellow correspond to 
transmembrane domains. 
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Although higher sequence coverage was obtained with SR, there was still around 40% of the 
protein undetected which mostly covers the hydrophobic regions of the protein (Fig.3.2). 
According to the Expasy PeptideMass tool and the parameters set, the maximum sequence 
coverage that should be attained with tryptic digestion is approximately 68.5% 
(Supplementary Fig.3.1). The in silico digest showed large uncovered areas of SERCA 
containing very few lysine and arginine residues which represents the transmembrane 
region of the protein. This is concurrent with the data from Fig.3.2; however, there was 
approximately 5-10% of the sequence covered by the PeptideMass tool that was not 
detected in the discovery MS/MS analysis. In an attempt to improve the sequence coverage, 
ProteaseMax, a surfactant used to expose inaccessible digestion sites, was added to the 
trypsin reaction incubation to determine whether higher sequence coverage could be gained, 
but the results showed that any overall increase found was insignificant (Fig. 3.3). Additional 
means to improve sequence coverage included the use of iodosobenzoic acid which cleaves 
at tryptophan residues (Fontana et al. 1983). Although iodosobenzoic acid resulted in the 
detection of two peptides within the transmembrane region of the sequence, this was 
coupled with loss of peptide detection in other areas resulting in no sign of improvement in 
overall coverage (data not shown). Therefore subsequent experiments were continued with 
trypsin in the presence of ProteaseMax. Although ProteaseMax did not improve the 
coverage significantly, it did nevertheless reduce the digestion incubation to one hour, 
allowing completion of the protocol in one day rather than two, therefore giving a more time-
efficient protocol.  
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Figure 3.3. Comparison of sequence coverage of SERCA and other proteins in SR 
samples with and without surfactant. A. Sequence coverage of SERCA with absence of 
surfactant represented as a purple bar and presence of surfactant represented as a red bar. 
Unpaired t-test showed data to be insignificant from triplicate values (P>0.05). B. Coverage 
from other proteins: Actin, cytochrome b, creatine kinase, transitional endoplasmic reticulum 
ATPase (TERA), 2-oxoglutarate dehydrogenase (2-OD). This data is representative of one 
of the replicates from the triplicates used in the above data (A). 
 
 
 
 
A 
B 
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3.2.2. Regulation of oxidation arising from experimental procedures 
While it important to increase the number of modified residues detected during MS, there is 
also a need to regulate oxidative artefacts that arise from the experimental processing and 
storage. A number of measures were taken to limit production of these artefacts, including 
the addition of exogenous methionine to the buffers. As methionine is the most susceptible 
amino acid to oxidation, theoretically it should act as an antioxidant and reduce oxidation of 
protein residues within the sample (Levine et al. 1996; Hawkins and Davies, 1999). 
Experiments were carried out to determine how effective the addition of exogenous 
methionine was at minimising oxidative artefacts. Several residues were quantified using a 
narrow window XIC approach, discussed earlier in section 1.5, which utilises the data from a 
discovery MS/MS method and quantifies the intensity of the precursor ion based on the 
retention time of the peptide without the need for setting up additional targeted experiments. 
Changes in methionine oxidation (OxM) in SERCA were compared between samples in the 
presence of the exogenous methionine and the absence of the scavenger (Table 3.1). The 
results demonstrate that similar residues were oxidised in both sets of sample; however, with 
the exception of Met452, higher levels of OxM were found in the absence of the methionine 
scavenger. Furthermore, Met250 from ADP/ATP translocase, Met327 from Actin alpha and 
Met757 from SERCA show a substantial difference in percentage modification. As the 
analysis was carried out by narrow window XIC analysis there is a chance that quantitation 
is influenced by co-eluting peptides with isobaric masses. Accurate determination of the 
levels of oxidation within the two samples would require MRM analysis where quantitation is 
based on the product ion intensity generated from the fragmentation of the precursor ion. 
Nevertheless, the data strongly support the value of methionine as an antioxidant in vitro. 
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Table 3.1. OxM in control SR samples with the presence of an oxidant scavenger 
(exogenous methionine) and the absence of the scavenger. Table shows peptide of 
SERCA with modified residue highlighted in red and corresponding percentage modification 
(±S.D.) *Significant difference (p<0.05) between presence and absence of methionine 
determined by an unpaired t-test (n=3). 
 
Residue Sequence 
Percentage modification 
With Methionine Without Methionine 
SERCA 
Met452 MNVFNTEVR 
17.4%±4.4 17.4%±4.8 
Met452 MNVFNTEVR 
Met757 AIYNNMKQFIR 
54.4%±0.9 80.1%±0.3* 
Met757 AIYNNMKQFIR 
Met969 ALDFTQWLMVLK 
80.2%±2.1 87.0%±9.2 
Met969 ALDFTQWLMVLK 
ADP/ATP translocase 1 
Met250 GADIMYTGTLDCWR 
34.2%±3.7 47.8%±3.4* 
Met250 GADIMYTGTLDCWR 
Actin alpha 
Met327 EITALAPSTMK 
19.7%±1.2 79.2%±0.9* 
Met327 EITALAPSTMK 
 
3.2.3. In vitro oxidation using hypochlorous acid and peroxynitrite 
After studies on limitation of oxidative artefacts and optimisation of the sequence coverage, 
in vitro oxidation was performed to generate a database of modifications for oxidised 
proteins in SR and MH samples for a range of oxidant concentrations. The oxidant 
concentrations used are given as protein: oxidant molar ratio and have been used to not only 
determine the susceptibility of residues within proteins but also to facilitate the production of 
targeted methods for quantitation. Incubating the samples at different concentrations 
provided an overview on which residues require minimal oxidant concentrations to be 
modified and at which concentrations a higher oxidative state is achieved. The two oxidants 
used in the in vitro experiments were hypochlorous acid (HOCl) and peroxynitrite (ONOO-). 
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Both oxidants not only oxidise but also have a secondary modifying nature; chlorination and 
nitration respectively, as explained in section 1.4. 
3.2.3.1. Imunoblotting for carbonyl groups within SR and MH oxidised with HOCl and 
ONOO- 
To evaluate the effects of HOCl oxidation on SERCA, SR samples were oxidised in a 
protein: oxidant molar ratio of 1:10, 1:25, 1:50, 1:100, 1:250, 1:500, and 1:1000 along with 
the control sample in the absence of oxidant. Western blotting with anti-SERCA antibody 
verified which bands contain SERCA (Fig.3.4A). In all samples, a band was observed above 
the 100 kDa protein mark where the 110 kDa membrane protein was expected to appear. 
However, this was not the only band to be identified in the western blot. There were two 
additional bands present; one band near to the stacking of the polyacrylamide gel in all the 
samples and the other at 75 kDa, only in the oxidised samples. These two additional bands 
suggested aggregation and fragmentation of the protein, which means that excising just the 
band at ~100 kDa would lead to bias selectivity. To avoid limiting detection of modifications 
to non-aggregated or non-fragmented bands and also leading to inaccurate quantitation, 
future experiments involved using the GeLC approach as an alternative method where bias 
selectivity is avoided (Shevchenko et al. 2007). 
In the OxyBlot, a difference can be seen between the control, 1:10-500, and 1:1000 (protein: 
oxidant molar ratio) (Fig.3.4B). The carbonyl detection showed increased carbonyl formation 
in the oxidised samples compared to the control sample; however, carbonyl formation could 
not be discerned from 1:10-500 (protein: oxidant) treatments. Only the 1:1000 oxidised 
SERCA showed a distinct difference in protein carbonyl formation to the others. Additionally, 
there is a band around 60 kDa which is not present in the blot probed with anti-SERCA and 
therefore indicates carbonyl formation on other proteins. Although carbonyl detection gives 
an impression of the overall oxidation of the SERCA protein, it does not provide additional 
information on the characterisation and location of the oxidised residues within the protein. 
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Figure 3.4. Western blot and OxyBlot with increasing protein: oxidant concentrations 
of HOCl oxidised SERCA from left to right. A. Western blot of HOCl oxidised SERCA with 
anti-SERCA antibody. B. OxyBlot of HOCl oxidised SERCA with anti-DNP antibody. 
Similarly, MH was oxidised at the same varying protein: oxidant molar concentrations with 
the oxidants to demonstrate the effects of the oxidant. Figure 3.5 shows the effects of 
ONOO- on carbonyl group production at concentrations between 1:10 - 1:1000. An increased 
level of carbonyl groups can be seen when comparing concentrations between 1:10 - 1:100 
to the control. The major changes occured at protein: oxidant ratios above 1:100. It can be 
deduced that oxidant concentrations above 1:100 lead to fragmentation of proteins, which is 
why a large dense band can be seen at lower molecular weights. Interestingly, very little is 
present at 1:1000 which could be due to excessive fragmentation and aggregation leading to 
a substantial loss of protein. To obtain a more quantitative view of the changes in carbonyl 
formation, the lanes of the oxyblot were quantified using densitometry and the results 
displayed in a bar chart (Fig. 3.5B). Carbonyl groups increase from the control to 1:250. After 
this concentration there is a decline in carbonyl groups, which may reflect alternative forms 
of oxidative modification. The immunoblotting demonstrated increased protein instability at 
higher concentrations of oxidants and a rough guide to which areas of the gel contained high 
levels of modification. However, obtaining more detailed information on the characterisation, 
Fragment of SERCA 
Aggregates of SERCA 
71 
 
location, and relative quantification of oxidised residues required MS/MS as an alternative 
method for analysing protein oxidation. 
  
 
Figure 3.5. Levels of carbonyl groups in MH oxidised with ONOO-. A. Oxyblot with anti-
DNP. B. Densitometry of above oxyblot. Error bars displayed as S.E.M (n=3).  
3.2.3.2. Characterisation of oxidised residues in HOCl and ONOO- oxidised SR and MH 
samples 
After immunoblotting was performed to determine the levels of oxidation in both the SR and 
MH samples at varying concentrations, MS/MS analysis was carried out using a QToF 
instrument to identify oxidative modifications and locate the residues that were modified. 
Although there have been many publications that have used in vitro oxidation to identify 
oxidative modifications, many of these focus on modifications within a selected protein. This 
study also mainly focuses on SERCA modifications but modifications in other proteins were 
also of interest and some were investigated. An advantage of using both SR and MH 
samples was that an increased number of SERCA peptides could be screened due to higher 
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sequence coverage in the SR sample, while more modified peptides including abundant 
non-SR proteins could be detected in MH samples. To illustrate the effects of oxidants on 
protein detection in MS/MS, a table of the top 10 proteins hits within the GeLC band 1 (area 
around 250 kDa MW) of MH, excised at MW100-250, for each oxidant treatment and its 
control was produced (Table 3.2). The top 10 hits are ordered by a Mascot score based on 
an algorithm combining the sequence coverage and peptide spectral matches to define the 
highest confidence protein matches (Perkins et al. 1999). The increase in oxidant 
concentrations changes the positioning of the proteins, affecting some proteins more than 
others. An example of this can be seen when comparing glycogen phosphorylase to 
SERCA. Glycogen phosphorylase is the top hit for all treatments bar 1:1000; however, the 
same pattern is not seen with SERCA. For many of the concentrations between the control 
and 1:100, SERCA is the second highest hit but between concentrations 1:250 and 1:1000 
there is a drop in the position of SERCA within the list. When this is coupled to the sequence 
coverage of the protein, SERCA drops from an average of 29.8 ± 4.9% (≤1:100) to an 
average of 15.7 ± 9.7% (≥1:250). On the other hand, glycogen phosphorylase maintains 
consistently high sequence coverage from 1:250 and 1:500 but drops from an average of 
44.6 ± 4.5% (≤1:500) to 6%  at 1:1000. Another notable difference is the change in Mascot 
scores throughout the treatments, where a high the Mascot score corresponds to high 
confidence that the protein is correctly identified. Additionally, creatine kinase is the only 
protein in the list that maintains a relatively high sequence coverage throughout all the 
treatments, with sequence coverages fluctuating between 25-39%. In fact, it seems to rise in 
sequence coverage at higher concentrations of 1:100 and 1:500, unlike the other proteins. 
These changes could reflect differential susceptibilities of the muscle homogenate proteins 
to oxidation by HOCl. The changes in Mascot score and sequence coverage demonstrates 
the effects of oxidation on MS analysis and illustrates the additional challenges of studying 
protein oxidation. 
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Table 3.2. Top 10 protein hits of MH oxidised with HOCl at a 1:500 (protein: oxidant molar ratio) with corresponding mascot scores 
and sequence coverages. Results were taken from a representative sample of GeLC band 1 covering area around 250 kDa MW. 
Top 10 hits  Mascot score Sequence coverage (%) 
Band 1 (Control) 
1 Glycogen phosphorylase  1092 37 
2 SERCA1  850 24 
3 Keratin type I  409 11 
4 Creatine kinase  316 25 
5 Keratin type II  315 5 
6 Glyceraldehyde-3-phosphate dehydrogenase  313 37 
7 Filamin C  177 2 
8 Fuctose bisphosphate adolase A  70 3 
9 Xyloside xylosyltransferase 1  43 8 
10 Lysozyme g-like protein 2  35 4 
Band 1 (1:10) 
1 Glycogen phosphorylase  2493 50 
2 SERCA1  1328 37 
3 Glyceraldehyde-3-phosphate dehydrogenase  1036 42 
4 Creatine kinase  940 37 
5 Filamin C  795 12 
6 Fuctose bisphosphate adolase A  186 11 
7 Keratin type II  143 6 
8 Keratin type I  123 5 
9 L-lactate dehydrogenase A chain  109 12 
10 Hemoglobin subunit alpha  107 30 
Band 1 (1:25) 
1 Glycogen phosphorylase  2471 46 
2 Creatine kinase  1357 37 
3 SERCA1  1092 30 
4 Glyceraldehyde-3-phosphate dehydrogenase  1029 49 
5 Filamin C  834 14 
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6 Fuctose bisphosphate adolase A  266 22 
7 Keratin type I  189 7 
8 Hemoglobin subunit alpha  186 30 
9 Hemoglobin subunit beta  170 44 
10 Keratin type II  165 4 
Band 1 (1:50) 
1 Glycogen phosphorylase  1822 44 
2 SERCA1  1158 27 
3 Creatine kinase  989 37 
4 Filamin C  613 12 
5 Glyceraldehyde-3-phosphate dehydrogenase  600 45 
6 Keratin type II  294 9 
7 Keratin type I  291 10 
8 Fuctose bisphosphate adolase A  218 16 
9 Glycogen starch synthase  110 7 
10 Hemoglobin subunit alpha  100 30 
Band 1 (1:100) 
1 Glycogen phosphorylase  2253 41 
2 SERCA1  1522 31 
3 Creatine kinase  1106 39 
4 Filamin C  1093 17 
5 Glyceraldehyde-3-phosphate dehydrogenase  703 45 
6 Keratin type I  227 7 
7 Fuctose bisphosphate adolase A  194 15 
8 Keratin type II  191 11 
9 AMP deaminase 1  157 13 
10 Glycogen starch synthase  152 7 
Band 1 (1:250) 
1 Glycogen phosphorylase  3220 49 
2 Creatine kinase  1988 36 
3 Pyruvate kinase  1069 38 
4 Beta enolase  807 28 
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5 SERCA1  659 18 
6 Fuctose bisphosphate adolase A  608 31 
7 Glyceraldehyde-3-phosphate dehydrogenase  445 30 
8 Keratin type II  354 10 
9 Keratin type I  305 11 
10 Phosphoglycerate mutase 2  233 24 
Band 1 (1:500) 
1 Glycogen phosphorylase  2861 45 
2 Pyruvate kinase  1445 37 
3 Creatine kinase  1140 39 
4 SERCA1  878 24 
5 Glyceraldehyde-3-phosphate dehydrogenase  666 43 
6 Fuctose bisphosphate adolase A  573 32 
7 Filamin C  502 10 
8 Beta enolase  490 25 
9 Keratin type II  416 7 
10 Keratin type I  416 11 
Band 1 (1:1000) 
1 Creatine kinase  587 25 
2 Keratin type I  461 10 
3 Pyruvate kinase  367 18 
4 Keratin type II  355 11 
5 Fuctose bisphosphate adolase A  258 17 
6 Glycogen phosphorylase  192 6 
7 SERCA1  132 5 
8 Glyceraldehyde-3-phosphate dehydrogenase  121 18 
9 Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase 
complex 
 98 10 
10 Xyloside xylosyltransferase 1  48 2 
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When mining the data retrieved from Mascot on the modifications detected within the 
samples, it was important that the modifications found were validated using de novo 
sequencing. There are times when using probability based software such as Mascot can 
result in mistakes. The search engine relies on matching the ions of a MS/MS spectrum to a 
theoretically generated database and determining the best fit according to the parameter 
input when submitting the search. When including variable modifications within the search, 
the software has to determine whether the unknown spectrum originates from a native 
peptide or modified peptide. To illustrate this, a spectrum of a peptide incorrectly identified 
as an oxidised peptide from SERCA is shown (Fig.3.6). After manual sequencing, the 
spectrum was determined to be a native peptide from creatine kinase. The initial step was to 
sequence the spectrum from the raw data file assuming the peptide identification by Mascot 
was correct. When the data failed to support the Mascot sequence, it was considered as a 
false positive, and the following step was to identify what series of amino acids best fit the 
fragmentation data. When an appropriate number of amino acids had been identified, the 
sequence was searched in Pubmed BLAST with Swissprot and Mus Musculus as selected 
for the database and taxonomy, and a list of potential proteins the sequence could have 
originated from was retrieved. The last step was to find a possible trypsin-digested sequence 
that matched the de novo sequenced spectrum and the precursor ion mass. For this 
particular example, the peptide was found to be an unmodified peptide, SFLVWVNEEDHLR, 
from creatine kinase. Other minor mistakes made by Mascot also included ions that were not 
identified in the MS/MS dataset (Fig 3.7). Overall, de novo sequencing has proved to be a 
valuable technique that users should implement in their workflow to filter out false positive 
data, especially in proteins containing PTMs. Nevertheless, Mascot is a powerful tool that 
aids the user in fast and efficient searches of protein and peptide identification that would not 
be possible on manual sequencing alone.  
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Figure 3.6. Mascot assignment of MS/MS spectrum to incorrect peptide and protein. A. Mascot output of SERCA sequence matched to 
spectrum. B. De novo sequenced MS/MS spectrum from raw data file. C. BLAST search results with queried peptide highlighted in yellow.
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Figure 3.7. Unallocated ion present in raw MS/MS files and highlighted in de novo 
sequenced spectrum. A. Detected ions by Mascot. B. De novo sequenced peptide showing 
ion is present in raw data.  
 
As well as filtering out false positive data, there are many sequenced peptides that confirm 
the presence of modifications (Fig.3.8). The MS/MS spectra of four modified peptides 
demonstrate the different types of sequencing involved. The types of sequencing included 
sequencing of a single modification in a peptide (Fig.3.8A&C), multiple modifications within a 
peptide (Fig.3.8B), and a modification at a terminus of a peptide (Fig.3.8D). Moreover, the 
detection of immonium ions provides further evidence for the presence of modifications in 
the samples. Immonium ions are generated when high amounts of collision energy create a 
charge on the amine group of an amino acid (Falick et al., 1993). In the case of ClTyr, the 
immonium ion of tyrosine, which is 136 Da, has a further 34 Da added owing to the addition 
of chlorine (35 Da) and subtraction of hydrogen (1 Da) from the aromatic ring. All four 
sequenced spectra are examples of the work undertaken to ensure that the modifications 
presented were correctly identified and provide an accurate representation of residue 
modifications when analysing samples by MS. 
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Figure 3.8. De novo sequenced peptides of SERCA from HOCl oxidised SR. Sequenced spectra of A. Cysteine trioxidation, B. Methioine 
oxidation and Tryptophan oxidation, C. Tryptophan oxidation, and D. Chlorotyrosine with labelled immonium ion.
A 
C 
B 
D 
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The number of false positives that arose from Mascot vs. correctly identified modified 
peptides is illustrated by the percentages of false positives, true positives, uncertain and 
misassigned oxidations for a representative data set, which were as follows: 61%, 13%, 20% 
and 6% respectively (Supplementary Table 3.1). A total of 19% of oxPTMs were validated 
and accepted as modifications, whereas the other 81% were false positives or could not be 
determined from the MS/MS fragmentation spectra. This ~20% result demonstrates how 
important manual verification is, even though it is a laborious and time consuming process. 
For oxPTM discovery MS/MS, SR and MH samples were oxidised with HOCl and ONOO- at 
protein: oxidant ratios of 1:10, 1:25, 1:50, 1:75, 1:100, 1:250, and 1:500. Oxidative 
modifications detected using a QToF mass spectrometer were identified and verified using 
Mascot and PeakView. All modifications with the exception of methionine oxidation were 
listed. These included methionine dioxidation (DioxM), cysteine trioxidation (TrioxC), tyrosine 
oxidation (OxY), phenylalanine oxidation (OxF), allysine (Ally), tryptophan oxidation (OxW), 
tryptophan dioxidation (DioxW), nitrotyrosine (nitroY) and chlorotyrosine (ClY). OxMet 
residues were excluded from the list because of the numerous amounts detected in all the 
samples due to the high susceptibility of methionine to oxidation.  
Tables 3.3 and 3.4 show validated modifications that were detected using Mascot in SERCA 
of HOCl- and ONOO--oxidised SR samples respectively. While there were more 
modifications detected in ONOO- oxidised samples up to 1:500 oxidant concentrations, 
HOCl shows many more modifications detected in 1:500 sample. Additionally, different 
modifications can be seen for each of the oxidants; however, this is also seen with the 
control samples as the control for the HOCl treatments contained a OxY whereas a DioxM 
was present in the ONOO- control. Although there are common modifications in both 
treatments, the two differing demonstrates different susceptibilities to the different oxidants. 
An example of this is EPLISGWLFFR, which first appears in the HOCl treatments at 1:500, 
but first appears at a 10 times lower concentration of ONOO-, specifically at 1:50. While 
chlorotyrosine was detected following HOCl treatment, demonstrating its chlorinating 
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potential, ONOO- did not show any of nitrating activity, but this may reflect the reduction in 
sequence coverage and fewer modifications detected at its highest treatment. Both oxidants 
caused most modifications in thiol-containing amino acids, which was expected as they are 
the most susceptible amino acids to oxidation.  Interestingly, while OxY is present in HOCl 
samples, even in the control, the modification was not detected in the ONOO- samples. The 
OxY modification originates from a single peptide, Tyr694, and the lack of detection in 
ONOO--treated sample could just be because it was not selected for MS/MS fragmentation 
during the data-dependent MS/MS routine. The same can be seen in reverse, with C12 
present in ONOO- following 1: 100 treatment but not detected at all in the HOCl-oxidised 
samples. The different modifications seen with the two oxidants provide fragmentation 
information for a large number of MRM transitions for quantification of oxPTMs in muscle 
samples. 
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Table 3.3. Mascot detection of oxidised residues following treatment of SERCA with 
varying HOCl concentrations. Summary of oxidative modifications detected through 
searches in Swiss-Prot database with carbamidomethyl as a fixed modification and the 
variable modifications in the table, as described in Chapter 2. Modified residues are 
highlighted in red in the peptide sequence. 
Protein : 
Oxidant 
Modification Sequence Residue 
0 TrioxC EVTGSIQLCR Cys614 
OxY IVEYLQSYDEITAMTGDGVNDAPALKK Tyr694 
1:10 OxY IVEYLQSYDEITAMTGDGVNDAPALKK Tyr694 
DioxM AEIGIAMGSGTAVAK Met720 
TrioxC TGTLTTNQMSVCK Cys364 
1:50 OxY IVEYLQSYDEITAMTGDGVNDAPALK Tyr694 
OxY IVEYLQSYDEITAMTGDGVNDAPALKK Tyr694 
DioxM MNVFNTEVR Met452 
TrioxC CLALATR Cys561 
1:100 DioxM MNVFNTEVR Met452 
DioxM AEIGIAMGSGTAVAK Met720 
DioxM ALDFTQWLMVLK Met969 
TrioxC CLALATR Cys561 
DioxW ALDFTQWLMVLK Trp967 
OxF NMLFSGTNIAAGK Phe209 
1:500 DioxW ALDFTQWLMVLK Trp967 
ClTyr YGPNELPAEEGK Tyr36 
TrioxC CLALATR Cys561 
TrioxC KEVTGSIQLCR Cys614 
TrioxC EVTGSIQLCR Cys614 
DioxM NMLFSGTNIAAGK Met207 
DioxM DQMAATEQDKTPLQQK Met239 
DioxM MNVFNTEVR Met452 
DioxM IVEYLQSYDEITAMTGDGVNDAPALKK Met700 
DioxM AEIGIAMGSGTAVAK Met720 
OxW EPLISGWLFFR Trp831 
OxM & OxW ALDFTQWLMVLK Trp967 & Met969 
DioxW ALDFTQWLMVLK Trp967 
TrioxC TGTLTTNQMSVCK Cys364 
TrioxC GTAIAICR Cys636 
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Table 3.4. Mascot detection of oxidised residues following treatment of SERCA with 
varying ONOO- concentrations. Summary of oxidative modifications found achieved 
through searches in Swiss-Prot database with carbamidomethyl as a fixed modification. 
Modified residues are highlighted in red in the peptide sequence. 
 
Protein : 
Oxidant 
Modification Sequence Residue 
0 DioxM TGTLTTNQMSVCK Met361 
TrioxC EVTGSIQLCR Cys614 
1:10 DioxM TGTLTTNQMSVCK Met361 
Allysine KEFTLEFSR Lys481 
TrioxC EVTGSIQLCR Cys614 
DioxM ALDFTQWLMVLK Met969 
1:50 TrioxC TGTLTTNQMSVCK Cys364 
TrioxC EVTGSIQLCR Cys614 
TrioxC GTAIAICR Cys636 
OxTrp EPLISGWLFFR Trp831 
OxM & DioxW R.ALDFTQWLMVLK.I Trp967 & Met969 
1:100 TrioxC STEECLSYFGVSETTGLTPDQVK Cys12 
DioxM NMLFSGTNIAAGK Met207 
TrioxC SLPSVETLGCTSVICSDK Cys344 
DioxM & TrioxC TGTLTTNQMSVCK 
Met361 & 
Cys364 
TrioxC KEVTGSIQLCR Cys614 
TrioxC EVTGSIQLCR Cys614 
TrioxC GTAIAICR Cys636 
DioxM R.ALDFTQWLMVLK.I Met969 
OxM & DioxW R.ALDFTQWLMVLK.I Trp967 & Met969 
1:500 TrioxC STEECLSYFGVSETTGLTPDQVK Cys12 
OxM & DioxM FMEYEMDLTFVGVVGMLDPPR 
Met585 & 
Met589 
TrioxC KEVTGSIQLCR Cys614 
TrioxC EVTGSIQLCR Cys614 
OxM & OxF TASEMVLADDNFSTIVAAVEEGR 
Met733 & 
Phe740 
 
Table 3.5 shows a list of validated modifications from the top 5 protein hits within a band 
excised around the 100 kDa molecular weight from a gel lane of 1: 250 ONOO- treated 
oxidised MH. Fewer oxidative modifications were detected in this band in comparison to the 
increase in nitrations detected. This is seen particularly in glycogen phosphorylase, where 
13 nitrotyrosine residues were detected and validated by de novo sequencing. An additional 
difference when comparing modifications detected in SERCA of SR and MH samples is that 
no modifications were detected in the MH sample, in contrast to 30 found in the SR samples. 
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This difference shows how purification of an organelle leads to increased discovery of 
modifications of proteins present in that organelle. 
Table 3.5. Mascot detection of oxidised residues in top 5 hit proteins of 1: 250 ONOO- 
oxidised muscle lysate (excised band MW~100). Summary of oxidative modifications 
found achieved through searches in Swiss-Prot database with carbamidomethyl as a fixed 
modification. Modified residues are highlighted in red in the peptide sequence. 
Protein ID Modification Sequence Residue 
PYGM 
(Glycogen 
phosphorylase) 
OxW EIWGVEPSR Trp826 
OxM&TrioxC INMAHLCIAGSHAVNGVAR Met442&Cys446 
TrioxC VFADYEEYIKCQDK Cys784 
NitroY YEFGIFNQK Tyr162 
NitroY ARPEFTLPVHFYGR Tyr204 
NitroY DFNVGGYIQAVLDR Tyr263 
NitroY VLYPNDNFFEGK Tyr281 
NitroY HLQIIYEINQR Tyr405 
NitroY DFYELEPHK Tyr473 
NitroY IGEDYISDLDQLR Tyr512 
NitroY LLSYVDDEAFIR Tyr525 
NitroY FSAYLER Tyr549 
NitroY VIFLENYR Tyr649 
NitroY GYNAQEYYDR Tyr732 
NitroY GYNAQEYYDR Tyr733 
NitroY VFADYEEYIK Tyr781 
KCRM 
(Creatine 
kinase) 
TrioxC RFCVGLQK Cys254 
NitroY VLTPDLYNK Tyr39 
NitroY GGDDLDPNYVLSSR Tyr125 
KPYM 
(Pyruvate 
kinase) 
TrioxC GIFPVLCK Cys474 
NitroY GDYPLEAVR Tyr670 
OxM&NitroY ITLDNAYMEK Tyr203&Met204 
TrioxC NTGIICTIGPASR Cys49 
ENOB 
Beta-enolase 
No modifications 
observed 
N/A N/A 
AT2A1 
SERCA 
No modifications 
observed 
N/A N/A 
 
3.2.3.3. MRM quantification 
After validation of the modified peptides with Mascot, the data obtained from the MS/MS 
searches were utilised to generate a list of transitions for subsequent production of MRM 
methods. Most of the modified peptides chosen for MRM analysis originated from SERCA as 
it is the primary model protein this research focuses on. In addition to SERCA, glycogen 
phosphorylase was another protein that peaked interest as it showed high susceptibility to 
nitration from ONOO- in comparison to other abundant proteins (Table 3.5). The first set of 
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transitions was produced to test the MRM approach on a QTRAP instrument (Table 3.6). All 
of the peptides in this transition list contained oxidised methionine, as it is a common 
modification and has been shown to be present alongside other oxPTMs within a few 
modified peptides. 
Table 3.6. Transition list for methionine oxidation in peptides from SERCA for the 
QTRAP instrument. Three product ions were used for identification of SERCA peptide. 
Modified residues highlighted in red. 
Peptide Precursor ion (m/z) Product ions (m/z) 
NMLFSGTNIAAGK 490 346.2 
573.4 
731.5 
NMLFSGTNIAAGK 484.7 204.1 
346.2 
573.4 
MNVFNTEVR 563.4 274.2 
618.4 
765.5 
MNVFNTEVR 555.4 274.2 
618.4 
765.5 
KAEIGIAMGSGTAVAK 507.3 218.1 
690.5 
837.6 
KAEIGIAMGSGTAVAK 502 218.1 
690.5 
821.6 
VIMITGDNK 503.3 534.3 
647.4 
794.5 
VIMITGDNK 495.8 261.2 
534.3 
778.5 
 
Following initial tests on the QTRAP instrument, several other transition lists were generated 
to begin analysis in in vitro oxidised samples. These are shown in Tables 3.7, 3.8 and 3.9, 
which list transitions for NitroY in glycogen phosphorylase and oxidised residues of SERCA 
detected in previous discovery MS/MS and nitrotyrosine residues of SERCA from a study by 
Knyushko et al. 2005. 
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Table 3.7. Transitions list for NitroY in glycogen phosphorylase for the QTRAP 
instrument. Three product ions were used for identification of glycogen phosphorylase 
peptide. Modified residues are highlighted in red. 
Protein/Residue Sequence 
Precursor 
ion (m/z) 
Product 
ions (m/z) 
Collision 
energy 
Glycogen 
phosphorylase 
Y525 
LLSYVDDEAFIR 720.9 
750.4 
37.7 865.5 
964.6 
LLSYVDDEAFIR 743.4 
750.4 
37.7 865.5 
964.6 
Glycogen 
phosphorylase 
Y405 
HLQIIYEINQR 713.9 
659.4 
37.4 822.5 
935.5 
HLQIIYEINQR 736.4 
659.4 
37.4 867.5 
980.6 
Glycogen 
phosphorylase 
Y281 
VLYPNDNFFEGK 721.9 
741.4 
37.8 856.5 
970.5 
VLYPNDNFFEGK 744.4 
741.4 
37.8 856.5 
970.5 
Glycogen 
phosphorylase 
Y263 
DFNVGGYIQAVLDR 783.9 
701.4 
40.5 814.5 
977.6 
DFNVGGYIQAVLDR 806.4 
701.4 
40.5 814.6 
573.3 
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Table 3.8. Transitions list for oxidised residues in SERCA for the QTRAP instrument. 
Three product ions were used for identification of SERCA peptide. Modified residues are 
highlighted in red. 
Modification Sequence Precursor ion (m/z) 
Product ion 
(m/z) 
Collision 
energy 
TrioxC 
 
Unmodified 
EVTGSIQLCR 
 
577.3 
 
326.1 
30.4 
 
439.2 
925.5 
EVTGSIQLCR 
 
581.8 
 
335.1 
30.4 
 
448.2 
934.5 
TrioxC 
 
Unmodified 
TGTLTTNQMSVCK 
 
716.4 
 
298.1 
36.5 
 
857.5 
958.5 
TGTLTTNQMSVCK 
 
720.8 
 
307.1 
36.5 
 
866.4 
967.4 
DioxM 
 
 
Unmodified 
 
 
OxW & OxM 
 
 
DioxW & OxM 
ALDFTQWLMVLK 
 
748.9 
 
522.3 
37.9 
 
635.4 
821.5 
ALDFTQWLMVLK 
 
732.9 
 
490.3 
37.9 
 
603.4 
789.5 
ALDFTQWLMVLK 
 
748.9 
 
506.3 
37.9 
 
619.4 
837.5 
ALDFTQWLMVLK 
 
756.9 
 
506.3 
37.9 
 
619.4 
821.5 
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Table 3.9. Transitions list for NitroY in SERCA for the QTRAP instrument. Three 
product ions were used for identification of SERCA peptide as well as measuring the 
immonium ion marker. Modified residues are highlighted in red. 
Modification Sequence 
Precursor 
ion (m/z) 
Product 
ion (m/z) 
Collision 
energy 
Unmodified 
GAIYYFK 
 
431.2 
 
457.3 
24 
 
620.3 
733.4 
NitroY (x2) 
 
GAIYYFK 
 
476.2 
 
502.2 
24 
 
710.3 
823.4 
Unmodified 
 
EYEPEMGK 
 
491.7 
 
561.3 
26.6 
 
690.3 
853.4 
NitroY 
 
EYEPEMGK 
 
522.2 
 
577.3 
26.6 
 
706.3 
914.4 
Unmodified 
 
VDGDVCSLNEFSITGSTYAPEGE
VLK 
 
929.8 
 
842.5 
50.5 
 
1005.5 
1106.6 
NitroY 
 
VDGDVCSLNEFSITGSTYAPEGE
VLK 
 
944.8 
 
842.5 
50.5 
 
1050.5 
1151.6 
Unmodified 
 
GAIYYFK 
 
431.2 
 
136.1 
65 
 
181.1 
120.1 
NitroY (x2) 
 
GAIYYFK 
 
476.2 
 
136.1 
65 
 
181.1 
120.1 
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Prior to quantitation with MRM, narrow window XIC analysis of NitroY residues in glycogen 
phosphorylase was carried out, as mentioned in section 1.5 (Fig. 3.9 and 3.10). This method 
utilises the data set obtained from discovery MS/MS to approximately quantitate modified 
peptides. Comparing modified peptides in the different ONOO- treatments enables an 
understanding of how different residues are modified by increasing oxidant concentrations 
(Fig. 3.9). The most susceptible residue appears to be Tyr281, followed by Tyr263, with 
Tyr525 being the least susceptible. Additionally, the quantitation follows the pattern seen in 
the immunoblot and MS/MS sequence coverage results, where there was a decrease after 
1:250. 
  
Figure 3.9. Quantification of nitrotyrosine in glycogen phosphorylase with protein: 
oxidant molar concentrations of ONOO-. (From representative sample) Blue: 
DFNVGGYIQAVLDR (Y263). Red: VLYPNDNFFEGK (Y281). Green: HLQIIYEINQR (Y405). 
Purple: LLSYVDDEAFIR (Y525). Modified residues are highlighted in red. 
 
XIC analysis with the MS/MS discovery results also showed changes in precursor ion 
abundancies for each NitroY in their respective peptide populations. By displaying the 
percentage modification in a graphical format, residue susceptibility is more apparent and 
demonstrates that not only the type of amino acid governs likeliness to modification, but also 
other factors, including structural positioning. In the case of glycogen phosphorylase treated 
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with 1: 250 protein: oxidant molar concentration of ONOO-, residues Tyr281, Tyr263, and 
Tyr473 were found to be modified about 50%, while Tyr512 and Tyr781 were the least 
modified residues showing less than 10% modification (Fig.3.10). 
 
Figure 3.10. Percentage modification of nitrotyrosine residues in 1:250 ONOO- 
oxidised MH samples using XIC analysis. Error bars of triplicate values displayed as 
S.E.M. 
Although XIC analysis is not necessarily an accurate method of quantifying modified 
residues due to the presence of isobaric peptides in samples of high complexity, it does 
provide an overall idea of residue susceptibility and in turn which residues may be best used 
for subsequent MRM quantitation. Choosing less susceptible modifications may result in 
them being difficult to quantify, especially if these methods are to be translated into analysis 
of in vivo samples. MRM quantitation of Nitrated Tyr281 of glycogen phosphorylase gave 
similar results to those obtained by XIC analysis (Fig. 3.11). There was a substantial 
increase in percentage modification when comparing the range of protein: oxidant molar 
concentration between 1: 0 and 1: 100 and those between 1: 250 and 1:1000. When 
comparing the trend seen in the earlier blots in section 3.2.3 to the MRM results, it can be 
elucidated that the fragmentation and aggregation of 1: 1000 sample is responsible for the 
drop in percentage modification. Additionally with MRM, NitroY was quantified in samples 
treated with oxidants at ratios as low as 1: 25, whereas it was not seen during XIC analysis; 
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
Y162 Y204 Y263 Y281 Y405 Y473 Y512 Y525 Y549 Y649 Y732 Y733 Y781
91 
 
however, below this ratio NitroY was not detectable. Whether this modification occurs in vivo 
will require further analysis. The trend observed follows what was seen in the immunoblots, 
which showed that western blotting and MS are both comparable methods. Only at a 
protein:oxidant ratio of 1:100 could the nitrated residue be clearly detected, which may mean 
NitroY will be difficult to measure in biological samples unless the tissue has been subjected 
to severe stress by high oxidant levels. 
 
Figure 3.11. MRM quantitation of NitroY (Y281) of glycogen phosphorylase treated 
with varying concentrations of ONOO-. Error bars of triplicate values displayed as S.E.M. 
 
Figure 3.12. MRM quantification of TrioxC in SERCA peptide CLALATR in samples 
with varying concentrations of HOCl. Error bars displayed as S.E.M. 
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Initially, several OxMet modified peptides with their respective unmodified counterparts were 
analysed using MRM. MRM demonstrates the ability to determine which residues are more 
susceptible to oxidation. For example, Met720 residues were found to be more modified than 
Met452. OxM modifications were easier to detect than other modifications, due to 
methionine’s high susceptibility to oxidation. When searching for TrioxC, DioxT, ClY, etc., it 
proved more difficult to obtain clear, intense and defined transitions because of their low 
occurrence. Optimisation of the MRM technique will also be required to quantify less 
susceptible modifications in addition to quantification of OxM. 
3.2.4. Comparisons of QToF vs. QTRAP systems in quantification 
The QTRAP system is designed to use MRM based techniques, whereas the QToF system 
required adaption of a product ion scanning mode to analyse selected ranges for pseudo-
MRM analysis. This method analyses a range rather than focusing on a particular mass. In 
order to test the application of these two instruments in quantification of oxPTM in biological 
samples, obese (ob/ob) and aged (C57BL6) mice models were used. This determined the 
effect the sensitivity and resolution of the instruments had on the quality and ease of 
quantification, demonstrating the pros and cons of using time of flight and trap-based 
systems for label-free quantification. More in-depth analysis for these models will be 
discussed later in chapters 4 and 5. This section discussed these models only to assess the 
two different instruments in quantification of oxPTMs. To test whether analysis could be 
performed with MH, several modifications were tested with both the SR and MH samples on 
the QTRAP (Fig. 3.13). The data show that oxPTMs can be detected in MH and additionally 
because higher protein concentrations can be obtained with MH, the signals are much 
higher than SR which, because of sample purification, has 30 times less protein. For all 
experiments thereafter MH was used for quantitation, instead of SR. 
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Figure 3.13. Comparison of MH and SR samples for quantitation of OxM residues 
using the QTRAP. Green boxes highlight transition peaks for oxidised 
KAEIGIAMGSGTAVAK (B) and NMLFSGTNIAAGK (D) and their respective native peptides 
(A&C). 
 
MH 
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SR 
MH 
SR 
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B) KAEIGIAMGSGTAVAK 
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D) NMLFSGTNIAAGK 
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Additionally, a few specific peptides were compared to determine the limit of detection and 
accuracy of the QToF system vs the QTRAP system. OxPTMs were compared in both 
systems and showed a significant difference (Table 3.10). Due to the fact that samples were 
processed at different times, it is difficult to say whether artefactual oxidation affected the 
results when comparing quantitation between the QToF and the QTRAP. Met720 has a 
larger contrast with a 17.7% increase in detection of OxM in the QToF, whereas Met452 only 
showed a 4.4% increase. This could be due to residue susceptibility, but does indicate that 
the two instruments cannot be compared based on oxidised residues. 
Table 3.10. Comparison of QToF and QTRAP quantitation of OxM modifications of 
Met452 and Met720 of SERCA. Quantitation was noted for each replicate and an average 
was calculated. S.E.M. determined for native and oxidised peptides measured by ToF and 
QTRAP (n=3). 
Replicates QToF QTRAP 
Met452 
1 Native 81% Native 87% 
Oxidised 19% Oxidised 13% 
2 Native 87% Native 91% 
Oxidised 13% Oxidised 9% 
3 Native 82% Native 85% 
Oxidised 18% Oxidised 15% 
Average Native 83.3 ± 3.2% Native 87.7 ± 3.1% 
Oxidised 16.7 ± 3.2% Oxidised 12.3 ± 3.1% 
Met720 
1 Native 70% Native 88% 
Oxidised 30% Oxidised 12% 
2 Native 76% Native 83% 
Oxidised 24% Oxidised 17% 
3 Native 61% Native 89% 
Oxidised 39% Oxidised 11% 
Average Native 69 ± 7.5% Native 86.7 ± 3.2% 
Oxidised 31 ± 7.5% Oxidised 13.3 ± 3.2% 
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On the other hand, when comparing nitration, there is less risk of artefactual changes in 
modification through sample storage or handling. The QToF and QTRAP still show 
differences in quantitation of the oxPTMs (Table 3.11), as well as better signal to noise for 
the QToF over the QTRAP (Fig. 3.14).  
Table 3.11. Comparison of QToF and QTRAP quantitation of NitroY in glycogen 
phosphorylase. Results are from a representative sample. Modified residue is highlighted in 
red. 
Peptide Residue QToF QTRAP 
LLSYVDDEAFIR Tyr525 7% 16% 
VLYPNDNFFEGK Tyr281 16% 14% 
HLQIIYEINQR Tyr405 0.34% - Noise level 
 
QToF      QTRAP 
 
 
 
Figure 3.14. Comparison of QToF and QTRAP XIC transitions for NitroY and native 
peptides from glycogen phosphorylase. Modified residues are highlighted in red. 
 
LLSYVDDEAFIR 
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There were also differences in the false positive peaks detected in both samples. Figure 
3.15 shows that an extra peak was detected in the QTRAP data when compared to the 
same XIC transitions in the QToF. This difference is most likely due to the higher resolution 
capabilities of a QToF instrument. 
 
 
Figure 3.15. Comparisons of QToF and QTRAP XIC of SERCA peptide EVTGSIQLCR. 
A. XIC transitions for peptide analysed using QToF. B. XIC transitions for peptide analysed 
using QTRAP. 
  
QToF 
QTRAP 
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Higher resolution enables selection of a precursor ion mass window to ensure isobaric 
peptides are not displayed. This is also seen in Figure 3.16, where there is very little to 
distinguish the two peptides in a QTRAP spectrum apart from the lack of the third transition, 
whereas the QToF can differentiate between the two peaks. 
 
 
Figure 3.16. Comparison of QTRAP and QToF MRM analysis of SERCA peptide 
GTAIAICR. A. XIC transitions of SERCA peptide measured in QTRAP instrument. B. XIC 
transitions of peptide measured in QToF instrument. XIC transitions generated from peaks 
labelled as 1 and 2 of different precursor ion peaks. 
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98 
 
For the QToF system, three methods were tested: selected product ion monitoring, full 
product scan and a focused product ion scan. The ToF instrument used in this study 
required adaptation to the product ion scanning mode to produce methods for quantitation. 
The mass windows were either narrowed to include a specific product ion mass window or 
wide enough to analyse a series of product ions generated from a chosen precursor ion 
mass of interest. 
3.2.4.1. Narrow window selected product ion monitoring QTOF analysis 
The selected product ion monitoring method involved taking three product ions that 
appeared consecutively in a sequence and using a narrow mass window scan that included 
the masses of these three product ions. By doing so, a hybrid MRM-product ion scan 
method was created and involved the user generating XICs from the list of product ions 
produced by the precursor ion mass input. Although this method worked well for some 
peptides, other peptides produced spectra in which false positive peaks could be seen (Fig. 
3.17). This also demonstrated the existence of isobaric peptides that generate similar mass 
fragments. To avoid this, a second method was produced that involved increasing the mass 
range to search for more transitions per precursor ion. Although this method has a greater 
similarities to the product ion scan, it still has a targeted approach as the range does not 
include product ions smaller than 200 Da and cuts off at high masses where MS/MS spectra 
are predominantly noise. The cut off points reduce the time spent on data collection in 
unnecessary mass ranges, where little data of importance would be collected. 
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Figure 3.17. Example from selected product ion monitoring method with XICs 
generated from range between 300-550 kDa. TrioxC of CLALATR SERCA peptide 
oxidised with 1:100 ONOO-. Spectrum has been Gaussian smoothed by 1.5 points.  
 
3.2.4.2. Wide window selected product ion monitoring QTOF analysis 
The selected product ion scan method with a wider mass window enables a larger number of 
transitions of the peptide to be searched and simplifies the choice when deciding which 
transitions are best suited for subsequent targeted approaches. This method also reduces 
false positive peak detection which can occur when using a method with limited transitions 
(Fig. 3.18). Typically, many standard MRM methods use a minimum of three transitions, but 
when analysing a complex mixture of proteins, the risk of detecting false positives is much 
greater. Although this method would be a good starting point to find which product ions are 
best used for subsequent targeted methods, it is time consuming to collect data on a single 
peptide and leads to fewer scan events within a single method program. 
 
 
Figure 3.18. Example of product ion scan of nitrotyrosine in glycogen phosphorylase. 
NitroY525 of LLSYVDDEAFIR in glycogen phosphorylase from 1:500 ONOO- oxidised 
sample. Scan ranges between 400-1400 kDa. 
Product ions ranging from 300 to 550 kDa: 
Generated XIC from selection of product ion range: 
Product ions ranging from 400 to 1400 kDa: 
Generated XIC from selection of product ion range: 
100 
 
3.2.4.3. Focused product ion scanning QToF analysis 
The third technique developed on the QToF was a highly targeted approach, whereby the 
transition mass ranges were shortened to a 1 Da mass range around the mass of the 
selected product ions. The 1 Da mass range was chosen so that the focused QToF method 
was directly comparable to the QTRAP MRM method. Figure 3.19 shows overlaid spectra 
from native, OxM and DioxM peptides. With this method a mass shift can be seen with the 
transitions, as well as changes in intensity between the native and modified peptides. 
Additionally, utilising a focused scan increases the time spent measuring a selected few 
transitions as opposed to measuring a larger number of product ions allowing for reduced 
duty cycles and increased number of peptide quantitation. It also produces a method nearest 
to typical MRM routines used in quadrupole and TRAP instruments. 
 
 
Figure 3.19. Example of targeted MRM method using selected product ions of native, 
OxM and DioxM from SERCA peptide AEIGIAMGSGTAVAK. Addition of oxygen 
represented as mass shift of +16. Modified residue is highlighted in red. 
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In all three methods, the retention time of the peptides is an important factor for 
distinguishing false positive peaks. As the quantitation is carried out on the same LC-MS 
system as discovery MS/MS, the retention time of the peaks is expected to be the same. 
The QTRAP system is at a disadvantage because the different LC set-ups can account for 
changes in the initial dead volume prior to the start of the LC gradient leading to different 
retention times exhibited in the two instruments (Fig. 3.14).  
The three methods used for quantitation were developed at different time points during the 
project, as throughout the study there was a continuous focus on developing and optimising 
methods best suited for the characterisation and quantitation of oxPTMs in muscle. 
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3.3. Discussion 
The aim of this study was to optimise current MS methods used for the analysis of oxidative 
modifications for the application to muscle tissue and develop these methods for 
characterisation and quantitation of oxPTMs. This was achieved by the development of non-
labelling discovery and quantitative MS methods for the analysis of oxPTMs in muscle 
proteins that could be used to study occurrence in ageing or disease. Optimisation of sample 
handling, oxPTM detection and quantitation was explored. 
3.3.1. Handling of samples 
It was essential to regulate the oxidative artefacts that arise during sample handling. As the 
focus of the study was to explore the oxidative modifications in muscle, preventing the 
introduction of adventitious oxidation required the addition of a scavenger (Levine et al.1996; 
Hawkins and Davies, 1999). These results showed higher levels of oxidised methionine 
residues when peptides were detected in the absence of exogenous methionine. While 
some residues demonstrated little to no change, other residues such as Met757 in SERCA 
and Met327 in actin showed higher susceptibility to oxidation in the absence of a scavenger. 
Additionally, many of these residues are surface exposed and are more easily accessible to 
oxidants. In view of the high susceptibility to oxidation, it is essential to minimise oxidation 
during handling and storage of samples, in order to quantify accurately oxidative 
modifications induced in vivo. The data demonstrated that addition of methionine was able to 
prevent experimental oxidation artefacts, thus improving data collection for correct 
understanding of oxidations induced in vivo and limitation of false positives. The addition of 
the scavenger had varied results in the protection of some residues over others which may 
lead to a greater separation of highly susceptible residues as well as indication of whether 
conformation plays a role.  
Additionally, a different approach was taken to handling gel slices from SDS-PAGE gels. 
Studies that focus on exploring individual modifications or single proteins will often select 
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bands to excise when performing in-gel digestion. The results from the immunoblots showed 
oxidised proteins are susceptible to aggregation and fragmentation which means a protein is 
not localised to one area on the gel. To refrain from unconscious bias selectivity of bands at 
the ‘correct’ molecular weight, the GeLC method was used to analyse the whole gel lane but 
still utilise electrophoresis for fractionation of the samples. GeLC has been used to analyse 
complex protein mixtures for downstream mass spectrometry approaches in other studies 
(Shevchenko et al. 2007; Piersma et al. 2013; Dzieciatkowska, Hill and Hansen, 2014). By 
using this method aggregate and fragments of proteins can also be analysed for oxPTMs. In 
this regard, a GeLC approach has significant advantages over cutting specific bands where 
the protein should appear on SDS-gel. 
3.3.2. In vitro oxidation 
To assess the suitability of the methods for analysis of oxPTMs in subsequent studies on 
aged and obese models, in vitro oxidation of muscle proteins was used as the starting point 
for the development of the MS approaches. Using MS techniques for global analysis, 
oxidations of methionine, cysteine, tyrosine, tryptophan, and phenylalanine and chlorination 
of tyrosine have been detected within oxidised SERCA. This included the discovery of 
chlorination to Tyr36, which had not been previously reported. It cannot be said for sure 
whether these modifications play a major role in disease, but their investigation will lead to a 
greater understanding of the impact ROS have on proteins in disease and may help in the 
identification of possible biomarkers. 
Western blotting demonstrated the effects of in vitro oxidation to the SERCA protein. Both 
aggregation and fragmentation of the protein could be seen. The additional SERCA band 
present near the stacking gel could have been caused by inter- and intra-molecular 
interactions leading to aggregation and oligomerisation. Additionally, this band was denser in 
the oxidised samples. One possible intermolecular interaction associated with oxidation that 
could contribute to this is the formation of dityrosine bonds, which are generated through 
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tyrosyl radical formation (Heinecke et al., 1993). There is a small amount of 
aggregation/oligomerisation in the control sample which may be due to the hydrophobic 
nature of the protein. HOCl promotes aggregation/oligomerisation by strong non-covalent 
interactions by alterations to the structure from the formation of chloramines, oxidations, and 
carbonyls (Chapman, et al. 2003). The detection of fragmented SERCA band after 
incubation with HOCl has been previously reported (Strosova et al. 2009). Peptide bond 
cleavage has been shown to occur when reactive oxygen species attack glutamyl, aspartyl, 
and prolyl side chains (Garrison, 1987), where oxidation of proline to pyrrolidone has been 
reported by Uchida et al., 1990. 
Following immunblotting, discovery MS/MS analysis determined the type and location of 
modifications in SERCA. Oxidised Met720 and Met452, found in the phosphorylation domain 
and nucleotide binding domain respectively, can be observed in lower protein: oxidant 
samples. These appeared to be more easily oxidisable than other methionine residues. 
Met720 in particular may be an important residue, as it is adjacent to Cys674, a key residue 
involved in redox regulation of SERCA (Adachi et al. 2004). The role of this residue may be 
to act as a scavenger for oxidants to prevent the further oxidation of Cys674 to an 
irreversible form (Ying et al. 2008).  
One particular modification of interest identified in 1:500 HOCl oxidised SERCA was Tyr36 
chlorination, which is found in the actuator domain. This represents a novel finding as there 
are no previous reports of ClY in SERCA, despite there being several studies of HOCl-
induced stress on SERCA. The detection of this novel modification further supports the 
importance of global analysis of modifications over focus on specific modifications. ClY in 
particular is an interesting modification because the chlorination is specific to HOCl. The 
formation of ClY has been proposed to occur through direct HOCl oxidation and via transfer 
of chlorine from chloramines (Domigan et al., 1995). Chloramines are produced from the 
reaction of HOCl with amino groups; R-NH2 + HOCl  R-NHCl + H2O, and are capable of 
transferring chlorine to other substrates but when other substrates are not available, 
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chloramines can be stabilised by hydrolysis to aldehydes (Winterbourn, 1985; Hazen et al., 
1998). Although Tyr36 chlorination had been detected in vitro in this study, it is not known 
whether this modification occurs in vivo and further analysis in disease models is required to 
determine this. If Tyr36 were to have an effect in the actuator domain, it may influence 
SERCA’s ability to revert back to the E1 state, which has high affinity calcium binding sites 
near to the cytoplasmic opening resulting in a reduction in calcium uptake (MacLennan et al. 
1970). 
Many publications on tyrosine modifications in SERCA are focused on NitroY formation 
(Viner et al. 1996; Knyushko et al. 2005). However, this study has demonstrated the 
presence of other oxidation states such as chlorination of Tyr36 and the addition of oxygen 
to Tyr694 in vitro. Similarly, Phe209 oxidation was also identified as a modification detected 
in the SR samples. Like Tyr36, Phe209 is also located in the actuator domain, whereas 
Tyr694 is located in the phosphorylation domain. The detection of Tyr694 oxidation in the 
control samples as well as the oxidised samples may be due to its accessibility as an 
exposed amino acid. The OxW residues detected in the samples are located in the 
transmembrane domain but there have not been many reports on modifications in this 
domain and links to activity. However, there has been a report suggesting conformational 
changes in the transmembrane domain of SERCA are linked to adjuvant arthritis (Strosova 
et al., 2009b). Whether the oxidised tryptophan residues in the transmembrane domain play 
a role in the conformational changes is still unknown. 
The final type of modification that was detected in the majority of the samples was TrioxC. 
Four residues with this type of modification were identified and these were Cys364, Cys561, 
Cys614, and Cys636. Both Cys364 and Cys561 were located in the nucleotide binding 
domain whereas Cys614 and Cys636 were located in the phosphorylation domain. Cys636, 
in particular, was found to be adjacent to Cys674 previously mentioned to be involved in 
redox regulation. This residue may work in the same manner as Met720 as protection from 
further oxidation. 
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Additional analysis of other proteins in the muscle led to the discovery of glycogen 
phosphorylase susceptibility to nitrotyrosine formation when subjected to peroxynitrite 
treatment. NitroY residues have been reported both in vitro and in ageing studies. When 
comparing the residues identified in a study by Sharov et al. 2006b, in which rat skeletal 
muscle glycogen phosphorylase was nitrated with peroxynitrite, seven of the tyrosine 
residues were modified at the same position: 204, 263, 281, 405, 473, 732 and 733. The 
remaining six residues were not seen in the rat study and additionally modifications seen in 
the rat study were not detected in mouse glycogen phosphorylase. Different sequence 
coverages could be a factor as to why some different modifications were seen but not 
others. The thirteen NitroY residues detected in glycogen phosphorylase may be due to the 
combination of the many surface exposed tyrosine residues and the protein being one of the 
most abundant proteins within the muscle lysate. The combination of the abundance of 
glycogen phosphorylase and easily accessible residues could explain why it contains many 
nitrotyrosine residues in comparison to the other proteins in the sample. 
3.3.3. Development of quantitative MS methods 
With a list of modifications identified using discovery MS/MS with in vitro oxidation, several 
targeted and non-targeted MS methods were performed to test quantitation of the oxPTMs in 
muscle proteins. Narrow mass window XIC analysis was performed on the data set obtained 
from discovery MS/MS. The quantitation of NitroY residues in glycogen phosphorylase 
demonstrated differences in susceptibility of the different tyrosine residues. Residues 
Tyr204, Tyr263, Tyr281, and Tyr473, that were also present in the rat study, showed high 
levels of nitration. Interestingly, neighbouring residues Tyr723 and Tyr733 were also shown 
to have different susceptibility. In an alternate study by Sharov et al. 2009, residues 
corresponding to Tyr281, Tyr473, Tyr405, Tyr473 and Tyr549 from this study, were shown to 
exhibit more than 50% nitration after 1 mM peroxynitrite treatment in the glycogen 
phosphorylase of rabbit muscle. While residues Tyr281 and Tyr473 do show high levels of 
nitration after peroxynitrite treatment, other residues are shown to have higher nitration than 
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Tyr405, Tyr473 and Tyr549. Additionally, at high levels of nitration maximum percentage 
modification of Tyr281 reaches around 90% whereas the study in rabbit muscle glycogen 
phosphorylase reached nitration levels of up to 99% with relative quantitation with MS/MS. 
However, quantitation of Tyr281 with MRM in mouse muscle shows a maximum of around 
75% nitration. The difference seen from the targeted approach demonstrates the advantages 
to using MRM as a quantitative tool to more accurately quantify oxidative levels. 
In order to develop a quantitative method using a non-labelling approach, MRM on the 
QTRAP was tested against pseudoMRM methods developed on the QToF instrument. The 
QTRAP and QToF instruments were sensitive enough to measure in vitro oxidised peptides 
in muscle homogenate which had a higher protein complexity compared with the isolated 
sarcoplasmic reticulum sample. The analyses of the QTRAP and QToF instruments 
occurred at different time points of the study and so are not directly comparable. However, 
the results from the comparisons showed advantages to using different mass analysers for 
quantitation. When comparing the levels of OxM residues, the QTRAP showed similar 
detection to the QToF in Met452 but a larger increase in oxidation was shown for Met720. 
This most likely suggests that although a scavenger was added to the storages buffer of the 
samples, highly susceptible residue will still be oxidised over time. Quantitation with NitroY in 
glycogen phosphorylase showed better signal to noise ratio for the QToF system enabling 
easier quantitation. Additionally, the QToF demonstrated better resolution of transitions. For 
this study, the QToF was more optimised for the application of oxPTM quantitation in muscle 
proteins. This is not to say the QToF is a better instrument as studies have shown 
advantages of different MS in other experiments (Rousu, Herttuainen and Tolonen, 2010). 
Moreover, several targeted methods were developed over the course of the study to adapt 
product scanning feature into a pseudoMRM approach. The three methods have advantages 
and disadvantages but ultimately show the routes taken to optimise methods for quantitation 
of oxPTMs in muscle. Similar methods have been reported and demonstrate the tactical 
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advantages to using semi-targeted and targeted approaches depending on the application 
(Sherrod et al. 2012; Lee, Paull and Person, 2013). 
3.3.4. Concluding remarks 
From these data it can be concluded that analysis of oxPTMs is not a simple process and 
requires caution when handling samples to prevent adventitious oxidation as well as 
unconscious bias towards selecting proteins of the corresponding molecular weight band 
that may lead to losing additional information about protein modification in aggregates and 
fragments. By analysing several modifications, novel modifications were detected with in 
vitro oxidation and quantitation of oxidised residues revealed information about residue 
susceptibility. The development of MS technology could potentially be translated to an 
analytical tool for detection of biomarkers in clinical samples. Although mass spectrometry is 
a powerful tool that can be used for detection and quantification of oxidised proteins, there 
are still limitations to this technique. Further development of these methods is required in 
order to assess the utility of modifications as potential biomarkers. However the MS 
techniques developed are applicable to aid the further understanding of the role of protein 
oxidation in ageing and obesity. 
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Chapter 4 
 
Identification and quantification of 
oxPTMs in muscle proteins of an 
obese model 
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4.1. Introduction 
Obesity is increasingly affecting the world population with a 400% rise in obese individuals 
reported in England over the past 20 years and £4.2 billion direct costs to the NHS 
(McCarthy, 2015). One of the major causes of obesity in humans is the increasing resistance 
to leptin, similar to the resistance to insulin that occurs in diabetes. Leptin is a hormone 
secreted by adipose tissue and act on receptors in the hypothalamus to suppress appetite 
(Bates and Myers, 2003). Obese individuals have high levels of leptin circulating in the 
blood; however, because of insensitivity to leptin the brain does not respond and causes the 
individuals to overeat. Factors that have been proposed to contribute to leptin resistance 
include: free fatty acids and impaired transport through the blood brain barrier (Banks, 
DiPalma and Farrell, 1999; Banks et al. 2004). 
4.1.1. Obesity and the effects on muscle 
Muscle inflammation is reported to arise during obesity which has been linked to muscular 
dysfunctions (Fink et al. 2013; Pellegrinelli et al. 2015). Additionally, when coupled to 
sarcopenia, it is shown that the combination of sarcopenia and obesity increased odds for 
difficulties in physical performance (Zhong, Chen and Thompson, 2007; Rolland et al. 2009). 
To determine whether oxidative modifications may be involved in muscle performance, 
oxPTM analysis was used to determine whether higher levels of oxidation exist in obese 
muscle proteins. 
4.1.2. The ob/ob mouse model 
Ob/ob mice are leptin deficient and are commonly used as models to study type II diabetes 
and obesity (Drel et al. 2006). Ob/ob mice have a deficiency of leptin, which causes 
overeating and leads to obesity. While leptin deficiency and leptin insensitivity is not 
comparable in the progression to obesity, both would eventually lead to obesity associated 
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problems i.e. diabetes, atherosclerosis, cardiovascular diseases, etc. Therefore ob/ob mice 
can be used to explore the effects of inflammation on muscular proteins.  
4.1.3. Aims 
Following on from the previous chapter, the methods developed were applied to the analysis 
of oxPTMs in biological samples. There is not much reported on oxidative modification to the 
muscle proteins in ob/ob mice and therefore this study focused on the characterisation and 
quantification of oxidised proteins in ob/ob mice, mainly using the MS approaches developed 
in the chapter 3. 
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4.2. Results 
When the muscle from the hind leg of the control and obese mice models was extracted and 
stripped from the fat, the weight of the muscle prior to homogenisation was recorded (Fig. 
4.1A). The average weights for control and obese mice were ~1.5 g and ~1 g respectively 
and demonstrated a significant drop in muscle weight for the ob/ob model to approximately 
one third of the control muscle. The muscle was homogenised and both the SR and MH 
samples were obtained from triplicate mice for both models. After preparation of the 
samples, the specific activity of SERCA was measured by calculating the difference between 
total ATP hydrolysis in the presence and absence of thapsigargin: a known SERCA inhibitor 
(Lytton, Westlin, and Hanley, 1991). The specific activity was measured in µmol of free 
phosphate min-1 mg-1 of protein and showed a drop in SERCA function (Fig. 4.1B). The 
reduction in SERCA specific activity elucidates that protein function decreases in the obese 
model, however, the loss in SERCA activity is non-significant. Nevertheless the loss of 
muscle mass indicates physiological differences in the models which may be the result of 
oxidative damage to a different subset of proteins from known oxidised proteins in the 
ageing model. 
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Figure 4.1. Comparisons of muscle weight and SERCA activity in both control and 
ob/ob models. A. Weight of whole hind mouse legs and B. Activity of SERCA normalised to 
the control. NS = non-significant data (p>0.05), n=3.  
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4.2.1. Immunoblotting with anti-nitrosothiol (-SNO) and anti-nitrotyrosine 
To determine whether the samples contain oxidised proteins, isolated SR and muscle 
homogenate were electrophoresed on a 10%-SDS gel and subjected to probing with anti-
SNO and anti-NitroY antibodies. NitroY was detected in the muscle homogenate of both the 
control and ob/ob samples; however, there appeared to be higher levels in the ob/ob 
samples (Fig. 4.2), although this was only apparent in the MH samples as no obvious bands 
were seen in the SR samples. The bands relating to NitroY detection were most dense in the 
mid to lower molecular weight region between 55 kDa and just below 25 kDa marker of the 
molecular weight ladder. 
 
Figure 4.2. NitroY detection in lean & obese mice of isolated SR and muscle 
homogenate using western blotting. Samples were ran of a 10% SDS-gel and transferred 
to a PVDF membrane and probed with anti-nitrotyrosine. 
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Similarly, higher levels of nitrosothiols were detected in ob/ob samples in comparison to the 
control samples (Fig. 4.3). There were fewer bands present in the SNO immunoblot and the 
densest bands appear to be just above the 35 kDa marker and just below the 25 kDa 
marker. To ensure that this was not due to the indiscriminate binding of the secondary 
antibody, blots of MH samples were probed with the secondary alone and displayed no 
binding as the resulting blots appeared blank (Supplementary figure 4.1). It also appears that 
similar bands are shown with the presence of SNO and NitroY modifications. 
 
   
Figure 4.3. SDS-gel and immunoblot of SNOs in control and obese MH. A. Expedeon 
stained SDS-gel of control (lanes 2-4) and ob/ob (lanes 5-7) triplicate MH samples. B. 
Immunoblot probed with anti-SNO in triplicates of control (lanes 2-4) and ob/ob (lanes 5-7) of 
MH. 
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Both immunoblots support the presence of the oxidative modifications but from this 
technique, the identity of the modified proteins cannot be determined using this method. The 
samples were therefore subjected to MS analysis to characterise and quantify the oxidative 
modifications present in the samples. 
4.2.2. Identification of oxidised residues in the control and ob/ob mice 
In a similar manner to the in vitro studies, the proteins were digested and subjected to MS 
analysis to characterise and locate the modifications present in the samples. To accomplish 
this, the whole gel lane was analysed, termed GeLC-MS/MS (Piersma et al. 2013), rather 
than excising specific bands as in the previous approach. By opting for a non-biased 
approach during sample processing, there is no selective exclusion of peptides with potential 
modifications. Multiple modifications on proteins can affect their migration on a SDS-gel and 
so if modifications cause aggregation of the protein, higher molecular weight bands should 
not be excluded. The same applies to fragmented proteins, which may be present in lower 
molecular weight bands. Figure 4.4 shows how both the isolated SR and MH samples were 
fractionated and subsequent data is associated with the fractions as numbered there. The 
SR gel was divided into 6 fractions. By dividing the fractions into six parts, there is still some 
level of increased resolution via the separation of proteins by molecular weight. The gel 
could be divided into more fractions, increasing the resolution further, but this would lead to 
too many MS runs and would not be very efficient. On the other hand, the MH gel required 
more fractions as there was a greater variety of proteins in the whole lysate compared with 
the purified sample and it required more resolution. In doing so, chances of detecting 
modifications should increase, which would lead to a better understanding on the effects of 
oxidation within obese muscle, as well as a longer list of modifications with potential for 
discovering novel modified residues. 
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Figure 4.4. Expedeon stained SDS-gel of isolated SR and muscle lysate from obese 
mouse hind legs. A. Isolated SR. B. Muscle lysate. GeLC fractions of each sample are 
highlighted in red boxes and numbered. 
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Table 4.1 lists the top 5 proteins identified in each fraction of isolated SR from muscle of 
ob/ob mice, with the exclusion of the common contaminant keratin. Although procedures 
were set in place to minimise contaminating the samples with keratin during processing, it 
cannot be completely avoided. The table also lists the mascot score, mass of protein and 
sequence coverage. This data set shows higher Mascot scores were found in the higher 
molecular weight region of the gel compared to the lower molecular weight region which 
reflects what is seen in SDS-gel as there is a higher abundance of proteins in the high 
molecular weight region. The masses for the top hits from GeLC fraction 1 to 6 were as 
follows: 223.6 kDa, 110.7 kDa, 74.9 kDa, 59.8 kDa, 43.2 kDa, and 33.1 kDa. Although this 
fits the electrophoretic separation of proteins by mass, SERCA and sarcalumenin were not 
detected in the expected fractions. Sarcalumenin, a 99 kDa protein, was found in fraction 4, 
where almost all other proteins ranged from 55-60 kDa. SERCA, a 110 kDa protein, was 
also found in this fraction, as well as in fractions 1, 2 & 3, suggesting possible aggregation 
and fragmentation of the proteins. Overall, the sequence coverage for the top 5 hits in all 
GeLC fractions ranged between 17-68%, with an average sequence coverage of ~39%. This 
level of sequence coverage was expected to be sufficient to detect a reasonable number of 
modifications in this protein list. 
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Table 4.1. List of modifications identified and validated in obese muscle. Top 5 protein hits of isolated SR in each GelC slice with 
exclusion of keratin. *Although the protein was identified, Mascot displayed an error when accessing protein information. 
GeLC 
fraction 
Hit Protein ID Protein Mascot 
score 
Mass 
(Da) 
Sequence 
coverage 
1 1 MYH4 Myosin heavy chain 4, skeletal 11661 223632 54% 
2 AT2A1 SERCA 9905 110723 54% 
3 AT1A2 Na+/K+ transporting ATPase subunit alpha-2 1769 113457 33% 
4 RYR1 Ryanodine receptor 1 1604 570381 19% 
5 DYSF Dysferlin 653 240040 23% 
2 1 AT2A1 SERCA 11317 110723 53% 
2 AT1A2 Na+/K+ transporting ATPase subunit alpha-2 2829 113457 39% 
3 PYGM Glycogen phosphorylase 1158 97681 37% 
4 ODO1 2-oxoglutarate dehydrogenase, mitochondrial  869 117572 40% 
5 B3AT Band 3 anion transport protein 283 103412 17% 
3 1 CMC1 Calcium binding mitochondrial carrier protein Aralar1 1588 74922 55% 
2 AT2A1 SERCA 1585 110723 33% 
3 ALBU Serum albumin 1443 70700 49% 
4 DHSA Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 1088 73623 - 
5 ANXA6 Annexin A6 945 76294 49% 
4 1 ATPA ATP synthase subunit alpha, mitochondrial 3851 59830 54% 
2 SRCA Sarcalumenin 1000 99522 29% 
3 KPYM Pyruvate kinase isozymes M1/M2 817 58378 41% 
4 ATPB ATP synthase subunit beta, mitochondrial 652 56265 51% 
5 AT2A1 SERCA 606 110723 26% 
5 1 KCRM Creatine kinase M-type 2271 43246 46% 
2 ENOB Beta-enolase 1713 47377 38% 
3 KCRS Creatine kinase S-type 1020 47899 52% 
4 ACTC Actin, alpha cardiac muscle 1 963 42334 36% 
5 QCR2 Cytochrome b-c1 complex subunit 2, mitochondrial 820 48262 36% 
6 1 ADT1 ADP/ATP translocase 1 846 33111 68% 
2 MYP0 Myelin protein P0 768 27775 23% 
3 SYPL2 Synaptophysin-like protein 2 427 29605 26% 
4 PGAM2 Phosphoglycerate mutase 2 411 28980 37% 
5 AT5F1 ATP synthase subunit b, mitochondrial 280 29044 20% 
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The Mascot results were exported to XML files and processed through PANTHER (Protein 
ANalysis THrough Evolutionary Relationships), which classified the protein list into their 
molecular function (Fig.4.5). When comparing the isolated SR and the muscle homogenate, 
according to the functional classification of the proteins they appear similar in most 
categories; however, the proteins that contribute to each category are different between the 
samples. Also the analysis does not take into account the abundance of a single protein but 
rather the association of each protein to the biological processes. One visible difference 
between the two samples is the increased percentage of proteins involved in localisation and 
the decrease in proteins involved in metabolic processes in the purified SR sample in 
comparison to muscle homogenate. 
 
 
Figure 4.5. Classification of ob/ob muscle homogenate and isolated SR proteins into 
biological processes. Pie chart classifying proteins listed in (A) Isolated SR and (B) Muscle 
homogenate XML files according to their molecular function using online PANTHER 
software. 
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Just as described in the previous chapter, de novo sequencing is important and required for 
validation of the Mascot results. Fig 4.6 shows two peptides that have been sequenced and 
validated. OxH and OxW of enolase and lactate dehydrogenase showed the variety of 
modifications detected as well as the start of exploring the effects of oxidation in other 
proteins. The two peptides were subsequently used for quantitation in obese muscle. 
 
Figure 4.6. De novo sequenced peptides in ob/ob muscle. A. OxH in Beta-enolase 3 
(IGAEVYHHoxLK) and B. OxW in L-lactate dehydrogenase A chain 
(LLIVSNPVDILTYVAWoxK). 
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Figure 4.7 shows the number of modified residues for TrioxC, DioxM and OxM in the control 
and obese models from the discovery MS/MS data sets for SERCA of SR samples. The 
presence of all three oxidised residues was significantly more abundant in the obese model, 
suggesting higher levels of oxidised peptides are present in obesity compared to the lean 
model. As these modifications were more abundant in muscle from obese animals, they 
were selected for further investigation by the MRM approach developed in the previous 
chapter. 
 
Figure 4.7. Number of modified residues detected in discovery MS/MS of SR samples 
in control and obese models for SERCA. Green indicates residues counted from control 
samples and blue indicates residues counted from ob/ob samples. **Statistically significant 
data (p<0.01) using unpaired t-test, n=3.  
Following analysis of the proteins and observation of several interesting oxidations, the 
oxPTMs listed in section 2.12 were set as variable modifications and de novo sequencing 
was performed to verify their occurrence. Table 4.2 presents some of the modifications 
detected in ob/ob SR samples using discovery MS/MS analysis. Many of the oxPTMs 
detected were found to be TrioxC, DioxM and OxW modifications. Additional modifications 
detected include DioxW, OxY and OxH. 
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Table 4.2. List of modifications detected and validated by de novo sequencing in band 
2 of ob/ob SR samples. Summary of oxidative modifications achieved through searches in 
Swiss-Prot database with carbamidomethyl as a fixed modification and the variable 
modifications in the table, as described in Chapter 2. Modified residues are highlighted in red 
in the peptide sequence. 
Protein Modification Sequence Residue 
SERCA TrioxC CLALATR Cys561 
TrioxC EVTGSIQLCR Cys614 
TrioxC GTAIAICR Cys636 
OxW EPLISGWLFFR Trp832 
DioxW EPLISGWLFFR Trp832 
DioxM AEIGIAMGSGTAVAK Met720 
DioxM TGTLTTNQMSVCK Met361 
Na+/K+ 
transporting 
ATPase subunit 
alpha-2 
OxW SPTWTALSR Trp416 
ADP/ATP 
translocase 1 
OxW GAWSNVLR Trp275 
Myeloperoxidase OxW IQWVGDPR Trp101 
Pyruvate kinase OxY and OxM ITLDNAYMEK Tyr148&Met149 
Creatine kinase M 
type 
TrioxC RFCVGLQK Cys254 
DioxM GQSIDDMIPAQK Met376 
Fructose 
bisphosphate 
aldolase A 
DioxM IGEHTPSALAIMENANVLAR Met165 
OxW CPLLKPWALTFSYGR Trp296 
OxW ALQASALKAWGGK Trp314 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
OxW LISWYDNEYGYSNR Trp311 
Glycogen 
phosphorylase 
DioxM MSLVEEGAVK Met429 
OxW EIWGVEPSR Trp826 
Pyruvate kinase TrioxC NICKVVEVGSK Cys165 
DioxM FGVEQDVDMVFASFIR Met239 
Enolase b OxH IGAEVYHHLK His191 
Lactate 
dehydrogenase 
OxW LLIVSNPVDILTYVAWK Trp148 
Fructose-
bisphosphate 
aldolase A 
OxW ALQASALKAWGGK Trp314 
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Additionally, oxPTMs were identified in MH samples with additional OxP, Ally and NitroY 
modifications (Table 4.3). The detection of NitroY in a biological sample suggested that the 
methods were sufficiently optimised for the analysis of formation of this modification in 
muscle in vivo. While there are similar proteins detected in both the isolated sarcoplasmic 
reticulum and the muscle homogenate, i.e. creatine kinase and glyceraldehyde-3-phosphate 
dehydrogenase, the modifications detected differ. Additionally while SERCA modifications 
are detected in the isolated sarcoplasmic reticulum sample, these are not present in the 
muscle homogenate alluding to the advantages of using enrichment techniques to unveil 
modifications of organelle specific proteins. 
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Table 4.3. Identification of oxPTMs discovered in obese muscle homogenate. All modifications were validated by de novo sequencing and 
modified residues are highlighted in red. The full table with uncertain and false positive data included is provided in Supplementary Material 
(Supplementary Table 4.1). 
Band Protein ID 
Protein 
description 
Protein 
mass 
Mass/ Charge 
(m/z) 
Peptide 
score 
Peptide 
expect Peptide sequence Modification 
1 K1B24_MOUSE 
Kallikrein 1-related 
peptidase b24 29478 407.2217,3+ 27.57 0.044 DKSNDLMLLR Ally; OxM 
2 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 524.7988,3+ 56.22 0.00062 VPTPNVSVVDLTCR OxP 
2 K1B24_MOUSE 
Kallikrein 1-related 
peptidase b24 29478 407.2259,3+ 44.11 0.024 DKSNDLMLLR Ally; OxM 
4 SYNJ2_MOUSE Synaptojanin-2 159578 455.5816,2+ 39.24 0.0065 GLPPDHGGK 2 OxP 
4 TNR11_MOUSE 
Tumor necrosis 
factor receptor 
superfamily 
member 11A 68460 469.2537,2+ 27.54 0.047 DSFAGTAPR OxP 
5 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 524.7977,3+ 39.4 0.0044 VPTPNVSVVDLTCR OxP 
5 K1B24_MOUSE 
Kallikrein 1-related 
peptidase b24 29478 602.3615,2+ 50.16 0.003 DKSNDLMLLR Ally 
5 PTPS_MOUSE 
6-pyruvoyl 
tetrahydrobiopterin 
synthase 16235 509.8174,2+ 35.79 0.024 LLPVGALYK NitroY 
6 KCRM_MOUSE 
Creatine kinase M-
type 43246 539.8088,2+ 36.98 0.026 VLTPDLYNK OxP 
6 ALDOA_MOUSE 
Fructose-
bisphosphate 
aldolase A 39787 603.3448,3+ 34.52 0.0034 CPLLKPWALTFSYGR Ally 
6 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 36072 599.2975,3+ 27.73 0.03 LISWYDNEYGYSNR OxW 
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dehydrogenase 
7 ALDOA_MOUSE 
Fructose-
bisphosphate 
aldolase A 39787 1129.621,3+ 92.63 0.000002 
ALANSLACQGKYTPSGQSGAAA
SESLFISNHAY OxY 
7 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 524.7943,3+ 40 0.033 VPTPNVSVVDLTCR OxP 
8 GSTP1_MOUSE 
Glutathione S-
transferase P 1 23765 608.9556,3+ 85.04 4.3E-07 EAAQMDMVNDGVEDLR DioxM 
10 HBB1_MOUSE 
Hemoglobin subunit 
beta-1 15944 645.8925,2+ 36.88 0.027 LLVVYPWTQR OxW 
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Although, the Mascot analysis has limited the modifications searched for to twelve, it is 
possible that modified peptides containing other oxPTMs remained unidentified. However, 
increasing the number of modifications searched in a single run would increase the 
complexity of spectral matching with the theoretical database giving rise to more false 
positives from the searches and also larger datasets would have to be mined. Although the 
modifications that were searched for are shown in the datasets above, there was an 
additional potential modification detected in the samples. While performing de novo 
sequencing for validation of a modification, one peptide that Mascot had reported as 
containing TrioxC was actually found to contain a cysteine that appeared to both alkylated 
and dioxidised (Fig. 4.8). This strange modification combines the addition of the mass of 
alkylation (57 Da) with the mass of a dioxidation (32 Da), corresponding to a total of 89 Da 
and has been reported in another study (Jaeho Jeong, et al. 2011). It is important to note 
that although subsequent quantitation of oxidised residues tried to include other feasible 
oxidations within the peptide of interest, not all potential modifications could be taken into 
account. Therefore the quantitation is not absolute but an approximation of the percentage 
modification based on the current understanding of residue susceptibility to oxidation. For 
many of the quantified peptides, OxM containing peptides were quantified alongside 
unmodified forms, owing to their susceptibility to oxidation. Although this is also heavily 
dependent on the accessibility to the methionine residues in the protein conformation, it is 
safer to presume that the methionine may be oxidised and always include it as a variable 
modification. 
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Figure 4.8. Potential unusual modification to a SERCA peptide found in an obese sample. Carbomidomethylated cysteine + 2 Oxygens 
(57+32=89) (103+89=192). 
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4.2.3. Quantification of oxidative modifications by MRM 
In addition to previous transitions used for MRM quantitation, a new list was produced 
incorporating modifications found in other proteins in the discovery MS/MS analysis of obese 
mouse muscle samples (Table 4.4). These include modified peptides from lactate 
dehydrogenase, beta-enolase and pyruvate kinase. 
Table 4.4. Transition lists for the additional modifications observed in muscle samples 
from obese mice. Modified residues highlighted in red. 
Protein Sequence/Modification 
Precursor 
ion 
Product 
ions CE 
L-lactate dehydrogenase A 
chain LLIVSNPVDILTYVAWoxK 980.6 682.4 48.2 
L-lactate dehydrogenase A 
chain LLIVSNPVDILTYVAWoxK 980.6 783.4 48.2 
L-lactate dehydrogenase A 
chain LLIVSNPVDILTYVAWoxK 980.6 896.5 48.2 
L-lactate dehydrogenase A 
chain LLIVSNPVDILTYVAWK 972.6 666.4 48.2 
L-lactate dehydrogenase A 
chain LLIVSNPVDILTYVAWK 972.6 767.4 48.2 
L-lactate dehydrogenase A 
chain LLIVSNPVDILTYVAWK 972.6 880.5 48.2 
Beta-enolase 3 IGAEVYHHoxLK 591.8 413.3 31.1 
Beta-enolase 4 IGAEVYHHoxLK 591.8 550.3 31.1 
Beta-enolase 5 IGAEVYHHoxLK 591.8 713.4 31.1 
Beta-enolase 6 IGAEVYHHLK 583.8 397.3 31.1 
Beta-enolase 7 IGAEVYHHLK 583.8 534.3 31.1 
Beta-enolase 8 IGAEVYHHLK 583.8 697.4 31.1 
Glycogen phosphorylase VLYnitroPNDNFFEGK 744.3 856.4 37.8 
Glycogen phosphorylase VLYnitroPNDNFFEGK 744.3 970.4 37.8 
Glycogen phosphorylase VLYnitroPNDNFFEGK 744.3 1067.5 37.8 
Glycogen phosphorylase VLYPNDNFFEGK 721.9 856.4 37.8 
Glycogen phosphorylase VLYPNDNFFEGK 721.9 970.4 37.8 
Glycogen phosphorylase VLYPNDNFFEGK 721.9 1067.5 37.8 
Pyruvate kinase NICtrioxKVVEVGSK 612.9 390.2 32.2 
Pyruvate kinase NICtrioxKVVEVGSK 612.9 519.3 32.2 
Pyruvate kinase NICtrioxKVVEVGSK 612.9 618.4 32.2 
Pyruvate kinase NICKVVEVGSK 616.8 390.2 32.2 
Pyruvate kinase NICKVVEVGSK 616.8 519.3 32.2 
Pyruvate kinase NICKVVEVGSK 616.8 618.4 32.2 
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Quantification of the modified peptides with targeted MS methods demonstrated the ability of 
mass spectrometry as a useful analytical tool for biological samples. Unfortunately, not all 
modified peptides could be quantified, but the ones that were showed interesting results. 
Figure 4.10 demonstrates how the percentage modification of a peptide was calculated 
using the MRM data. Extracted ion chromatograms were used to identify the retention time 
at which all transitions appeared. This determined which peaks were used for quantification. 
The area under the peak was calculated for the unmodified and modified peptides to give an 
overall percentage modification. The highlighted ions show the sequence of the 
corresponding peak where a mass shift can be seen relating to the addition of one or two 
oxygen to the peptide when modified. 
Not all MRM analyses were successful. Figure 4.9 displays the XIC of the OxW transitions 
from SERCA in an obese sample that showed signals at noise level. Many modifications 
gave similarly poor results, which may reflect the limited of sensitivity of the approach and 
requires further optimisation for the quantitation of oxPTMs that are less susceptible to 
modification. 
 
Figure 4.9. MRM spectrum of OxW of SERCA peptide EPLISGWLFFR in obese MH. 
Transitions coloured blue, orange and pink.  
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Figure 4.10. MRM spectra of TGTLTTNQMSVCK OxM & DioxM in obese sample. Data are represented as extracted ion chromatograms of 
product ions (A) and sequenced peptides from MRM (B). +16 Da = Addition of oxygen.  = Mass shift. 
A) Extracted ion chromatograms: 
B) Sequenced peptides: 
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From quantification of the raw data, bar charts were produced to represent the difference 
between ob/ob and control samples (Fig.4.11). All peptides show higher levels of oxidation in 
the ob/ob samples, but only two showed statistically significant results. The large error bars 
are due to biological variation and demonstrate the need for many more biological replicates 
to determine whether ob/ob samples are more oxidised overall than the corresponding 
controls. Some modifications were shown to be different between the control and obese 
samples i.e. GTAIAICR with ~6 fold increase and AEIGIAMSGTAVAK with ~1.8 fold 
increase in obese muscle. As mentioned in the previous chapter, both these peptides are 
adjacent to Cys674, a key residue involved in the redox regulation of SERCA, and again 
supports the theory that these two residues play a protective role in order to prevent 
irreversible modification to Cys674. 
Unfortunately, due to limits on MS sensitivity, all of the SERCA peptides successfully 
quantified contained highly susceptible residues i.e. methionine and cysteine. Although this 
does provide information on residue susceptibility and possible effects of location of residue 
to function, there is not enough information to give a complete picture of how oxidants from 
inflammation, modify muscle proteins in obesity. 
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Figure 4.11. Quantitation of SERCA peptides in obese muscle. Percentage modification 
of OxM (A) and DioxM (B) in TGTLTTNQMSVCK, TrioxC (C) in EVTGSIQLCR, OxM (D) and 
DioxM (E) in AEIGIAMGSGTAVAK, and TrioxC (F) in GTAIAICR peptides of SERCA. 
*Statistically significant data (p<0.05), n=3. 
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4.3. Discussion 
4.3.1. Muscle loss and reduction in SERCA activity 
Obese mice showed a decrease in muscle mass which suggests that these changes are a 
result of the obese state of the mouse model. The reduction seen in this study was 
approximately one third of the control mouse weight and concurs with the evidence from the 
literature. It is in agreement with a study that found a reduction in muscle mass in ob/ob mice 
and further reported ~30% decrease in predominant muscle fibre size (Kemp et al. 2009). 
The reduction in muscle mass has been linked to impaired muscle generation brought about 
by the decrease in macrophage accumulation, activity of myoblasts and angiogenesis 
(Nguyen, Cheng and Koh, 2011). On the other hand, the specific activity of SERCA was 
shown to be non-significantly reduced in the ob/ob mice in this study. Studies with SERCA in 
liver of obese mice have showed decreased activity, alongside reports on muscle changes, 
which have correlated the impairment of SERCA function with changes in phospholipid 
composition due to dietary influence (Fu et al. 2011; Funai et al. 2013). Moreover, literature 
on SERCA in diabetic models has linked the reduction in activity to the presence of oxPTMs 
(Ying et al. 2008). Although a number of reasons have been suggested for what causes the 
reduction in SERCA activity, one possible candidate is the effects of oxidative modification 
on the function of SERCA, which was shown to occur at higher levels than the control in this 
study. 
4.3.2. Increased levels of nitrative modifications in immunoblots 
The immunoblots showed higher levels of SNO and NitroY detected in the obese model in 
comparison to the control. An increased level of NitroY has previously been detected using 
immunofluorescent histochemistry in the sciatic nerve, spinal cord, dorsal root ganglion of 
ob/ob mice (Drel et al. 2006). NitroY has also been detected in mitochondrial proteins in liver 
tissue of ob/ob mice (Garcia-Ruiz et al. 2006). Both of these studies indicate the presence of 
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increased NitroY in other tissues and coincide with what has been detected in the skeletal 
muscle used in this study. 
S-nitrosation of insulin receptor beta subunit and protein kinase B/Akt were observed in 
ob/ob mice (Carvalho-Filho et al. 2005), demonstrating the presence of s-nitrosation in 
muscle and concurring with the results from the immunoblot probed with anti-SNO. The 
presence of nitrative species in the muscle of ob/ob mice at higher levels is in agreement 
with the literature and confirms that a higher frequency of proteins in the ob/ob model are 
present as oxidised biomolecules. 
4.3.3. Characterisation of oxPTMs in skeletal muscle proteins of ob/ob mice 
In a single band from the SR samples, 12 proteins were shown to contain oxPTMs that were 
not oxidation of methionine residues: SERCA, Na+/K+ transporting ATPase subunit alpha-2, 
ADP/ATP translocase 1, myeloperoxidase, pyruvate kinase, creatine kinase M type, fructose 
bisphosphate aldolase A, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), glycogen 
phosphorylase, pyruvate kinase, enolase b, lactate dehydrogenase, and fructose-
bisphosphate aldolase A. The majority of these proteins are involved in glucose metabolism 
and energy production, and while it has been reported that there is increased abundance of 
GAPDH and aldolase A in obese muscle, it has previously also been reported that these 
proteins are susceptible to oxidative stress (Shenton and Grant, 2003; England et al. 2004; 
Hittel et al. 2005). GAPDH in particular has been reported to be susceptible to cysteine 
oxidation, resulting to the change in interactors depending on whether GAPDH is present in 
its oxidised form (Hwang et al. 2009). Na+/K+ transporting ATPase subunit alpha 2 pumps 
sodium ions out and potassium ions into the cell, and has been shown to be important in 
maintaining contraction of the skeletal muscle and resisting fatigue that results from the 
reduced force unable to compensate for the demand (Radzyukevich et al. 2013). 
Myeloperoxidase is found in neutrophils and produces hypochlorous acid as an effective 
defence mechanism against pathogens (Klebanoff, 1999). In addition to this role, 
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myeloperoxidase has been reported to have vasoconstricting properties in the skeletal 
muscle (Csató et al. 2015). 
SERCA had the highest number of oxPTMs detected: three TrioxC, two DioxM, one OxW 
and one DioxW, resulting in a total of 7 oxPTMs identified. Met720 and Met361 were found 
in the phosphorylation domain and nucleotide binding domain of SERCA respectively. 
Met720 in particular may be an important residue as it is adjacent to Cys674, a key residue 
involved in redox regulation of SERCA (Adachi et al., 2004). The role of this residue may be 
to act as a scavenger for oxidants to prevent the further oxidation of Cys674 to an 
irreversible form. Cys561 was located in the nucleotide binding domain, whereas Cys614 
and Cys636 were located in the phosphorylation domain. Cys636, in particular, was also 
found to be adjacent to Cys674 previously mentioned to be involved in redox regulation. This 
residue may function in the same manner as Met720, i.e. as an endogenous scavenger to 
protect cysteine from irreversible oxidation. The last modified residue, Trp832, was found in 
the transmembrane domain of SERCA. As there is very little on functional studies of these 
modified residues it is difficult to determine whether these changes have an impact on 
protein function. However, if these protein functions are affected, it could explain the physical 
outcomes of lower muscle performance in obesity. 
From the muscle homogenate samples, nine proteins were found to be oxidised: kallikrein 1-
related peptidase b24, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), synaptojanin-
2, tumor necrosis factor receptor superfamily member 11A, 6-pyruvoyl tetrahydrobiopterin 
synthase (PTPS), creatine kinase M-type, fructose-bisphosphate aldolase A, glutathione S-
transferase P1, and hemoglobin subunit beta-1. Kallikrein 1-related peptidase b24 releases 
bradykinin which is a vasodilator and is involved in reducing blood pressure (Matsui et al. 
2005). There are no reports in the literature that show this protein to be modified from 
Lys119 to Allysine119. GAPDH is involved in glycolysis, but it has also been reported to 
contribute to modulation of vesicle endocytosis via binding to Pro234 (Robbins, Ward and 
Oliver, 1995). Substitution of this residue was shown to disrupt endocytosis, however, the 
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residue that was found to be oxidised in this study was its neighbouring proline residue 
Pro236. Synaptojanin-2 is involved in membrane trafficking, signal transduction pathways 
and clathrin mediated endocytosis (Rusk et al. 2003). In this study, two neighbouring proline 
residues were found to be oxidised in the C-terminal, which is proline rich. OxP was also 
detected in TNF receptor superfamily member 11A at Pro577. The protein is a receptor 
activator of nuclear factor-kappaB and important for energy metabolism in skeletal muscle as 
well as suggested candidate for obesity determination (Zhao et al. 2006). The enzyme PTPS 
is involved in the production of tetrahydrobiopterin, which contributes to the conversion of 
phenylalanine to tyrosine and is involved in production of neurotransmitters (Bonafe et al. 
2005). PTPS is the only protein with a validated NitroY modification in the current study. 
Interestingly, this protein was found in the GeLC fraction 5 band, although its native mass is 
16 kDa and it was expected to be further down the SDS-gel.  When comparing this to the 
NitroY immunoblot, one of the denser bands is in the same region as the excised GeLC 
fraction 5 band. Thus not only has NitroY been detected with immunoblotting but also the 
one of the proteins containing NitroY was identified using MS. Tyr127 is a residue within 
PTPS that is commonly phosphorylated, and while it is known that phosphorylation to Ser19 
is important for maximal activity, additional studies have not yet shown the significance of 
Tyr127 phosphorylation on activity (Scherer-Oppliger et al. 1999; Bian et al. 2014). However, 
nitration of Tyr127 is likely to interfere with its phosphorylation, and potentially its function. 
Deficiency in tetrahydrobiopterin production could lead to insufficient production of protein 
due to reduced conversion of phenylalanine to tyrosine. Detection of NitroY and carbonyl 
groups in creatine kinase have been reported in the literature in aged skeletal muscle (Nuss 
et al. 2009). The protein is important for suppyling energy to the muscle and so the group 
proposed that the nitrotyrosine and carbonyl groups lead to aggregation of the protein and 
loss of function, which may result in muscle frailty. Haemoglobin subunit beta-1 is important 
for the transport of oxygen in the blood, and studies involving tryptophan oxidation monitored 
by fluorescence have suggested that oxidised haemoglobin releases the haem group (Chiu 
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et al. 1996). One example of a study that looked into oxPTMs in obese mice was the 
identification of carbonyl groups in adipose tissue, which used mass spectrometry to detect 
filamin A, eukaryotic elongation factor 1a-1, glutathione peroxidase 1, peroxiredoxin 1, 
glutathione S-transferase M1 (Grimsrud et al. 2007). As this was reported in adipose tissue, 
the characterisation of the oxidised proteins in the muscle of ob/ob mice could potentially be 
novel modifications detected in relation to the model. Of the proteins listed, glutathione S-
transferase was also detected in the current study; however, the modification identified was 
methionine dioxidation. Glutathione S-transferase has an important role in protection against 
oxidative stress via catalysing the reaction of reduced glutathione (Nebert and Vasiliou, 
2004). 
4.3.4. Quantitation of oxidised muscle proteins 
The results from the MRM studies showed successful quantitation of a few oxidised residues 
in SERCA. From the six quantified peptides, two were considered to have a statistically 
significant difference when comparing triplicate values from the obese and control muscle. 
Furthermore only DioxM and TrioxC were quantified using MRM approaches and as these 
residues are the most susceptible to oxidation, the current methods developed for this study 
are limited to abundant modifications. While the MRM approach was not particularly 
successful, it still demonstrated the higher levels of oxidation detected in the ob/ob model. 
While there does not appear to be previous quantitation of oxPTMs in muscle tissue of ob/ob 
mice with which to make comparisons, there are alternative studies that do show successful 
quantitation of oxidised proteins in obesity related models. The effect of antioxidants from 
green tea was tested on Zucker diabetic fatty (ZDF) rats to determine oxidative changes in 
plasma proteins by SRM based methods (Madian et al. 2011). Proteins containing carbonyl 
groups were enriched from plasma by biotinylation and subsequently seventeen carbonyl 
groups were detected and quantified. As these oxidised proteins were identified in plasma 
samples there were no reports of modified proteins discovered from this muscle study. 
However, in comparison to the plasma study, the identification of twelve modifications in the 
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muscle of the ob/ob mice, in which two of the peptides were shown to contain allysine, does 
demonstrate the advantages and disadvantages of enrichment for specific modifications. 
While more carbonyl groups were detected in the plasma samples, the opportunity for 
characterisation and quantitation of other oxPTMs was lost. Nonetheless, the study did show 
carbonyl group formation on lysine, arginine, proline and threonine residues and 
demonstrated reduction of oxidation with green tea treatment. Additional differences in the 
methodology used to quantify the biotinylated enriched carbonyl groups included the 
fractionation of the plasma samples with a propylsilane (C3) reverse phase column and the 
use of two transitions for peptide quantitation. This approach increases the concentration of 
the targeted peptides within a sample injection volume and has a much lower risk of 
targeting isobaric peptides for MS/MS fragmentation. It also explains the reduced number of 
peptide transitions used in the study, which would lead overall to reduced cycle times, more 
peptides quantified in one MS run, and in turn develop high throughput SRM methods. 
Comparisons to this study indicate the many possible approaches to sample preparation and 
development of quantitative MS methods when study oxPTMs. 
4.3.5. Concluding statement 
From these data it can be concluded that enrichment of proteins by isolating SR resulted in 
characterisation of more oxPTMs, compared to the whole muscle homogenate. On the other 
hand, the analysis with the muscle homogenate led to the identification of other 
modifications in proteins that were absent in the isolated SR samples. Thus both types of 
samples have advantages and disadvantages when identifying oxPTMs using MS/MS 
approaches.  Based on known functions of the proteins described previously in the literature, 
the consequences of protein oxidation can be suggested; for example, the oxPTMs detected 
may affect neurosignalling, energy metabolism, protein building, skeletal function and 
regulation of blood pressure and oxygen transport. Functional studies are required to 
determine whether the oxPTMs discovered in this study result in functional disruption and in 
turn lead to the physical traits of obesity. Our current findings have demonstrated detection 
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of novel modifications, not previously characterised in the muscle of aged model used in this 
study. The current study reports for the first time the application of pseudoMRM techniques 
developed to identify Ally, OxP, NitroY, OxW and OxY in the whole muscle homogenate 
whereas TrioxC, OxW, DioxW, DioxM, OxY and OxH were detected in isolated sarcoplasmic 
reticulum. The modifications identified in the muscle homogenate have not been previously 
observed in muscle in obesity and this provides molecular information on which future 
functional studies of obesity can build an understanding on the role of oxidation in obesity.  
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Chapter 5 
 
Identification and quantification of 
oxidised proteins in the muscle of 
aged mice and comparisons to the 
obese model  
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5.1. Introduction 
Research on ageing has been an ongoing process for many scientists and still has yet to 
uncover the mechanisms involved in triggering the event that leads to the deterioration of the 
body through the advancement to death. The peak age at which cognitive abilities, bone 
mass, muscle strength and athletic performance is at optimum level is 30 years on average 
(O’Flaherty, 2000; Hughes et al. 2001; Rust et al. 2012; Hartshorne and Germine, 2015). 
However, it remains undiscovered as to why this declines after approximately 30 years of the 
average lifespan. The ageing field encompasses experiments on many theories with various 
biological systems, tissues and samples to discover what triggers the decline of the body’s 
health and performance after 30. This project specifically investigates the role of oxPTMs in 
ageing which stems from a theory proposed in 1956 by Denham Harman. Though it is widely 
debated whether oxidative damage is the cause of the ageing process, early studies 
demonstrated the presence of oxidation at higher levels in aged tissue. Therefore it was 
hypothesised that oxidation of biomolecules may be the result of the ageing process and 
contributes to the deterioration of the body; however to explore this further, preliminary 
studies were required to understand which oxPTMs were involved and which proteins are 
inflicted with oxidative damage. This led to a study on the analysis of oxidised proteins in 
sarcopenia using an aged mouse model. 
5.1.1. The sarcopenic model and its association to oxidation 
Sarcopenia, the age associated loss of muscle mass and function, inflicts 5% of the elderly 
population at 65 years and one in two individuals beyond the age of 80 years. (Morley, 
2012). The primary focus of this study was on the SERCA protein but analysis of other 
muscular proteins was carried out. The presence of oxidised proteins has been reported for 
muscle, with particular focus on SERCA oxidation, in many studies (Viner, et al., 2000; 
Schoneich and Sharov, 2006; Strosova, et al., 2009b). In addition, ageing studies have 
shown that there is a slower turnover rate of protein in the muscle, 27 ± 5% for SERCA, 
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which could be related to the increased presence of oxidised species in aged tissue 
(Ferrington, Krainev and Bigelow, 1998). With the diverse studies undertaken on detection of 
oxidation in muscle, this chapter was set to explore global oxidation within muscle and detect 
oxPTMs without the need for enrichment for a specific modification.  
5.1.2. Analysis of oxPTMs using mass spectrometry 
There are a number of ways to detect and measure protein oxidation with both mass 
spectrometry and non-mass spectrometry methods. Antibodies specific for oxidative 
modifications, most commonly utilised in immunoblotting, can be used to determine the 
presence of the modification. Another immunoblotting technique involves the reaction of 
dinitrophenylhydrazine (DNPH) with protein carbonyls and anti-DNP antibodies to detect the 
modification (Levine et al., 1994). Although immunoblotting techniques are more sensitive 
than MS, it lacks the ability to pinpoint the location of the modification or be used in 
quantitational studies. Mass spectrometry methods involve both labelling and non-labelling 
methods. With labelling there are different types of tags used: isobaric, isotopic, biotinylated, 
etc. (Jaffrey et al. 2001; Zhou et al. 2014). Although the labelling and enrichment strategy 
reduces the complexity of the sample, the focus is usually on one modification so a lot of 
information is lost when removing other peptides with different modifications or with a 
different oxidative state. On the other hand, label-free methods opens up to the detection 
and quantification of multiple modifications in the same sample. In chapter 3, several 
quantitation methods were explored and developed for the quantitation of oxPTMs. These 
MS approaches were then applied in chapter 4 to understand the role of oxidation in an 
obese model. This chapter outlines the steps that were taken to apply the same MS 
approaches to an aged model and address similarities and differences between the models. 
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5.1.3. Aims 
The aim of this study was to identify oxPTMs in the muscle of an aged mouse model and 
determine the percentage of oxidised residues using quantitative MS/MS approaches. In 
addition to the analysis applied on the ageing skeletal muscle proteome, the work reported in 
this chapter explored the differences between oxPTMs in ageing and the ob/ob model from 
the previous set of experiments. This was achieved by discovery tandem mass spectrometry 
and multiple reaction monitoring. 
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5.2. Results 
Unlike previous experiments, the full muscle of the hind leg was not available. Subsequent 
experiments were performed on the gastrocnemius muscle kindly provided by Malcolm J. 
Jackson, University of Liverpool. The lack of tissue available for the study resulted in muscle 
homogenate samples solely produced and utilised for the analysis of oxidised residues in the 
aged model. The experiments from the previous chapters have shown successful MS 
analysis with a complex mixture of proteins. 
5.2.1. Muscle weight and SERCA assay in young and aged muscle extracts 
Sarcopenia is defined by the loss of muscle mass and function. In order to confirm the 
sarcopenic properties of the aged model, the weight of the gastrocnemius muscle samples 
and the specific activity (µmol of free phosphate min-1 mg-1) of an individual protein were 
assessed. SERCA has been shown to have decreased activity in aged muscle (Xu and 
Narayanan, 1998; Knyushko et al. 2005) and so is a suitable candidate to test the level of 
functional decrease. As seen in Fig.5.1A, there is a reduction in muscle mass in the aged 
model when compared to the younger model of approximately 0.08g of muscle. This loss of 
muscle mass is also coupled with a reduction in SERCA activity of around 30% in Fig.5.1B. 
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Figure 5.1. Indication of sarcopenia by measurements of the weight of gastrocnemius 
muscle and functional activity of SERCA. A. Weight of gastrocnemius muscle of control 
and aged mice; p<0.05*; n = 4 (unpaired t-test). B. Activity assay of SERCA (unpaired t-test 
p<0.01**). Weights of gastrocnemius muscle were provided by Dr Kasia Whysall, University 
of Liverpool. 
* ** 
A B 
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These initial results confirm the loss of muscle seen in sarcopenia in addition to the reduced 
activity of SERCA in the aged model. The next step was to ascertain the global presence of 
oxidation within the muscle homogenates of both models. This was determined by western 
blotting with focus on the presence of carbonyl groups and nitrative modifications. These 
modifications were chosen based on availibility of antibodies to these modifications as well 
as well established methods present in the literature. 
5.2.2. Immnuoblotting for oxidative modifications of proteins 
The carbonyl groups and nitrosothiol were detected using the appropriate antibodies. 
Carbonyl group detection involved derivartisation with dinitrophenylhydrazine to be detected 
by anti-DNP. From the first immunoblot, there are not many bands detected in the separated 
proteins by the electrophoresis (Fig.5.2). The densest band is shown to be just below the 
wells of the SDS-gel. This may indicate that carbonyl groups, in bands of almost equal 
density, are present in aggregated proteins in both the young and aged muscle samples. It is 
not clear whether aggregated proteins were formed in vivo or are artefacts but from the 
loading control there is consistent loading for both samples. Tubulin has a molecular weight 
of approximately 50 kDa and was used to demonstrate the samples were loaded 
consistently. 
    
                       Tubulin loading control 
Figure 5.2. Oxyblot of young and aged muscle samples. A. Derivartised carbonyl groups 
were probed with anti-DNP and B. Protein loading was assessed by detection of tubulin. 
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The second blot, probed with anti-SNO, shows denser bands in the separated proteins but 
also targeted the same areas of both samples (Fig.5.3). Although this blot seemed to work, 
there is very little difference seen in the young and aged replicates. From the loading control, 
there is consistent loading, however, the expected result of an increase in SNO-groups in 
aged samples was not present. As these are the results achieved and replicates of the blot 
do not show any additional differences, it can be assumed that there either is no difference 
in SNO in the models used in this study or resulted from indiscriminate binding of a 
degrading antibody. 
  
Marker Young    Young     Aged   Aged Young     Aged 
 Tubulin loading control  
Figure 5.3. Immunoblotting with anti-SNO of young and aged samples in duplicate. A. 
Immunoblot of young and aged samples probed with anti-SNO. B. SDS-PAGE of young and 
aged samples. Fractions are labelled and outlined with orange boxes. C. Loading control 
assessed with anti-tubulin. 
With the current results from the immunoblot, there were no oxPTM differences detected 
between the two models. This may be due to problems associated with the immunoblotting 
technique so it was decided that the project would utilise MS analysis to confirm or reject the 
results obtained from the immunoblots. Several attempts were made to fix the problem but 
the resulting figures could be down to failure of the antibodies as these sets of experiments 
were completed much later in comparison to the earlier blots shown in the previous 
chapters. 
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5.2.3. Identification of proteins and oxPTMs in young and aged muscle 
The next set of experiments involved MS/MS analysis of digested peptides from the muscle 
homogenate of the young and aged models. The analysis was accomplished by submission 
of protein IDs to an online gene ontology tool: PANTHER. The gene ontology tool groups 
proteins into a category that is common to the set of proteins. This was used to group the 
proteins from the aged muscle into categories of biological processes. The results from the 
gene ontology study demonstrated that a higher proportion of proteins in the aged model 
accounted for metabolic processes, biological regulation and response to stimuli while fewer 
were involved in reproduction, cellular component organisation or biogenesis, and 
developmental processes (Fig.5.4). However without protein quantitation, it cannot be 
determined whether proteins from these categories are over or under expressed but does 
give an indication that the changes in protein abundance may have led to increased or 
decreased discovery of proteins from the most influenced groups. 
 
Figure 5.4. Gene ontology study on MS discovered proteins in aged gastrocnemius 
muscle in comparison to proteins from ob/ob whole muscle. Colours represent 
biological processes colour coded in the key. Pie chart from the previous obesity chapter is 
shown in top-left box. 
148 
 
Similarly to the previous chapters, the identified modified peptides from Mascot were 
subjected to de novo sequencing to validate whether the identification was a true positive or 
false positive. Fig.5.5 demonstrates sequencing of a true positive MS/MS spectrum and a 
false positive. The presence of a proline oxidation in the steryl-sulfatase peptide was 
confirmed both by Mascot and de novo sequencing whereas the peptide from proactivator 
polypeptide-like shows an alternative sequence from manual sequencing that fits the MS/MS 
spectrum better than the proposed sequence from Mascot. 
 
 
Figure 5.5. De novo sequenced oxidised peptides detected by Mascot. A. Spectrum of 
proline oxidation of Steryl-sulfatase peptide DLMP(ox)LLR validated as true positive result. 
B. Spectrum of oxidised proline of ASPISVP(ox)R peptide from Proactivator polypeptide-like 
shown to be a false positive result. Mascot detected sequence labelled in black whereas 
alternative labelling from manual sequencing is highlighted in red. 
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The results from the aged model could only confidently return 5 verified peptides (Table 5.1). 
The lack of modifications detected was due to problems with the instrument performance; 
however, there still was a list of oxPTMs detected from the model. While there were similar 
protein/peptide identifications when compared to the obese sample, there are also additional 
ones not previously detected. The differences in oxidised peptide identifications could be 
due to the observed differences in protein IDs from whole ob/ob muscle and the aged 
gastrocnemius muscle. With very few modifications detected due to the poorer quality 
dataset obtained, it is difficult to determine whether there is a substantial difference in 
oxidation when comparing the control and aged samples. To overcome many of the 
problems, with additional time, repeated experiments could elucidate whether more 
modifications could be detected with a second MS/MS run. 
Table 5.1. Table of oxidised peptides discovered utilising Mascot. Summary of oxidative 
modifications achieved through searches in Swiss-Prot database with carbamidomethyl as a 
fixed modification and the variable modifications in the table, as described in Chapter 2. The 
results are identified by the protein of origin, modified residue and type of modification as 
well as the sequence of the oxidised peptide. Residues that were modified in the peptide 
sequence are highlighted in red. 
Protein Modification & Residue Sequence 
Glycogen phosphorylase OxY52 
 
DYFFALAHTVR 
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) 
OxP236 
 
VPTPNVSVVDLTCR 
Acid sphingomyelinase-like 
phosphodiesterase 3a 
DioxM297 DSLMVLSDK 
Steryl-sulfatase OxP436 DLMPLLR 
Phosphoglycerate mutase 2 OxP125 SFDTPPPPMDEK 
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5.2.4. Quantification of oxPTMs in young and aged muscle 
In order to assess the percentage of modified peptides, the aged and young samples were 
subjected to the same quantitation methods used for the obese sample. Figure 5.6 shows 
overlaid spectra from native, OxM and DioxM peptide from SERCA. With this method a 
mass shift can be seen with the transitions as well as changes in intensity between the 
native and modified peptides. Not only can this be used to quantify oxPTMs but the 
sequence can also be verified by the differences seen between the transitions. 
 
Figure 5.6. Example of targeted MRM method using transitions of native, oxidised and 
dioxidised product ions from SERCA peptide AEIGIAMGSGTAVAK MS/MS 
fragmentation. Transitions from native and oxidised peptides are colour coded and labelled 
to show mass shifts in peptide sequence. The addition of oxygen is labelled as +16, 
 
Using this method, quantitation of the fractions of both the obese study and aged study were 
compared. Table 5.2 shows quantification in a single peptide from SERCA assessing 
oxidation of the methionine residue. While there seems to be consistency in the total 
modification of the aged and obese samples, the controls for each differ with higher levels of 
methionine dioxidation and lower levels of methionine oxidation found in the young sample 
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when compared to the lean sample. The control models are from two different mice: NMRI 
and C57BL/6J. In this data set, there are higher levels of total modification in the obese 
sample. When separating the two modifications, the obese sample has higher methionine 
oxidation whereas the aged sample has higher methionine dioxidation. In both sample 
datasets, there are higher amounts of total modification in the obese and aged samples in 
comparison to their controls. The data also shows the benefits of quantification with non-
biased GeLC fractionation. From the quantification, there are modified and native forms of 
the peptide detected throughout the gel. The highest level of native peptide is found in the 
high molecular region where the protein should be present. There are peptides detected at 
the mid and low MW ranges. For the methionine oxidised peptides, higher levels are 
detected in the mid to low range whereas the methionine dioxidised seem to be present 
more in the mid-MW range of the SDS-gel. For many of these cases, it can be assumed that 
the modifications are more prevalent in aggregated and fragmented forms of the protein.  
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Table 5.2. MRM quantitation of AEIGIAMGSGTAVAK of SERCA in aged and obese 
mice. Peak area and percentage modification are displayed in the table. Total modification is 
highlighted in a darker shade to differentiate between results from individual fractions. 
Fractions are not the same in the obese and aged sets. 
Lean Frac. 
1 
Frac. 
2 
Frac. 
3 
Frac. 
4 
Frac. 
5 
Frac. 
6 
Frac. 
7 
Frac. 
8 
Frac. 
9 
Frac. 
10 
Total 
Peak area 
(native) 
1.91E
+03 
1.42E
+04 
3.12E
+03 
3.31E
+02 
3.32E
+02 
4.18E
+02 
2.41E
+01 
1.21E
+01 
1.21E
+01 
0.00E
+00 
2.03E+
04 
Peak area 
(OxM) 
1.00E
+03 
4.36E
+03 
1.73E
+03 
2.84E
+02 
2.30E
+04 
4.47E
+03 
1.35E
+03 
1.69E
+02 
6.03E
+01 
3.62E
+01 
3.65E+
04 
Peak area 
(DioxM) 
0.00E
+00 
0.00E
+00 
0.00E
+00 
0.00E
+00 
1.46E
+02 
2.17E
+02 
6.63E
+01 
0.00E
+00 
0.00E
+00 
0.00E
+00 
4.30E+
02 
% Modified 
(OxM) 
34% 24% 36% 46% 98% 88% 94% 93% 83% 100% 64% 
% Modified 
(DioxM) 
0% 0% 0% 0% 1% 4% 5% 0% 0% 0% 1% 
Obese Frac. 
1 
Frac. 
2 
Frac. 
3 
Frac. 
4 
Frac. 
5 
Frac. 
6 
Frac. 
7 
Frac. 
8 
Frac. 
9 
Frac. 
10 
Total 
Peak area 
(native) 
2.20E
+03 
1.64E
+04 
3.85E
+03 
4.53E
+02 
1.01E
+03 
4.10E
+02 
4.83E
+01 
2.41E
+01 
0.00E
+00 
0.00E
+00 
2.44E+
04 
Peak area 
(OxM) 
1.33E
+03 
8.19E
+03 
1.17E
+03 
1.57E
+02 
3.21E
+04 
3.15E
+03 
9.44E
+02 
6.03E
+01 
9.65E
+01 
3.62E
+01 
4.72E+
04 
Peak area 
(DioxM) 
0.00E
+00 
0.00E
+00 
0.00E
+00 
0.00E
+00 
3.02E
+03 
9.65E
+01 
2.41E
+01 
1.21E
+01 
0.00E
+00 
1.21E
+01 
3.16E+
03 
% Modified 
(OxM) 
38% 33% 23% 26% 89% 86% 93% 63% 100% 75% 63% 
% Modified 
(DioxM) 
0% 0% 0% 0% 8% 3% 2% 12% 0% 25% 4% 
Young Frac. 
1 
Frac. 
2 
Frac. 
3 
Frac. 
4 
Frac. 
5 
Frac. 
6 
Frac. 
7 
Frac. 
8 
Total   
Peak area 
(native) 
2.76E
+04 
1.64E
+04 
5.19E
+02 
9.96E
+02 
2.59E
+02 
2.41E
+01 
0.00E
+00 
0.00E
+00 
4.58E
+04 
  
Peak area 
(OxM) 
1.29E
+04 
8.55E
+03 
4.28E
+02 
1.08E
+04 
9.53E
+02 
1.69E
+02 
7.24E
+01 
4.83E
+01 
3.39E
+04 
  
Peak area 
(DioxM) 
0.00E
+00 
0.00E
+00 
0.00E
+00 
3.22E
+03 
4.74E
+01 
0.00E
+00 
0.00E
+00 
0.00E
+00 
3.26E
+03 
  
% Modified 
(OxM) 
32% 34% 45% 72% 76% 87% 100% 100% 41%   
% Modified 
(DioxM) 
0% 0% 0% 21% 4% 0% 0% 0% 4%   
Aged Frac. 
1 
Frac. 
2 
Frac. 
3 
Frac. 
4 
Frac. 
5 
Frac. 
6 
Frac. 
7 
Frac. 
8 
Total   
Peak area 
(native) 
3.49E
+04 
3.77E
+04 
2.28E
+03 
5.77E
+03 
2.16E
+03 
9.65E
+01 
0.00E
+00 
0.00E
+00 
8.28E
+04 
  
Peak area 
(OxM) 
3.59E
+04 
1.46E
+04 
1.60E
+03 
3.78E
+04 
6.05E
+03 
3.78E
+02 
3.68E
+02 
1.15E
+02 
9.68E
+04 
  
Peak area 
(DioxM) 
2.29E
+02 
4.83E
+01 
1.45E
+02 
7.94E
+03 
1.17E
+02 
2.41E
+01 
0.00E
+00 
0.00E
+00 
8.50E
+03 
  
% Modified 
(OxM) 
51% 28% 40% 73% 73% 76% 100% 100% 51%   
% Modified 
(DioxM) 
0% 0% 4% 15% 1% 5% 0% 0% 5%   
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MRM quantitation was applied to additional SERCA peptides in order to compare the level of 
oxPTMs present in aged samples versus the control. From quantification of the raw data, bar 
charts had been produced to represent the difference between aged and control samples 
(Fig.5.7). All peptides showed higher levels of oxidation in the aged samples; however, only 
one result was statistically significant: GTAIAICR. The large error bars were due to biological 
variation and demonstrate the need for far more biological replicates to determine whether 
aged samples are overall more oxidised than the controls. The other peptides did appear to 
have higher levels of oxidation, but owing to the variation between the replicates the 
differences were not significant. Unfortunately, due to limits on MS sensitivity, all of the 
successful SERCA peptides quantified contained highly susceptible residues i.e. methionine 
and cysteine. Though this does provide information on residue susceptible and possible 
effect of location, there are not enough data to give a complete picture on how oxidants from 
inflammation, in ageing, modify the protein. 
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Figure 5.7. Quantification of cysteine and methionine oxidation in SERCA of aged and 
young samples. Percentage modification of TrioxC (A) in CLALATR, OxM (B) and DioxM 
(C) in TGTLTTNQMSVCK, TrioxC (D) in GTAIAICR, and OxM (E) and DioxM (F) in 
AEIGIAMGSGTAVAK peptides of SERCA. *Statistically significant data (p<0.05), n=3. 
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5.3. Discussion 
5.3.1. Reduction in muscle mass and SERCA activity 
The aim of the work described in this chapter was to identify and measure oxidised residues 
in sarcopenic muscle and compare this both with young animals, and with the results 
obtained from the analysis of the ob/ob model. As sarcopenia is the loss of muscle mass and 
function in association with ageing, the aged model was tested to see if it could be 
characterised as a sarcopenic model. The first part of the analysis involved measuring the 
difference in muscle weight between young and old muscle tissue. As expected, aged 
muscle showed a loss of approximately 22% of the control in gastrocnemius muscle weight. 
A similar loss in mass (around 23%) has been reported previously (Russ et al. 2014); 
however, the same study also showed a 17% reduction in SR calcium release but no change 
in calcium uptake, which is a result that was not replicated in this study. SERCA activity has 
been shown to decrease in aged muscle. A few studies have reported a 33% decrease in 
SERCA function with examples of these studies performed on elderly women and in the 
aged rat myocardium (Froehlich JP, et al. 1978; Hunter SK, et al. 1999). A very similar result 
of approximately 30% decrease in SERCA activity was seen in the aged muscle. 
5.3.2. Immunoblotting 
The immunoblotting did not give the results anticipated, and suggested some problems with 
the assays. A number of reasons could have caused this result but by judging the outcome 
of the Oxyblot and the immunoblot probed with anti-SNO, notable differences can be seen 
between the 2 procedures were seen. The Oxyblot had dense bands appear near the well 
which could be the result of the problems at the derivatisation stage leading to aggregation 
of the protein near the well of the SDS-gel. The anti-SNO blot does not show the same 
aggregation but rather several bands can be seen in both the control and aged sample with 
no differences. This could be caused by indiscriminate binding of either the primary or 
secondary antibody, possibly caused by deterioration through age. While it could be 
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suggested that the samples stored in the freezer for a substantial amount of time may result 
in increased aggregation and reduced the discrimination between the oxidative state of the 
control and aged samples, this appears to conflict with the increase in oxidation shown in the 
aged samples using the MS approaches.  
5.3.3. Gene ontology 
The differences in the proteins identified with MS/MS between the aged and obese studies 
was probably due to the change in the type of muscle sample used for the two studies. While 
the whole hind leg muscle was used in the obese study, only the gastrocnemius was used in 
the aged study. The gastrocnemius muscle contains more glycolytic fibres, which have a 
smaller mitochondrial capacity than oxidative fibres such as those in the soleus muscle 
(Philippi and Sillau, 1994). Glycolytic fibres have been shown to differ with increased 
glycolytic enzymes and reduced mitochondrial enzymes when compared to oxidative fibres 
(Donoghue et al. 2007). Ageing muscle has been shown to exhibit a shift from glycolytic to 
oxidative fibres displaying decreased expression of glycolytic proteins such as enolase and 
pyruvate kinase, whereas mitochondrial proteins such as NADH dehydrogenase and 
succinate dehydrogenase are shown to have increased (Gelfi et al. 2006; Capitanio et al. 
2009; O’Connell and Ohlendieck, 2009). However, without quantitative analysis of protein 
expression in the aged muscle, it cannot be determined whether there is an increase or 
decrease in the abundance of proteins in the aged muscle in comparison to the control. A 
group from the Korea Institute of Science and Technology demonstrated upregulation and 
downregulation of different proteins in aged gastrocnemius muscle when compared to the 
younger control by MRM analysis of mTRAQ labelled peptides (Hwang et al. 2014). mTRAQ 
is an amine-specific stable isotope labelling method that was utilised in this study to 
determine the abundance of protein in the aged and young gastrocnemius muscles labelled 
with light and heavy mTRAQ labels respectively. While the loss of global muscle mass was 
defined at approximately 10%, the study did report 53 proteins that were differentially 
expressed of which 20 had reduced expression and 33 had increased expression. The 
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results from this study elucidate to ageing affecting protein synthesis or degradation, which 
may explain the increase in expression of some proteins and decreased expression of 
others. 
5.3.4. Identification of oxPTMs in aged gastrocnemius muscle 
Five modified residues were identified in glycogen phosphorylase, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), acid sphingomyelinase-like phosphodiesterase 3a, 
steryl-sulfatase, and phosphoglycerate mutase 2. Glyceraldehyde-3-phosphate 
dehydrogenase was found to be oxidised at the same proline residue identified in the obesity 
oxPTM MS/MS discovery experiments from the previous chapter. This suggests that some 
proteins may be susceptible to oxidation and the susceptibility of these proteins is not 
disease-specific. Glycogen phosphorylase has been shown to contain oxidised tyrosine at 
position 52. Tyr52 is in helix 2; a region involved in interactions with adenosine 
monophosphate (AMP) (Rath et al. 2000). It has been reported that there is a SR associated 
glycogen increase by 30% with ageing (Russ et al. 2014). If modifications to glycogen 
phosphorylase have an effect on the enzyme’s conformation, it could in turn disrupt its 
function and may affect breakdown of glycogen which would lead to an increase in glycogen 
levels. The function of acid sphingomyelinase-like phosphodiesterase 3a is still being 
explored. While it was initially thought to be involved in the catabolism of sphingomyelin, a 
component of the nerve cell membranes, there have been a few reports on alternate 
possible roles such as a nucleotide phosphodiesterase function (Traini et al. 2014). It is 
unclear whether modifications to this protein would impact on muscle ageing without 
knowing the exact function of this protein in skeletal muscle. Steryl-sulfatase is involved in 
the regulation of oestrogen homeostasis but also has been found to regulate energy 
metabolism and improve insulin sensitivity (Jiang et al. 2014). Additionally, this study 
suggested protective effects by the protein via decreased inflammation in skeletal muscle 
with the overexpression of steryl-sulfatase. Phosphoglycerate mutase 2 is involved in 
glycolysis in skeletal muscle and studies in phosphoglycerate mutase deficiency have shown 
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partial defects to energy metabolism and exercise induced cramps possibly through the 
increased lactic acid and intracellular acidosis (Argov et al. 1987; Oh et al. 2006). 
5.3.5. Quantitation of oxidised peptides in SERCA 
It was reported that aged muscle fibres at rest showed an increase in oxidant production 
(Palomero et al. 2013). The same study also suggests that the increase in oxidation is more 
likely due to oxidant generation over reduced scavenger capability. Additionally, the paper 
also refers to research by Muller et al. 2007 which discusses the increase in mitochondrial 
release of hydrogen peroxide in denervated muscle fibres which are also present in aged 
muscle tissue. These studies indicate there is a higher production of oxidants which would 
lead to the presence of more oxidised proteins in the aged muscle. This is shown in the 
quantitative dataset obtained from the research in this chapter; however, the usage of only 
three replicates meant many of the quantified peptides were insignificant. Even so, the rise 
in oxidised SERCA residues in the aged gastrocnemius muscle could contribute to the 
reduction of SERCA activity demonstrated earlier in the chapter. 
5.3.6 Summary 
In conclusion, the work presented in this chapter has shown that the MS methods for 
detecting oxPTMs in muscle-derived proteins can be applied to the study of changes in 
muscle ageing, although with limited success. Only a small number of modifications were 
identified and quantified, and these were mostly oxidations of the susceptible sulfur-
containing residues cysteine and methionine. Nonetheless, the work demonstrates that 
specific oxidations of a variety of muscle proteins do occur, and interestingly, may be 
disease or condition-specific, and there were differences between those observed in obese 
and aged tissue. 
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Chapter 6 
 
General discussion 
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The objective of this research was to develop MS methods for the identification and 
quantification of oxPTMs of muscular proteins within aged C57BL/6 and obese ob/ob mouse 
models to gain a deeper understanding of the role of oxidative stress in ageing and disease, 
and to distinguish whether oxidative stress affects the models in a similar manner. As 
discussed in the background literature, numerous oxidised residues have been 
characterised and higher levels are reported in aged and diseased models in comparison to 
their control counterparts. Nevertheless, many of these studies focus on a particular protein, 
a specific modification, a single oxidant, a type of model, or a combination of the four and 
therefore lose out information on whether proteins are oxidised at the same sites or if the 
same modified residues are quantitatively similar when comparing the different models.  This 
study successfully applied non-labelling quantitative MS/MS analysis to measure oxPTMs 
identified by discovery MS/MS in both isolated sarcoplasmic reticulum and whole muscle 
lysate. Novel oxPTMs have been detected both in the aged and obese models not 
previously identified in muscle tissue. 
6.1. Summary of findings 
6.1.1. Detection and characterisation of oxPTMs in both models 
The physiological changes of both models demonstrated loss of muscle mass but only the 
aged model demonstrated significant reduction in SERCA activity. Additionally, the proteins 
identified differed based on gene ontology analysis. This was determined to be the result of 
different muscles used in the experiments. The obesity study utilised the whole muscle 
which included the soleus, extensor digitorum longus (EDL), and gastrocnemius whereas the 
ageing study had only utilised the gastrocnemius muscle tissue. The gastrocnemius muscle 
contains high levels of glycolytic fibres which exhibit increased glycolytic enzymes and 
reduced mitochondrial enzymes when compared to oxidative fibres (Donoghue et al. 2007). 
The difference in protein expression could also have contributed to the different oxPTMs 
detected in both studies. The oxidised residues of abundant proteins from whole muscle 
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homogenate and isolated sarcoplasmic reticulum were characterised in the obese model 
whereas only the muscle homogenate was analysed for the aged model. This was due to the 
availability of smaller amounts of muscle tissue in the aged mouse model. Nevertheless, for 
both models high levels of oxidation were measured when compared to their control 
counterparts. This was demonstrated both using western blotting techniques and the 
oxPTMs identified in the obese and aged muscle using discovery MS/MS. The increase in 
oxidation mimics what is seen in the literature for both models. Increased nitrative 
modifications, nitrotyrosine and s-nitrosothiols, have been detected in other tissues of ob/ob 
mice (Carvalho-Filho et al. 2005; Drel et al. 2006; Garcia-Ruiz et al. 2006). Additionally, 
carbonyl groups and nitrative modifications have been detected in aged tissues (Feng et al. 
2008; Murakami et al. 2012). Preliminary experiments with oxidations generated in vitro 
demonstrated that high sequence coverage was gained by enriching proteins via isolation of 
the sarcoplasmic reticulum, in comparison to the sequence coverage obtained from the 
same proteins in the muscle homogenate. While this meant more sequence coverage for 
particular proteins resulted in detection of additional modifications, the isolation filtered out 
other proteins with potential modifications of interest. Research groups do adopt pre-
enrichment strategies focusing on a particular modification or subset of modification e.g. 
carbonyl groups and oxidation states of cysteine (Guo et al. 2014; Bollineni, Hoffmann and 
Fedorova, 2014). Nonetheless, the approaches used in this study successfully identified 
novel different oxPTMs in obese muscle and aged gastrocnemius muscle. The obesity study 
showed a range of modification identified by Mascot: Ally, OxP, NitroY, OxW and OxY. On 
the other hand, fewer modifications were identified in the aged gastrocnemius muscle: OxY, 
OxP and DioxM. This could be due to the differences in muscle fibre types where 
gastrocnemius contains high levels of glycolytic fibres in comparison to the soleus which 
contains more oxidative fibres. The higher amounts of mitochondria could lead to oxidative 
fibres being more susceptible to oxidation than glycolytic fibres. 
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6.1.2. Quantitation of oxPTMs in both models 
In addition to detection, the oxPTMs were quantified using MRM to assess changes in the 
level of modified peptides for each model. Only a small number of peptides were quantified 
due to time constraints; however, the data set produced from the peptides demonstrated 
higher levels of oxidation in the diseased and aged models. This was limited by the number 
of replicates processed and analysed throughout the study, which resulted in many of the 
comparisons made being statistically insignificant. Nevertheless, this study has succeeded in 
producing MS methods for characterisation and quantitation of oxPTMs in muscle for 
biological material. In addition, the ob/ob model was compared to the aged model with the 
final findings suggesting that higher levels of oxidative stress is present in aged muscle 
tissue more so than in obese tissue. Many studies incorporate quantitation and discovery 
into one MS run decreasing the number of samples processed through MS (Ghesquiere et 
al. 2011; McDonagh et al. 2012; Qu et al. 2014), however, only ions selected for MS/MS 
fragmentation would be quantified. This means proteins would need to be abundant which 
would possibly require enrichment strategies. 
6.1.3. Comparison of QToF and QTRAP MS instruments 
Another achievement of this study was the comparison of different quantitative methods 
utilising both the QToF and QTRAP instruments available in the lab. The study 
demonstrated that both instruments have their advantages and disadvantages in quantifying 
oxPTMs but also required further fine tuning to develop more suitable methods. While only 
the standard MRM method was used for the QTRAP, several pseudoMRM methods were 
developed for the QToF instrument by adapting the product ion scan. These methods have 
been reported with other instruments but can be adapted to all instruments. A PseudoMRM 
method was used to measure spiked phosphopeptides in a BSA sample whereby the whole 
range of product ions were scanned for a targeted precursor ion and quantitation was 
performed by generating XICs of transitions through manual selection (Sherrod et al. 2012). 
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This method has also been applied to measure cysteine dioxidation and trioxidation detected 
in nucleoside diphosphate kinase and heat shock 70 kDa protein 8 that was oxidised with 
varying concentrations of hydrogen peroxide (Lee, Paull and Person, 2013). Targeted 
methods were developed in this study to demonstrate quantitation of oxPTMs in vivo and 
show that the same instrument used for discovery MS/MS can also be utilised for targeted 
approaches with the advantages of having the same LC so retention times can be utilised in 
scheduled MRM methods. 
6.2. Future work 
6.2.1. Optimising modification searches 
Another common modification that should have been included in the Mascot identification of 
peptides is deamidation (NQ) (Robinson and Robinson, 1991). Deamidation is a process in 
protein degradation by which the amide containing sides chains of glutamine and asparagine 
residues are converted to release NH3 and subsequently produce glutamate and aspartate 
respectively. It is one of the most common modifications along with the oxidation of 
methionine and has been shown to increase peptide identification when searching with the 
deamidation modification as a variable (Jenkins 2007; Yang and Zubarev 2010; 
Nepomuceno et al. 2014). Deamidation has also been reported as an indicator for protein 
turnover and ageing (Lindner and Helliger, 2001; de la Mora et al. 2015). The modification 
disrupts protein stability and increasing levels indicate the progression towards ageing 
(Hains and Truscott, 2010). Additionally, it has been reported that oxidation can impact the 
presence of deamidation in proteins mimicking those present in ageing (Barbariga et al. 
2014). By adding this modification to the search, there is a higher chance that additional 
oxPTMs may be discovered by increasing the total number of identified peptide sequences. 
With multiple modifications in a single peptide, subsequent quantitation will involve 
measuring more combinations of native, deaminated and oxidised peptides. The extended 
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list of peptides will increase the time spent on acquiring MRM data. Nevertheless, accurate 
quantitation requires common modifications to be present so that the data is not skewed. 
6.2.2. Additional quantitation of oxPTMs detected in discovery MS/MS 
The methods optimised for the study enabled quantitation of highly susceptible residues, 
cysteine and methionine; however it was difficult to implement these methods on the 
modifications detected by Mascot of lesser susceptible residues. Given additional time, more 
optimisation could lead to efficiency of MRM scans and accurate quantitation of oxPTMs in 
this study’s models. With a larger database of quantified modifications, elucidation of how 
oxidation from the obese and aged models affect the levels of modification would result in a 
clearer understanding of the role of oxidation and susceptibility of proteins. By increasing the 
number of residues that were quantified, the susceptibility of residues can be demonstrated 
as heat maps on proteins with 3D crystal structures. This can then be linked to known 
functional properties of the domains the residues reside in and understand how oxidation 
may impact protein function that may result to ageing and inflammatory-related disease. 
6.2.3. Increasing number of replicates 
Many of the differences observed in the oxidised peptides of SERCA that were quantified for 
the aged and obese studies were not statistically significant, which may have been the result 
of the small number of replicates processed during the study. The two peptides that were 
significant in the obese study were TGTLTTNQM(ox)SVCK and GTAIAIC(triox)R whereas 
only GTAIAIC(triox)R was found to be significant in the ageing study. While there are studies 
that address the problems with technical and biological variation (Molloy et al. 2003), the 
deviation between biological replicates is inherent. In order to ascertain the modifications 
and the relative percentage modification of residues within protein it would require many 
more replicates. Due to the GeLC fractionation approach used in this study, additional 
replicates would increase the number of fractionated samples needing to be processed by 
the LC-MS instruments which in turn would lead to inefficient time spent on collecting 
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enough data for MRM quantification of oxPTMs. To avoid this problem, alternative 
approaches would need to be considered. The GeLC method enabled higher resolution and 
selection of lower abundant peptides for fragmentation in discovery MS/MS. Additionally, the 
differences detected in the abundance of modified peptides within each fraction translated to 
how oxidised proteins in the control and obese/aged models ran on a SDS-gel. 
Nevertheless, there are multiple advances in the MS field that address the challenges of 
oxPTM detection in biological samples (Verrastro et al. 2015) 
6.2.4. Scheduled MRM 
Standard MRM methods are set up to cycle through and measure targeted product ions from 
specified precursor ion masses for the total acquisition time of the MS/MS method. An 
advantage of using LC-MS is obtaining knowledge on the retention times of the targeted 
modified peptide from discovery MS/MS. By utilising the retention times of the precursor ion, 
scheduled MRM approaches enables more peptide analysis as it focuses acquisition of 
transitions of the targeted peptide within the region of the chromatogram at the expected 
retention time and enables assignment of several time points on the chromatogram to a 
number of targeted peptides. Early studies have used scheduled MRM to demonstrate 
measurement of larger peptide and transition lists without compromising sensitivity (Stahl-
Zeng et al. 2007; Picotti et al. 2009) This method has also been employed in studies using 
MRM to quantify cysteine oxidation called oxMRM (Held et al. 2010). The same principle 
could be applied to measure multiple oxPTMs by increasing the number of peptides 
quantified within a single run. While additional peptides could be added to the method 
program, peptides eluting within the same regions of the chromatogram would have to be 
separated on different MS runs to ensure the duty cycle is not compromised. 
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6.3. Final conclusions 
Our current findings have demonstrated that mass spectrometry is a powerful technique that 
had enabled detection of novel modifications, not previously characterised in the muscle of 
the mice models used in this study, and demonstrated quantitation of modifications using 
non-labelling and non-enrichment based methods on two instruments with different mass 
analysers. By utilising quantitative MS approaches, heat maps can be generated from 3D 
crystal structures of the proteins to demonstrate changes in modification. Figure 6.1 shows 
the percentage increase in oxidation of SERCA residues within the aged and obese models 
from their respective controls.This enables visual depiction of changes to residues within the 
protein’s 3D conformation and grants further insight to the effect of location on residue 
susceptibility. As seen in both models, the modified residues are clustered around Asp351 
and Cys674; the active site and a residue involved in redox regulated changes in activity. As 
mentioned before, the modified residues could serve as protection by scavenging oxidants. 
Additionally, when comparing the increase in oxPTMs in both models, Cys636, Met720 and 
Cys561 in the ageing model were found to be more oxidised than the obese model. This 
may explain why we see a significant drop in SERCA activity in the aged muscle and not in 
the obese muscle. From the data obtained in this study and the research undertaken in other 
groups, increased oxidation in ageing and obesity is a downstream result of a combination of 
factors resulting from the rise in oxidant production and the reduction of protein degradation. 
The proteasome’s key role is the degradation of proteins and studies have shown oxidised 
proteins are degraded at a higher rate particularly for the 20S proteasome and the 
immunoproteasome (Friguet et al. 2000; Jung, Hohn and Grune 2014). However, ageing 
contributes to the decreased expression of the proteasomes and so it can be suggested that 
the increased oxidant production coupled with the reduction of proteasome expression 
explains the increased levels of oxPTMs found in the ageing tissue (Keller, Huang and 
Markesbery, 2000; Huber et al. 2009; Saez and Vilchez 2014). In obesity, higher levels of 
oxidation and proteasome dysfunction was seen which supports the data shown in this 
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thesis (Otoda et al. 2013; Diaz-Ruiz et al. 2015). While the methods can still be further 
optimised to increase the number of modifications detected and expand the types of oxPTMs 
for quantitation, these current methods can be adapted to assign candidates of oxidative 
biomarkers for ageing and inflammation related diseases and demonstrate the differences in 
the role of oxidative damage to muscle proteins. 
 
 
Fig.6.1. Heat map of quantified oxidised residues in SERCA. 3D crystal structures depict 
percentage increase of oxidation in obese and aged models from respective controls. A. 
Heat map of obese model. B. Heat map of ageing model. Residues are highlighted and 
coloured according to key ranging from 0-20% percentage increase. 
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Figure S3.1. Sequence coverage attained by in silico digest of SERCA with trypsin 
and settings including cysteine residues treated with iodoacetamide. Mass of peptide 
covered ranges from 500-3000 Da. 
 10         20         30         40         50         60  
MEAAHSKSTE ECLSYFGVSE TTGLTPDQVK rHLEKYGPNE LPAEEGKSLW ELVVEQFEDL  
        70         80         90        100        110        120  
LVRilllaac isfvlawfee geetvtafve pfvillilia naivgvwqer NAENAIEALK  
       130        140        150        160        170        180  
EYEPEMGKvy radrksvqri karDIVPGDI VEVAVGDKVP ADIRILSIKS TTLRVDQSIL  
       190        200        210        220        230        240  
TGESVSVIKH TDPVPDPRAV NQDKkNMLFS GTNIAAGKAV GIVATTGVST EIGKirDQMA  
       250        260        270        280        290        300  
ATEQDKTPLQ QKLDEFGEQL SKvislicva vwlinighfn dpvhggswfr GAIYYFKIAV  
       310        320        330        340        350        360  
ALAVAAIPEG LPAVITTCLA LGTRrmakkN AIVRSLPSVE TLGCTSVICS DKTGTLTTNQ  
       370        380        390        400        410        420  
MSVCKMFIID KVDGDVCSLN EFSITGSTYA PEGEVLKNDK PVRAGQYDGL VELATICALC  
       430        440        450        460        470        480  
NDSSLDFNET KGVYEKVGEA TETALTTLVE KMNVFNTEVR slskverANA CNSVIRQLMK  
       490        500        510        520        530        540  
kEFTLEFSRd rkSMSVYCSP AKssrAAVGN KMFVKGAPEG VIDRCNYVRV GTTRVPLTGP  
       550        560        570        580        590        600  
VKekIMSVIK EWGTGRDTLR CLALATRDTP PKrEEMVLDD SAKFMEYEMD LTFVGVVGML  
       610        620        630        640        650        660  
DPPRkEVTGS IQLCRDAGIR VIMITGDNKG TAIAICRrIG IFSENEEVTD RAYTGREFDD  
       670        680        690        700        710        720  
LPLAEQReac rrACCFARVE PSHKskIVEY LQSYDEITAM TGDGVNDAPA LKkAEIGIAM  
       730        740        750        760        770        780  
GSGTAVAKTA SEMVLADDNF STIVAAVEEG RAIYNNMKQF IRylissnvg evvcifltaa  
       790        800        810        820        830        840  
lglpealipv qllwvnlvtd glpatalgfn ppdldimdrp prspkEPLIS GWLFFRymai  
       850        860        870        880        890        900  
ggyvgaatvg aaawwflyae dgphvsyhql thfmqctehn pefdgldcev feapepmtma  
       910        920        930        940        950        960  
lsvlvtiemc nalnslsenq sllrmppwvn iwllgsicls mslhflilyv dplpmifklr  
       970        980        990  
ALDFTQWLMV LKISLPVIGL DELLKFIARN YLEG 
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Figure S4.1. Blot probed with secondary antibody alone. Molecular weight marker 
present in first lane. 
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Table S3.1. Mascot results of modifications detected in top 5 proteins hits in MH treated with HOCl and validated by de novo 
sequencing. True positives are green, spectra that could not be sequenced are yellow, false positives that are deemed to be another 
modification are orange, and absolute false positives are red. 
Protein Modification Sequence Residue Notes 
Glycogen 
phosphorylase 
Y ox DYYFALAHTVR Y53 Partially sequenced however cannot say if 
modification is present 
Y Cl TLQNTMVNLALENACDEATYQLG
LDMEELEEIEEDAGLGNGGLGR 
Y114 False positive 
Y N 
C Triox 
TLQNTMVNLALENACDEATYQLG
LDMEELEEIEEDAGLGNGGLGR 
Y114 
C109 
False positive 
Y N 
C Triox 
M ox 
TLQNTMVNLALENACDEATYQLG
LDMEELEEIEEDAGLGNGGLGR 
Y114 
C109 
M100 
False positive 
M ox 
C Triox 
Y ox 
M diox 
TLQNTMVNLALENACDEATYQLG
LDMEELEEIEEDAGLGNGGLGR 
M100 
C109 
Y114 
M120 
False positive 
C Triox 
M diox 
LAACFLDSMATLGLAAYGYGIR C143 
M148 
False positive 
Y ox 
Y Cl 
LAACFLDSMATLGLAAYGYGIR Y156 
Y158 
False positive 
Y Cl YEFGIFNQKICGGWQMEEADDWL
R 
Y162 Possibly a ClY? 
Y N 
K Ally 
C Triox 
YEFGIFNQKICGGWQMEEADDWL
R 
Y162 
K170 
C172 
Partially sequenced however cannot say if 
modifications are present 
M Diox ICGGWQMEEADDWLR M177 Sequenced and could potentially also be OxM and 
OxW at W175 and M177 
M Diox 
C Triox 
ICGGWQMEEADDWLR M177 False positive 
M ox 
Y N 
WVDTQVVLAMPYDTPVPGYR M225 
Y234 
False positive 
M diox WVDTQVVLAMPYDTPVPGYR M225 False positive 
Y ox WVDTQVVLAMPYDTPVPGYR Y227 False positive 
K Ally LWSAKAPNDFNLK K248 Possibly an Allysine although MSMS spectra not 
great 
190 
 
P ox VAIQLNDTHPSLAIPELMR P348 Unsure whether false positive or P ox 
M Diox VAIQLNDTHPSLAIPELMR M351 Sequenced and validated 
P ox 
M Diox 
VAIQLNDTHPSLAIPELMR P343 
M351 
False positive 
C Triox 
Y ox 
TCAYTNHTVLPEALER C373 
Y375 
Sequenced from r to t. Possible that this is correct 
however Tyr immonium ion present with no mod 
C Triox 
Y Cl 
TCAYTNHTVLPEALER C373 
Y375 
False positive 
P ox WPVHLMETLLPR P389 Sequenced and validated 
P ox 
M ox 
WPVHLMETLLPR P389 
M393 
Sequenced and validated (although MSMS of not 
great quality) 
P ox VAAAFPGDVDR P420 After sequencing it is found to be Phe oxidation at 
F419 
M Diox MSLVEEGAVK M429 Sequenced and validated 
C Triox INMAHLCIAGSHAVNGVAR C446 Sequenced and validated 
M ox 
C Triox 
INMAHLCIAGSHAVNGVAR M442 
C446 
Sequenced and validated 
M Diox 
C Triox 
INMAHLCIAGSHAVNGVAR M442 
C446 
Not great quality MSMS but sequencing shows it 
may be modified with stated modifications 
C Triox RWLVLCNPGLAEVIAER C496 Unsure of whether it is modified or not due to MSMS 
spectrum 
P ox RWLVLCNPGLAEVIAER P498 False positive 
C Triox WLVLCNPGLAEVIAER C496 Sequenced and validated 
C Triox 
P ox 
WLVLCNPGLAEVIAER C496 
P498 
Possibly a false positive due to poor MSMS data 
P ox WLVLCNPGLAEVIAER P498 Correct peptide but can’t find modification 
C Triox QLLNCLHIITLYNR C581 Sequenced and validated 
Y ox TIMIGGKAAPGYHMAK Y614 False positive 
M Diox 
Y N 
M ox 
P ox 
TIMIGGKAAPGYHMAK M616 
Y614 
M605 
P612 
False positive 
Y Cl 
M Diox 
AAPGYHMAK Y614 
M616 
False positive 
M Diox 
K Ally 
M ox 
Y ox 
AAPGYHMAKMIIK M616 
K618 
M619 
Y614 
False positive 
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P ox VIPAADLSEQISTAGTEASGTGNM
K 
P659 False positive 
M Diox DIVNMLMHHDR M767 After sequencing it is found to be His dioxidation at 
H768 
C Triox VFADYEEYIKCQDK C784 Sequenced and validated 
SERCA Y ox STEECLSYFGVSETTGLTPDQVK Y15 Possible Tyr ox but could also be Phe ox. Could not 
fully sequence to determine 
Y N 
P ox 
HLEKYGPNELPAEEGK Y36 
P42 
False positive 
K Ally 
Y N 
M ox 
P ox 
Y ox 
EYEPEMGKVYR K130 
Y128 
M126 
P124 
Y122 
False positive 
Y Cl 
K Ally 
M ox 
C Triox 
KSMSVYCSPAK Y497 
K492 
M494 
C498 
False positive 
K Ally 
K Ally 
Y N 
M ox 
KSMSVYCSPAK K492 
K502 
Y497 
M494 
False positive 
K Ally 
M ox 
P ox 
C Triox 
SMSVYCSPAK M494 
C498 
P500 
K502 
False positive 
M ox 
P ox 
Y ox 
SMSVYCSPAK M494 
Y497 
P500 
False positive 
K Ally 
Y N 
M ox 
C Triox 
SMSVYCSPAK M494 
Y497 
C498 
K502 
False positive 
M Diox AAVGNKMFVK M512 False positive 
Actually peptide SFLVWVNEEDHLR (3+) from 
Creatine kinase M-type 
Y Cl IVEYLQSYDEITAMTGDGVNDAPA
LK.K 
Y694 Couldn’t find presence of ClY but found Met700 to 
be oxidised 
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M Diox TASEMVLADDNFSTIVAAVEEGR M733 Cannot sequence to determine is modification is 
present 
Transitional 
endoplasmic 
reticulum ATPase 
(TERA) 
P Ox 
Y N 
P Ox 
K Ally 
AVEFKVVETDPSPYCIVAPDTVIH
CEGEPIK 
P172 
Y173 
P178 
K190 
False positive 
M ox 
P ox 
Y Cl 
C Triox 
FGMTPSKGVLFYGPPGCGK M508 
P510 
Y517 
C522 
False positive 
M ox 
P ox 
Y Cl 
P ox 
FGMTPSKGVLFYGPPGCGK M508 
P510 
Y517 
P520 
False positive 
M Diox 
P ox 
Y Cl 
P ox 
FGMTPSKGVLFYGPPGCGK M508 
P510 
Y517 
P520 
False positive 
Y Cl 
P ox 
P ox 
GVLFYGPPGCGK Y517 
P519 
P520 
False positive 
Y ox FPSGNQGGAGPSQGSGGGTGG
SVYTEDNDDDLYG 
Y805 MS/MS spectra of poor quality 
Aconitate 
hydratase 
M ox 
P ox 
Y ox 
MAPYSLLVTRLQK M1 
P3 
Y4 
False positive 
M Diox 
P ox 
Y ox 
VAMSHFEPSEYIR M34 
P39 
Y42 
False positive 
M ox 
M ox 
P ox 
K Ally 
VAMQDATAQMAMLQFISSGLPK M105 
M107 
P116 
K117 
False positive 
M ox 
M ox 
P ox 
VAMQDATAQMAMLQFISSGLPK M105 
M107 
P116 
False positive 
Elongation factor M ox 
K Ally 
NMSVIAHVDHGKSTLTDSLVCK M22 
K42 
False positive 
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K Ally 
P ox 
M ox 
M Diox 
M Ox 
IKPVLMMNKMDR K152 
P153 
M156 
M157 
M160 
False positive 
P ox ALLELQLEPEELYQTFQR P171 Unsure if Pro oxidation or unmodified Pro 
Y N QFAEMYVAK Y232 False positive 
Y N 
Y Ox 
P Ox 
P Ox 
M Ox 
K Ally 
YRCELLYEGPPDDEAAMGIK Y367 
Y373 
P376 
P377 
M383 
K386 
False positive 
C Triox 
K Ally 
M Ox 
Y Ox 
SCDPKGPLMMYISK C388 
K391 
M395 
Y397 
False positive 
K Ally VFSGVVSTGLKVR K426 False positive 
K Ally ARPFPDGLAEDIDKGEVSAR K619 False positive 
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Table S4.1. Mascot results of modifications detected in obese sample and validation by de novo sequencing. The table complements 
Figure 4.3. Full list of validated Mascot results are shown with peptide expect cut off at 0.05. UC = uncertain, FP = false positive, and TP = true 
positive. 
Band Protein ID 
Protein 
description 
Protein 
mass 
Mass/ 
Charge 
(m/z) 
Peptide 
score 
Peptide 
expect Peptide sequence Modification Validation 
1 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 749.0771,3+ 45.27 0.0013 
VIISAPSADAPMFVM
GVNHEK OxM; OxP 
UC – 
possible 
Met ox 
1 SYNE2_MOUSE Nesprin-2 787997 421.2712,4+ 45.34 0.007 
AAKLSAELPADRPAP
K Ally; 3 OxP FP 
1 CB072_MOUSE 
Uncharacterized 
protein C2orf72 
homolog 30701 458.9465,4+ 36.24 0.037 
AQDGGVHIPPDPPED
TR 2 OxP FP 
1 GNDS_MOUSE 
Ral guanine 
nucleotide 
dissociation 
stimulator 95226 406.2507,3+ 34.02 0.039 HGASSTLPRMK OxM; OxP FP 
1 PRKDC_MOUSE 
DNA-dependent 
protein kinase 
catalytic subunit 476471 565.7887,4+ 30.34 0.021 
VMHYSLDIKNTCTSV
YTK 
ClY; DioxM; 
Ally; NitroY; 
TrioxC FP 
1 ECM29_MOUSE 
Proteasome-
associated protein 
ECM29 homolog 205398 571.9569,4+ 26.26 0.047 
IKPLGPMLLNGLTKLI
NEYK 
2 Ally; OxM; 
OxP FP 
1 ABCA2_MOUSE 
ATP-binding 
cassette sub-family 
A member 2 272788 641.8777,4+ 28.72 0.036 
CTCSAQGTGFSCPS
SVGGHPPQMR 
OxP; 2 
TrioxC FP 
1 K1B24_MOUSE 
Kallikrein 1-related 
peptidase b24 29478 407.2217,3+ 27.57 0.044 DKSNDLMLLR Ally; OxM TP 
1 LTBP1_MOUSE 
Latent-transforming 
growth factor beta- 195032 597.8776,4+ 26.09 0.024 
KQSYHGYTQMMECL
QGYK 
Ally; 2 
NitroY; 2 FP 
195 
 
 
binding protein 1 OxM; OxY 
2 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 524.7988,3+ 56.22 0.00062 VPTPNVSVVDLTCR OxP TP 
2 DLGP4_MOUSE 
Disks large-
associated protein 
4 108940 588.3424,2+ 51.69 0.005 TSATLDKSLLK Ally FP 
2 K1B24_MOUSE 
Kallikrein 1-related 
peptidase b24 29478 407.2259,3+ 44.11 0.024 DKSNDLMLLR Ally; OxM TP 
2 ECM29_MOUSE 
Proteasome-
associated protein 
ECM29 homolog 205398 571.9564,4+ 39.31 0.021 
IKPLGPMLLNGLTKLI
NEYK 
2 Ally; OxM; 
OxP FP 
2 ODC_MOUSE 
Mitochondrial 2-
oxodicarboxylate 
carrier 33322 686.3938,4+ 38.32 0.011 
LGPGGGVMLLVYEYT
YAWLQENW 2 ClY; OxP FP 
2 MIIP_MOUSE 
Migration and 
invasion-inhibitory 
protein 43428 747.095,2+ 32.57 0.034 LFPEPVDPGAPCR 
3 OxP; 
TrioxC FP 
2 CODA1_MOUSE 
Collagen alpha-
1(XIII) chain 73640 770.4245,3+ 32.52 0.025 
GKPGDMGPAGPQGP
PGKDGPPGMK 
DioxM; OxM; 
2 OxP FP 
2 IL3_MOUSE Interleukin-3 18757 965.5369,4+ 30.04 0.034 
FYMVHLNDLETVLTS
RPPQPASGSVSPNR
GTVEC 
DioxM; 
NitroY; 2 
OxP; TrioxC FP 
2 MARH5_MOUSE 
E3 ubiquitin-protein 
ligase MARCH5 31781 671.3787,4+ 29.37 0.032 
ADPLFLLIGLPTIPVML
ILGKMIR DioxM; OxM FP 
2 LRTM1_MOUSE 
Leucine-rich repeat 
and 
transmembrane 
domain-containing 
protein 1 39315 971.051,4+ 29.03 0.043 
MLNEGLCCGAWAMK
GTLLLVSSVGLLLPG
VGSCPMK 
DioxM; OxM; 
2 OxP; 2 
TrioxC FP 
2 FUBP1_MOUSE 
Far upstream 
element-binding 68668 777.3713,4+ 26.36 0.034 
KMGQAVPAPAGAPP
GGQPDYSAAWAEYY
2 ClY; OxP; 
OxY FP 
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protein 1 R 
3 PYGB_MOUSE 
Glycogen 
phosphorylase, 
brain form 97353 676.3401,3+ 72.52 9.7E-06 
KTCAYTNHTVLPEAL
ER 
ClY; Ally; 
TrioxC 
UC – could 
not 
sequence 
3 PYGB_MOUSE 
Glycogen 
phosphorylase, 
brain form 97353 452.5715,3+ 33.61 0.019 DYFFALAHTVR OxY FP 
3 LECT1_MOUSE 
Leukocyte cell-
derived chemotaxin 
1 37829 531.7884,4+ 36.48 0.022 
GNDNHIYNVHYSMSI
NGK NitroY; OxM FP 
3 INT7_MOUSE 
Integrator complex 
subunit 7 108048 428.773,2+ 39.55 0.031 LALSPSPR OxP FP 
3 RSMB_MOUSE 
Small nuclear 
ribonucleoprotein-
associated protein 
B 23811 597.8643,4+ 36.25 0.022 
GTPMGMPPPGMRPP
PPGMRGLL 
2 DioxM; 
OxM; 4 OxP FP 
3 UAP1L_MOUSE 
UDP-N-
acetylhexosamine 
pyrophosphorylase-
like protein 1 57319 515.2413,4+ 34.59 0.013 
LGVTYPKGMYQVGL
PSQK 
Ally; NitroY; 
OxM; 2 OxP FP 
3 CYTSB_MOUSE Cytospin-B 118713 511.7001,3+ 31.42 0.043 VTLEGLKMENGSLK Ally; OxM FP 
3 INT11_MOUSE 
Integrator complex 
subunit 11 68541 744.0636,3+ 31.1 0.048 
VPIYFSTGLTEKANHY
YK 
2 ClY; Ally; 
OxP; OxY FP 
3 CTSRB_MOUSE 
Cation channel 
sperm-associated 
protein subunit beta 127053 516.7991,4+ 29.06 0.046 
SVLIPGYSSFLIMNITD
K 
ClY; OxM; 
OxP FP 
3 COBA1_MOUSE 
Collagen alpha-
1(XI) chain 181548 711.4023,3+ 26.04 0.036 
GEAGPPGAAGPAGIK
GPPGDDGPK Ally; 4 OxP FP 
3 RGS9_MOUSE 
Regulator of G-
protein signaling 9 77499 614.876,4+ 24.86 0.029 
HPHRYVLDAAQTHIY
MLMK 
2 ClY; 
DioxM; OxM; 
OxP FP 
3 F262_MOUSE 6-phosphofructo-2- 60458 589.3372,4+ 24.65 0.048 IECYKVTYQPLDPDN ClY; Ally; FP 
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kinase/fructose-2,6-
bisphosphatase 2 
YDK NitroY; OxP 
3 PTPRQ_MOUSE 
Phosphatidylinositol 
phosphatase 
PTPRQ 257878 503.3252,4+ 23.59 0.047 
GGHTYNISVYAINSA
GAGPK ClY FP 
3 TAOK1_MOUSE 
Serine/threonine-
protein kinase 
TAO1 116434 426.2518,3+ 21.02 0.047 MSYSGKQSTEK 
Ally; OxM; 
OxY FP 
4 KPYM_MOUSE 
Pyruvate kinase 
PKM 58378 836.781,3+ 42.2 0.002 
AEGSDVANAVLDGA
DCIMLSGETAK Ally; OxM FP 
4 KPYM_MOUSE 
Pyruvate kinase 
PKM 58378 839.4425,3+ 27.93 0.048 
AEGSDVANAVLDGA
DCIMLSGETAK 
DioxM; 
TrioxC FP 
4 ALBU_MOUSE Serum albumin 70700 956.1642,4+ 31.44 0.0068 
YEATLEKCCAEANPP
ACYGTVLAEFQPLVE
EPK 
2 OxP; 2 
OxY; 3 
TrioxC FP 
4 SAPL1_MOUSE 
Proactivator 
polypeptide-like 1 58905 421.7683,2+ 40.38 0.046 ASPISVPR OxP FP 
4 SYNJ2_MOUSE Synaptojanin-2 159578 455.5816,2+ 39.24 0.0065 GLPPDHGGK 2 OxP TP 
4 LEG4_MOUSE Galectin-4 36405 1120.177,4+ 38.92 0.032 
AYVPAPGYQPTYNPT
LPYKRPIPGGLSVGM
SVYIQGMAK 
ClY; Ally; 3 
NitroY; 7 
OxP; OxY FP 
4 ADGB_MOUSE Androglobin 189464 1140.19,4+ 38.4 0.049 
SMESYPCYQDEETKL
AFADHTVNYADQPP
NSWFIVFR 
ClY; NitroY; 
2 OxP; 
TrioxC FP 
4 SGT1_MOUSE 
Protein SGT1 
homolog 72064 483.2613,4+ 28.98 0.041 
YKPAKGGVPAHMYG
MTK 
ClY; 3 Ally; 2 
OxM; OxP; 
OxY FP 
4 CO5A1_MOUSE 
Collagen alpha-
1(V) chain 184248 480.9388,3+ 28.9 0.032 EPAPTQKPVEAAR Ally; 3 OxP 
FP 
apqvstptlve
aar from 
serum 
albumin 
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4 TNR11_MOUSE 
Tumor necrosis 
factor receptor 
superfamily 
member 11A 68460 469.2537,2+ 27.54 0.047 DSFAGTAPR OxP TP 
4 SUV3_MOUSE 
ATP-dependent 
RNA helicase 
SUPV3L1, 
mitochondrial 87919 509.8125,3+ 25.43 0.045 MSLPRCTLLWAR 
OxM; OxP; 
TrioxC FP 
5 ENOA_MOUSE Alpha-enolase 47453 594.8367,2+ 33.56 0.024 IGAEVYHNLK NitroY FP 
5 KCRS_MOUSE 
Creatine kinase S-
type, mitochondrial 47899 714.0618,4+ 28.17 0.024 
MTPSGYTLDQCIQTG
VDNPGHPFIK 
NitroY; OxM; 
OxP UC 
5 PGK1_MOUSE 
Phosphoglycerate 
kinase 1 44921 456.2436,3+ 33.88 0.016 AHSSMVGVNLPQK Ally FP 
5 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 524.7977,3+ 39.4 0.0044 VPTPNVSVVDLTCR OxP TP 
5 K1B24_MOUSE 
Kallikrein 1-related 
peptidase b24 29478 602.3615,2+ 50.16 0.003 DKSNDLMLLR Ally TP 
5 SRRM2_MOUSE 
Serine/arginine 
repetitive matrix 
protein 295521 449.779,2+ 41.51 0.0062 VKTVISPR Ally FP 
5 PTPS_MOUSE 
6-pyruvoyl 
tetrahydrobiopterin 
synthase 16235 509.8174,2+ 35.79 0.024 LLPVGALYK NitroY TP 
5 UGDH_MOUSE 
UDP-glucose 6-
dehydrogenase 55482 381.7257,2+ 32.4 0.034 MVEIKK Ally; OxM FP 
5 FGD1_MOUSE 
FYVE, RhoGEF 
and PH domain-
containing protein 1 107552 504.2508,2+ 34.94 0.04 YLILFNDRLLYCVPR 2 ClY; TrioxC FP 
5 ANKY2_MOUSE 
Ankyrin repeat and 
MYND domain-
containing protein 2 49712 1042.095,2+ 31.29 0.016 
CSVCKMVIYCDQTCQ
K 
DioxM; Ally; 
3 TrioxC FP 
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5 TMC7_MOUSE 
Transmembrane 
channel-like protein 
7 84423 496.7634,2+ 30.64 0.048 
ITSCGDSTCELCGYN
QK TrioxC FP 
5 PKP4_MOUSE Plakophilin-4 132268 622.3748,2+ 27.44 0.041 
GLYPGSSKPSPIYISS
YSSPAR 
ClY; 2 
NitroY; 3 
OxP FP 
5 C1QR1_MOUSE 
Complement 
component C1q 
receptor 71761 446.1723,2+ 26.04 0.047 
ESTMPPTEMPSSPS
GSK OxM; OxP FP 
6 KCRM_MOUSE 
Creatine kinase M-
type 43246 624.3482,2+ 40.07 0.0087 DLFDPIIQDR OxP 
UC – could 
either be 
oxP or oxF 
6 KCRM_MOUSE 
Creatine kinase M-
type 43246 539.8088,2+ 36.98 0.026 VLTPDLYNK OxP TP 
6 ALDOA_MOUSE 
Fructose-
bisphosphate 
aldolase A 39787 603.3448,3+ 34.52 0.0034 CPLLKPWALTFSYGR Ally TP 
6 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 898.4677,2+ 60.29 
0.00002
5 LISWYDNEYGYSNR OxY FP 
6 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 749.0779,3+ 66.02 0.00014 
VIISAPSADAPMFVM
GVNHEK OxM; OxP FP 
6 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 599.2975,3+ 27.73 0.03 LISWYDNEYGYSNR OxY 
FP – 
Correct 
sequence, 
wrong 
modificatio
n = oxW 
6 KDM5A_MOUSE 
Lysine-specific 
demethylase 5A 194944 520.2762,4+ 35.93 0.0047 
QGPDSPGQAPPPPF
LMSYK OxM; 3 OxP FP 
6 UBP33_MOUSE Ubiquitin carboxyl- 104544 1064.627,4+ 35.85 0.04 GLTGLKNIGNTCYMN OxP; 2 FP 
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terminal hydrolase 
33 
AALQALSNCPPLTQF
FLDCGGLAR 
TrioxC 
6 DESP_MOUSE Desmoplakin 335158 567.3073,2+ 35.74 0.029 ALYKAISVPR OxY FP 
6 TRA2A_MOUSE 
Transformer-2 
protein homolog 
alpha 32354 761.3902,4+ 35.23 0.049 
AHTPTPGIYMGRPTH
SGGGGGGGGGGGG
GGGGGGGR 
DioxM; 3 
OxP FP 
6 MAST1_MOUSE 
Microtubule-
associated 
serine/threonine-
protein kinase 1 171747 471.2377,4+ 33.82 0.015 
GLKEPVAQMPLMPD
APR DioxM FP 
6 VAV2_MOUSE 
Guanine nucleotide 
exchange factor 
VAV2 101163 694.4076,3+ 31.71 0.03 
WMEQFEMAMSNIKP
DK 
2 DioxM; 
OxM; OxP FP 
6 SSRP1_MOUSE 
FACT complex 
subunit SSRP1 81152 441.7799,4+ 30.85 0.047 
NMSGSLYEMVSRVM
K DioxM FP 
6 ENO4_MOUSE 
Enolase-like protein 
ENO4 68380 862.9738,3+ 29.66 0.033 
HDQEQPSTFSMPLL
MGSVLSCGK 
DioxM; Ally; 
OxM; TrioxC FP 
6 PXDN_MOUSE 
Peroxidasin 
homolog 167621 498.2523,4+ 27.87 0.047 
SGKPLLPFATGPPTE
CMR 
Ally; OxM; 
OxP FP 
6 PTC1_MOUSE 
Protein patched 
homolog 1 160711 529.2876,4+ 25.81 0.041 
VASGYLLMLAYACLT
MLR 
NitroY; 2 
OxM; TrioxC FP 
6 ST14_MOUSE 
Suppressor of 
tumorigenicity 14 
protein homolog 96875 642.8141,3+ 24.88 0.032 
CQNGLCLSKGNPEC
DGK 
OxP; 3 
TrioxC FP 
6 MOFA1_MOUSE 
MORF4 family-
associated protein 
1 14185 389.7237,2+ 24.43 0.038 IEKSESS Ally FP 
7 TPIS_MOUSE 
Triosephosphate 
isomerase 32684 809.9998,2+ 31.79 0.048 VVLAYEPVWAIGTGK OxY FP 
7 CAH3_MOUSE 
Carbonic 
anhydrase 3 29633 926.5382,3+ 36.7 0.013 
SLFSSAENEPPVPLV
GNWRPPQPVK 2 OxP FP 
7 CAH3_MOUSE Carbonic 29633 653.6678,3+ 32.8 0.019 HDPSLQPWSASYDP OxP FP 
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anhydrase 3 GSAK 
7 ALDOA_MOUSE 
Fructose-
bisphosphate 
aldolase A 39787 1129.621,3+ 92.63 
0.00000
2 
ALANSLACQGKYTPS
GQSGAAASESLFISN
HAY OxY TP 
7 ALDOA_MOUSE 
Fructose-
bisphosphate 
aldolase A 39787 1129.618,3+ 62.03 0.0023 
ALANSLACQGKYTPS
GQSGAAASESLFISN
HAY Ally; OxY UC 
7 PGAM2_MOUSE 
Phosphoglycerate 
mutase 2 28980 688.8443,2+ 58.38 
0.00008
8 SFDTPPPPMDEK OxP FP 
7 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 749.0803,3+ 47.49 0.0057 
VIISAPSADAPMFVM
GVNHEK OxM; OxP UC 
7 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 524.7943,3+ 40 0.033 VPTPNVSVVDLTCR OxP TP 
7 LITD1_MOUSE 
LINE-1 type 
transposase 
domain-containing 
protein 1 88705 812.9937,4+ 42.18 0.0033 
IGMPCLTLYLTSPSES
LGAGSDGPKSHSCT
K 
Ally; OxP; 2 
TrioxC FP 
7 FR1L4_MOUSE Fer-1-like protein 4 225120 761.4287,4+ 36.4 0.05 
AQDFQVGVTVLEAQ
KLVGVNINPYVAVR Ally; OxY FP 
7 FXYD4_MOUSE 
FXYD domain-
containing ion 
transport regulator 
4 9548 592.8933,4+ 35.66 0.048 
THKPSSLPGKATPLII
PGSANTC 
2 Ally; 2 
OxP; TrioxC FP 
7 ZEP1_MOUSE 
Zinc finger protein 
40 291073 494.6153,4+ 33.91 0.027 
MLSPANSLDIAMEKH
QK 
DioxM; 2 
Ally; OxM; 
OxP FP 
7 SOX14_MOUSE 
Transcription factor 
SOX-14 26669 454.2667,4+ 33.59 0.041 YVFPLPYLGDTDPLK 
Ally; NitroY; 
2 OxP FP 
7 SSRP1_MOUSE 
FACT complex 
subunit SSRP1 81152 441.7835,4+ 33.29 0.04 
NMSGSLYEMVSRVM
K DioxM FP 
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7 SRRM2_MOUSE 
Serine/arginine 
repetitive matrix 
protein 2 295521 449.78,2+ 29.7 0.045 VKTVISPR Ally FP 
7 M3K7_MOUSE 
Mitogen-activated 
protein kinase 
kinase kinase 7 64928 570.3024,4+ 31.34 0.017 
ESMAVFEQHCKMAQ
EYMK Ally; 2 OxM FP 
7 TET3_MOUSE 
Methylcytosine 
dioxygenase TET3 182147 492.2576,4+ 30.72 0.016 
KPPTPAGGPVGAEKT
TPGIK Ally; 4 OxP FP 
7 OLA1_MOUSE Obg-like ATPase 1 44929 542.3251,4+ 29.42 0.038 
HLFLTSKPMVYLVNL
SEK 
ClY; 2 Ally; 
OxM FP 
7 F262_MOUSE 
6-phosphofructo-2-
kinase/fructose-2,6-
bisphosphatase 2 60458 589.5749,4+ 28.86 0.018 
IECYKVTYQPLDPDN
YDK 
ClY; NitroY; 
OxP FP 
7 CO4A4_MOUSE 
Collagen alpha-
4(IV) chain 166046 470.5653,4+ 26.75 0.045 
GAPGPGGPPGQPGE
NGEKGR 4 OxP FP 
7 EPHA3_MOUSE 
Ephrin type-A 
receptor 3 111652 472.2629,3+ 26.14 0.041 VVGAGEFGEVCSGR TrioxC FP 
7 GOLM1_MOUSE 
Golgi membrane 
protein 1 44470 734.9005,4+ 25.77 0.02 
GIINVPVGSERQSHIL
NQVGIHIPQQA 2 OxP FP 
7 CPNE2_MOUSE Copine-2 61681 799.944,4+ 25.08 0.046 
ITRPLLLMNDKPAGK
GVITIAAQELSDNR 
DioxM; 2 
Ally; 2 OxP FP 
7 SAHH2_MOUSE 
Putative 
adenosylhomocyste
inase 2 59997 512.2607,3+ 22.43 0.04 NGPFKPNYYRY 
3 ClY; Ally; 
OxP FP 
8 GSTP1_MOUSE 
Glutathione S-
transferase P 1 23765 608.9556,3+ 85.04 4.3E-07 
EAAQMDMVNDGVED
LR DioxM TP 
8 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 749.0818,3+ 56.93 0.0015 
VIISAPSADAPMFVM
GVNHEK OxM; OxP FP 
8 G3P_MOUSE 
Glyceraldehyde-3-
phosphate 
dehydrogenase 36072 524.7956,3+ 32.72 0.018 VPTPNVSVVDLTCR OxP 
UC – may 
be a 
OxThreonin
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e 
8 PRDX1_MOUSE Peroxiredoxin-1 22390 826.9895,2+ 38.63 0.0054 
QGGLGPMNIPLISDP
K OxP 
UC – 
possible 
OxM 
8 DLGP4_MOUSE 
Disks large-
associated protein 
4 108940 588.3465,2+ 40.78 0.021 TSATLDKSLLK Ally FP 
8 INT7_MOUSE 
Integrator complex 
subunit 7 108048 428.7752,2+ 36.78 0.046 LALSPSPR OxP FP 
8 SRRM2_MOUSE 
Serine/arginine 
repetitive matrix 
protein 2 295521 449.7827,2+ 33.42 0.028 VKTVISPR Ally FP 
8 NR4A1_MOUSE 
Nuclear receptor 
subfamily 4 group A 
member 1 66009 366.6475,3+ 29.57 0.039 AHLDSGPSTAK Ally; OxP FP 
8 NPRL3_MOUSE 
Nitrogen permease 
regulator 3-like 
protein 64148 455.1785,4+ 29.26 0.037 RMTENLLASLSEHER DioxM FP 
8 CMC1_MOUSE 
Calcium-binding 
mitochondrial 
carrier protein 
Aralar1 74922 632.367,3+ 28.05 0.043 
VSALNVLQDLGLFGL
YK NitroY FP 
8 BCL9L_MOUSE 
B-cell 
CLL/lymphoma 9-
like protein 156978 478.2504,4+ 27.33 0.029 
GLSMSMCHPGQMSL
LGR DioxM; OxM FP 
8 SPIT1_MOUSE 
Kunitz-type 
protease inhibitor 1 58322 526.1954,3+ 24.63 0.05 CARFTYGGCYGNK 
2 OxY; 
TrioxC FP 
9 PPIA_MOUSE 
Peptidyl-prolyl cis-
trans isomerase A 18131 674.864,3+ 52.22 0.0023 
VNPTVFFDITADDEPL
GR OxP UC 
9 GAS8_MOUSE 
Growth arrest-
specific protein 8 56400 637.3712,2+ 44.53 0.0063 AEGTVVMKLAQK Ally FP 
9 TENA_MOUSE Tenascin 237304 414.7694,2+ 58.19 0.0021 AVDIPGLK OxP FP 
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9 GAS6_MOUSE 
Growth arrest-
specific protein 6 76500 703.924,4+ 41.19 0.0024 
GGLKLSPDMDTCEDI
LPCVPFSMAK DioxM FP 
9 RRP5_MOUSE 
Protein RRP5 
homolog 209302 527.2703,4+ 38.93 0.031 
GLVPSMHLADIMMKN
PEK 
2 DioxM; 
Ally; OxM; 
OxP FP 
9 SPR2H_MOUSE 
Small proline-rich 
protein 2H 12852 926.4984,3+ 38.55 0.043 
CPEPCPPPKCTEPCP
PPSYQQK 
2 Ally; 8 
OxP; OxY; 2 
TrioxC FP 
9 MIIP_MOUSE 
Migration and 
invasion-inhibitory 
protein 43428 747.711,2+ 36.6 0.022 LFPEPVDPGAPCR 
3 OxP; 
TrioxC FP 
9 INT7_MOUSE 
Integrator complex 
subunit 7 108048 428.7746,2+ 36.1 0.047 LALSPSPR OxP FP 
9 IMPG2_MOUSE 
Interphotoreceptor 
matrix proteoglycan 
2 139099 362.1709,4+ 33.74 0.037 HPDSLSSVENAMK DioxM; Ally FP 
9 GFI1B_MOUSE 
Zinc finger protein 
Gfi-1b 38103 417.9292,4+ 33.01 0.035 
SHSGTRPFACDVCG
K Ally; TrioxC FP 
9 SH2B2_MOUSE 
SH2B adapter 
protein 2 67257 513.2802,4+ 29.5 0.031 
SSPEPDGGATPKAAE
PASEPR Ally FP 
9 SHRM4_MOUSE Protein Shroom4 165475 638.3306,4+ 28.94 0.02 
ASEPVDSLPQKEKPG
LETVLPPR Ally; 4 OxP FP 
9 SOCS4_MOUSE 
Suppressor of 
cytokine signaling 4 50855 351.6202,4+ 27.97 0.047 NCSGRHSPGLPSK OxP; TrioxC FP 
9 CRIS2_MOUSE 
Cysteine-rich 
secretory protein 2 28499 962.0521,4+ 26.43 0.049 
IGCGIAYCPNQDNLK
YFYVCHYCPMGNNV
MK 
2 DioxM; 
Ally; OxP; 
OxY; 4 
TrioxC FP 
10 HBB1_MOUSE 
Hemoglobin subunit 
beta-1 15944 645.8925,2+ 36.88 0.027 LLVVYPWTQR OxP 
Correct 
sequence, 
wrong 
modificatio
205 
 
 
n = OxW 
10 HXA4_MOUSE 
Homeobox protein 
Hox-A4 30733 425.5849,3+ 46.87 0.001 EPVVYPWMKK 2 Ally FP 
10 FABPH_MOUSE 
Fatty acid-binding 
protein, heart 14810 467.2353,4+ 32.99 0.035 
NFDDYMKSLGVGFA
TR NitroY FP 
10 SAPL1_MOUSE 
Proactivator 
polypeptide-like 
1PE=1 SV=2 58905 421.7665,2+ 41.7 0.016 ASPISVPR OxP FP 
10 PI51A_MOUSE 
Phosphatidylinositol 
4-phosphate 5-
kinase type-1 alpha 60789 454.2575,4+ 36.83 0.027 FYGLYCVQAGGKNIR 2 ClY FP 
10 PI51A_MOUSE 
Phosphatidylinositol 
4-phosphate 5-
kinase type-1 alpha 60789 454.2652,4+ 36.28 0.034 FYGLYCVQAGGKNIR 
ClY; Ally; 
NitroY; 
TrioxC FP 
10 K1B24_MOUSE 
Kallikrein 1-related 
peptidase b24 29478 602.3633,2+ 39.68 0.036 DKSNDLMLLR Ally FP 
10 SEM3A_MOUSE Semaphorin-3A 89840 466.7076,4+ 38.83 0.019 
EMSSSMTPSQKVWY
R 
DioxM; Ally; 
OxP FP 
10 SRRM2_MOUSE 
Serine/arginine 
repetitive matrix 
protein 295521 449.7815,2+ 33.48 0.025 VKTVISPR Ally FP 
10 IRS2_MOUSE 
Insulin receptor 
substrate 2 137876 857.4639,3+ 34.12 0.029 
SGGPNSCKSDDYMP
MSPTSVSAPK 
2 OxM; 2 
OxP; OxY; 
TrioxC FP 
10 FAT3_MOUSE Protocadherin Fat 3 505005 477.7163,3+ 32.62 0.0052 IKAYDADSGFNGK NitroY FP 
10 BCAS1_MOUSE 
Breast carcinoma-
amplified sequence 
1 homolog 67793 486.7292,4+ 26.63 0.025 
DPSEHGALPVAAAPG
QAPDK OxP FP 
10 PRRX2_MOUSE 
Paired mesoderm 
homeobox protein 2 26524 788.9577,4+ 25.72 0.042 
MDSAAAAFALDPPAP
GPGPPPAPGDCAQA
RK 
DioxM; 8 
OxP; TrioxC FP 
 
